¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2020/7/23 ¤U¤È 12:04:01
²Ä 3183 ½g¦^À³
|
§ÚËı±o·Q½æªº³£½æ¤F ²{¦b¶}©l·Q¶Rªº¡A¼K¼K¡K·Q¹³ªÅ¶¡¤j |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gtimchan51610148760 |
µoªí®É¶¡:2020/7/23 ¤W¤È 11:39:35
²Ä 3182 ½g¦^À³
|
11ÂI¥´¶}¶^°± ! ·Q½æ¤£·QÂà´«ADRªº¤H¤µ¤Ñ°ò¥»¤W³£·|½æ±¼¤F ! ¤£·Q½æªº¤HÀ³¸Ó¤]¤£·|½æ¤F ! µ¥Âà´«ADR !!! ¤µ¤Ñ¦³¾÷·|¬D¾Ô¨È·à±d¾ú¥v¥¨¶q 2018/4/3 6700±i ! ·í®ÉªÑ»ù¬O±µªñ60 ! ²{¦b¥u³Ñ¤U4¶ô¦h ¦¹¤@®É©¼¤@®É¤] ! ¦pªG¤µ¤Ñ±µªº¶q¦³¥´ºâÂà´«¨ì ADR ¨ºªÑ»ù´N¦³ºû«ù¦b4.x¥ª¥k Åý·Q½æªº¤H¥i¥H½æ±¼ ±µ¤U¨Ó¨ì8/25¤§«e¤]¤£·|¦³¤jªi°Ê¤F ! °£«DADR¤jº¦ ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/23 ¤W¤È 10:20:09
²Ä 3181 ½g¦^À³
|
®Ú¾ÚEvaluatePharmaªº»¡ªk¡AKeytruda¥i¯à·|¦b2019¦~ªº111»õ¬ü¤¸ªº¾P°âÃB¤W¼W¥[32.9»õ¬ü¤¸ªº¥þ²y¾P°âÃB¡A¨Ï2020¦~ªºÁ`¾P°âÃB¹F¨ì143.9»õ¬ü¤¸¡C
www.fiercepharma.com/special-report/keytruda-top-20-drugs-by-sales-increase-2020
Keytruda ¤½¥q¦WºÙ¡GMerck¡®Co. ¥Î©ó¡G¶Â¦â¯À½F¡A«D¤p²ÓMªÍÀù¡AÀYÀV³¡Å쪬²ÓMÀù¡AÀN©_ª÷²O¤Ú½F¡A¤jB²ÓM²O¤Ú½F¡A§¿¸ô¤W¥ÖÀù¡A·L½Ã¬P¤£Ã©w©Ê°ª¤ô¥Àù¡AGÀù¡A¹¹DÀù¡A®cÀVÀù¡A¨x²ÓMÀù¡AÀq§Jº¸²ÓMÀù¡AµÇ²ÓMÀù¡A¤l®c¤º½¤Àù 2019¦~¾P°âÃB¡G111»õ¬ü¤¸
¦b¥«³õ¤W¾P°â¤F¤»¦~¤§«á¡AÀq§J¤½¥qªºPD-1 / L1¶W¯Å¥¨¬P¾ÌÂǤj¶q¤wÀò§å㪺¾AÀ³¯géT¦a¦¨¬°¤F»sÃÄ·~ªº¥þ²yºZ¾P²£«~¤§¤@¡C¦ý¬O¦³®ÉÔ´I¤H·|Åܱo§ó¥[´I¸Î¡A¦Ó2020¦~¥i¯à¹ïKeytruda¨Ó»¡¬O¥iÆ[ªº¬Õ§Q¤§¦~¡C
®Ú¾ÚEvaluatePharmaªº»¡ªk¡AKeytruda¥i¯à·|¦b2019¦~ªº111»õ¬ü¤¸ªº¾P°âÃB¤W¼W¥[32.9»õ¬ü¤¸ªº¥þ²y¾P°âÃB¡A¨Ï2020¦~ªºÁ`¾P°âÃB¹F¨ì143.9»õ¬ü¤¸¡C
¬°¤F¹ê²{³o¤@¸ÅD¡AKeytruda±N±q2019¦~Àò±oªº¤CÓ·sFDA§å㤤¸õ¥X¨Ó¡A¨Ã¦b2020¦~1¤ëÀò±o¥t¤@Ó¡C
¬ÛÃö¡G²¾¶}¡A¯Q¦Ì©Ô¡C³ø§iºÙ¡AÀq¨FªFªºKeytruda±N¦b2024¦~¦û¾Ú¦æ·~³Ì°ªªº¾P°âÂI
§åã¨÷¶}©l©ó2019¦~2¤ë¡A·í®ÉKeytrudaÀò±o¤FFDAÂIÀYªvÀø²O¤Úµ²¨ü²Ö¶Â¦â¯À½Fªº´£¦W¡C
¦¹«á¡AÀq§J©ó2019¦~4¤ëÀò±oFDA§åã§@¬°Âಾ©Ê«D¤p²ÓMªÍÀùªº¤@½uªvÀøÃĪ«;·í¤ë±ß¨Ç®ÉÔ»PInlytaÁp¦XªvÀøµÇ²ÓMÀù¡F§@¬°¤»¤ë¥¼´¿ªvÀø¹LªºÀYÀVÀùªº³æ¿W©MÁp¦XªvÀø¡F¤@©P«á§@¬°¥ý«eªvÀøªº¤p²ÓMªÍÀùªº³æ¿WªvÀø¤èªk¡C
¤U¥b¦~¡A¥¦¦b¤C¤ë¦¬¶°¤Fºñ¿O§@¬°§½³¡ªvÀø±ß´Á©ÎÂಾ©ÊÅ쪬²ÓMÀùªº³æ¿WÀøªk¡F¨Ã©ó¤µ¦~9¤ëµ²§ô¡A§@¬°¬Y¨Ç±ß´Á¤l®c¤º½¤ÀùªºÁp¦XÀøªk¡C
¸ÓÃĪ«¦b1¤ë¥÷Àò±o¤FFDA§å㪺¦´Á»H¯ÖÀùÃĪ«¤§«á¡A¨ú±o¤F³s³Ó¡C
ÁÙ¦³§ó¦hªº¥i¯à¡C Keytruda¥¿¦b¤@²Õ3´Á¬ã¨s¤¤¶i¦æµû¦ô¡A¥]¬AÁx¹DÀù¡Aªc§¿¹DÀù¡Aµ²¸zª½¸zÀù¡A¶¡¥Ö½F¡A»ó«|Àù¡A§Z±_Àù©M«e¦C¸¢Àù¡C³Ìªñ¡A¦b2¤ë¡AKeytruda©M¤Æ¾ÇÃĪ«ªº²Õ¦X¦bªý¤î¨ã¦³¤@©w¤ô¥¥Íª«¼Ð»xª«PD-L1ªº¤T³±©Ê¨Å¸¢Àù±wªÌªº¯e¯f¶i®i¤è±¿W¥eloÀY¡C
¾¨ºÞÀq§J¤½¥q±NKeytrudaªº¥¨¤j¦¨¥\±À¦V¤Fµ}Á¡ªºªÅ®ð¡A¦ý¤H̾á¤ß¡AÀHµÛÄvª§ªÌªº´é¤J¡A§K¬Ì¸~½F¾Ç©ú¬P«Ü§Ö´N·|¹F¨ì³»®p¡C
¬ÛÃö¡GÀq§J¡]Merck¡^ªºKeytrudaªÍÀù¾P°â¥i¯à±Á{·sªºÀ£¤O¡A¦ý§ë¸êªÌ¤£À³¸Ó«_³oÓÀ£¤O¡G¤ÀªR®v
¦b«D¤p²ÓMªÍÀù¥«³õ¤¤¡A¦Ê®É¬ü¬I¶QÄ_¡]Bristol Myers Squibb¡^ªºOpdivo¡Aªü´µ§Q±d¡]AstraZeneca¡^ªºImfinzi©Mù¤ó¡]Roche¡^ªºTecentriq¦b¨CÓ©u«×¬°Keytruda¦b¬ü°êªº¾P°âÃB´£¨Ñ¤F14»õ¬ü¤¸ªº¥«³õ¡A¤w¸gÀò±o¤F¦Û¤vªº§åã©Î¥¿¦bª§¨ú¥L̪º§åã¡C
SVB Leerink¤ÀªR®vÀ¹®R¡P®æ¹p³Õ´µ¡]Daina Graybosch¡^À½¦b¨º®y©Ð¤l¸Ì¡A¦b11¤ëµ¹§ë¸êªÌªº³ø§i¤¤¹w´ú¡A°ò¯S¾|¹FªºªÍÀù¾P°â±N¦b¤µ¦~¶}©l¤U°¡C Graybosch¼g¹D¡A³oÓ¥«³õ¬O¦p¦¹ÃöÁä¡A¥H¦Ü©óKeytruda¦b¬ü°êªº¾ãÅé¾P°âÃB¦b2020¦~±N¹F¨ì82»õ¬ü¤¸ªº¤ô¥¡A¨Ã¦b2023¦~¤~¶}©l¦^¤É¡C¦pªG³oºØ¤U°±o¥H¹ê²{¡A¨ºªÖ©w·|¹ïEvaluate¹w´úªº32.9»õ¬ü¤¸²£¥Íªýê¡C¦~¼Wªø¡C
¦ý¬O¡A¬Æ¦ÜGraybosch¤]©Ó»{Keytrudaªº¨ä¥L³\¦h¾AÀ³¯g-¥]¬A¹ï¸û·sªº«D¤p²ÓMªÍÀù±wªÌªº«e¤©Ê§åã-¦Ü¤Ö¥i¥H©è®øÄvª§ªº¥[¼@¡C
®æ¹p³Õ¬I»¡¡G¡§¼ç¦bªºªø´ÁªvÀø©M§ó¤jªº¥iªvÀø¤H¸s¬°ÀˬdÂI§í»s¾¯´£¨Ñ¤F³Ì¤jªº¥¼¶}µo¥«³õ¡C¡¨
---------------------------------------------------------------- ÃĤý¥¼¨Ó¬O Àq§J¶°¹Îªº PD¤@1 §í¨î¾¯ Keytruda ,,2025¦~±N¾P222»õ¬ü¤¸¡C 2018¦~¾P72»õ¬ü¤¸¡C
Keytruda±N¦¨ºZ¾PÃĤýªÌ ¹w´ú2025¦~¾P°âÃB±N¹F222»õ¬ü¤¸ 2019.10.07 Àô²y¥Í§ÞÂø»x°OªÌ/§õªLÀõ ½sĶ
¤é«e(4)¡A¬ã¨s¾÷ºcGlobalData¹w´ú¨ì¤F2023¦~¡AÀq¨FªF(MSD)ªºPD-1§í¨î¾¯Keytruda±N¦¨¬°¥@¬É¤W³ÌºZ¾PªºÃĪ«¡A¥B¨ì¤F2025¦~¨ä¦~¾P°âÃB±N¹F¨ì222»õ¬ü¤¸¡C
¥Ñ©óÄvª§¥[¼@©M±M§Q¨ì´Á¡Aì¥ý³ÌºZ¾PÃĪ«Humira¥¿¦b¨«¤U©Y¡A¦ã§Bºû¡]AbbVie¡^ªºHumira©ó2018¦~±a¨Ó¤F¶W¹L200»õ¬ü¤¸ªº¦¬¤J¡A¨Ï¨ä¦¨¬°¥þ²yÃÄ«~¾P°âªº¤ýªÌ¡C
¦ý¨ì¤F2023¦~¡AHumira±N¥¢¥h¬ü°êªº±M§Q«OÅ@¡A¥«³õ±N¥[¤J§ó¦hÄvª§ªÌ¡A¦p2018¦~11¤ë¡AFDA§åã¤FSandozªºHyrimoz¡A¸ÓÃĬO¤@ºØHumiraªº¥Íª«¬Û¦üÃÄ¡A¦ý¥Ñ©ó¥Ø«e¨ü¨ì±M§Q«OÅ@¡A¦]¦¹n¨ì2023¦~¤~¯à¦b¬ü°ê¤W¥«¡C
GlobalData ÂåÃÄ·~¤ÀªR®vKeshalini Sabaratnamªí¥Ü¡AKeytruda¦³±æ¶W¹L¦ã§BºûªºHumira¦¨¬°¥þ²y³ÌºZ¾PªºÃĪ«¡AKeytruda¤w¦b¬ü°êÀò±o¶W¹L20ºØ¸~½F¾Ç¾AÀ³¯gªº§åã¡A¨Ã¥B¥¿«ùÄò¦V¥þ²yÂX®i¨ì·sªº¾AÀ³¯g©M¥«³õ¡C
Àq¨FªF¥ý«eªº³ø§i«ü¥X¡A2018¦~¡AKeytrudaªº¾P°âÃB¬°72»õ¬ü¤¸¡A¥BªÑ»ù¤Wº¦¤F18%¡AµØº¸µó¤ÀªR®v¹wp2019¦~ªº¾P°âÃB¬°108»õ¬ü¤¸¡A¤µ¦~¨ì¥Ø«e¬°¤îªÑ»ù¤Wº¦¤F9.7¢H¡C
GlobalData¹wpKeytruda¨ì¤F2023¦~¾P°âÃB±N¹F¨ì199»õ¬ü¤¸¡A¤ñµØº¸µó¤ÀªR®vªº¹w¦ô§ó¬°¤jÁx¡C
GlobalData¹w´ú¡A¨ì2025¦~¡A¥²ªv§´¬I¶QÄ_¡]BMS¡^©M ½÷·ç¡]Pfizer¡^ªº§Ü¾®¦å¾¯Eliquis ±N¦¨¬°²Ä¤G¤jºZ¾PÃĪ«¡A²Ä¤T¦ì¬°¥²ªv§´¬I¶QÄ_¦¬ÁʪºCelgene¡A¨ä§ÜÀùÃĪ«Revlimid¡A¦Ó²Ä¥|¦ì¬°ª½±µ»PKeytrudaÄvª§ªº¥²ªv§´¬I¶QÄ_Opdivo¡C
www.gbimonthly.com/2019/10/54139/
Àq¨FªFªº¾ú¥v
§Ú̦b¬ü°ê³QºÙ¬° Merck & Co., Inc. (Merck)¡A¦b¬ü°ê¤Î¥[®³¤j¥H¥~ªº¦a°Ï¥HÀq¨FªFÃļt (Merck Sharp & Dohme¡AMSD) ¬°¦W¡CÀq¨FªFÃļtªº¥ø·~Á`³¡¦ì©ó¬ü°ê¯Ã¿A¦è¦{ (Kenilworth, New Jersey, United States)¡A«e¨¬°¤@®a¦ì©ó¼w°ê¹F©i¬I¶ð¯S (Darmstadt) ªº¤Æ¾Ç²£«~¤½¥q¡C¦è¤¸1891¦~®É¥Ñ³ìªv¡DÀq§J (George Merck) ©ó¬ü°ê¯Ã¬ù³Ð¥ß¤À¤½¥q¡A¨Ã¥Ñ¼w°ê¶i¤f¤Æ¾Çª««~°â¤©·í¦aªºÃľ¯®v¡C
ÀHµÛ·~°È¤é¯q¦¨ªø¡A¦è¤¸1902¦~®É George Merck ©ó¬ü°ê¯Ã¿A¦è¦{¦¨¥ß Merck & Co.¡A¶}©l¥H»s³y¨ú¥N¶i¤f·~°È¡A³v¨B¼W¥[²£¯à¤Î©Ý®i¥«³õ¡A¨Ã©ó¦è¤¸1917¦~²Ä¤@¦¸¥@¬É¤j¾Ô´Á¶¡¡A¥¿¦¡µ²§ô»P¼w°ê¥À¤½¥q¤§¶¡ªºÃö«Y¡C
¦è¤¸1930¦~¥Nªì´Á¡AMerck & Co., Inc. ¶}©l±NÀç¹B½dÃ¥ÂX¤j¦ÜÃĪ«¬ã¨s¡A¨Ã±N·~°ÈIJ¨¤©µ¦ù¦Ü®ü¥~¥«³õ¡C¦è¤¸1953¦~¡A»PSharp & Dohme ¦X¨Ö¡A¥¿¦¡¦¨¥ßÀq¨FªFÃļt (Merck Sharp & Dohme¡AMSD)¡A«Ø¥ß°_¬ãµo¡B»s³y»P¾P°â¤@Åé¤Æªº¸ó°êÃÄ«~¥ø·~¶°¹Î¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/23 ¤W¤È 08:41:49
²Ä 3180 ½g¦^À³
|
´x´¤¹L¥h¡A²`¬ã¥¼¨Ó¡Aª¾Ävª§¤O¡A¤èª¾¿ú°]
°ê»Ú±ÂÅv¦X¬ù¡A¤£¬OÀH«Kñªº¡I
4ºØ AD ¼Ð¹v¾ú¥v
1.2012-2014¦~ ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È7»õ¬ü¤¸. 2.2014 ¦~ ¨È·à±d 舆 CSL ñq ¦@¦P¶}µoASLAN004 ¨ì·§©À©ÊÁ{§É¡A«á¦A±ÂÅv¥þ²y¤Æµo®i¡þ¥Í²£/¾P°â ¡A§Q¼í§¡¤À¡C 3.2014 /11¤ë Dupilumab ÀòB丅D(Breakthrough Therapy Designation ) in AD. 4.2016/ 9¤ë, ÀòFDA Ãĵý¥[³t䆺¬d(Priority review) . 5.2016¦~,LEO Pharma©ó2016¦~±qªü´µ§Q±d¡]LSE¡GAZN¡^Àò±o¤F¥Ö½§¯e¯f¤¤ªºtralokinumabªºÅv§Q¡A¸Ó¥æ©ö¯A¤Î¦V^°ê-·ç¨å»sÃÄ¥¨ÀY¹w¥I1.15»õ¬ü¤¸¡A¥H¤Î°ª¹F10»õ¬ü¤¸ªº°Ó·~¬ÛÃö¨½µ{¸O©M²£«~¾P°âªº¯S³\Åv¨Ï¥Î¶O¤ñ¨Ò¤£¶W¹L¦Ê¤À¤§¤Q (隠§t³Ì°ª¾P°â23»õ¬ü¤¸) 6. 2017¦~ªì ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È50»õ¬ü¤¸.(¤T´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 380%~450%)
2017¦~3¤ëDupilumab ÀòÃĵý,¥þ²y²Ä¤@Ó ¤¤¤@««×AD ¼Ð¹vÃĵý.
3Ó¤º¤ëREGN ªÑ²¼¥«È¤jº¦140»õ¬ü¤¸. 2017¦~Q3 ¤W¥«¶}©l¾P°â/2017¦~ ¤U¥b¦~¾P°â2.3»õ¬ü¤¸.
7.2017/8/8 Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv, «eª÷8000¸U¬ü¤¸¡A 2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A ¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A °£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸, ¥[¾P°â¤À¼í<= 10%. (Áô§t³Ì°ª¾P°â 28 »õ¬ü¤¸) 8.2018¦~Dupilumab ¾P°â8»õ¬ü¤¸ 9. 2019/05/31 ¨È·à±d ¡A½T»{ASLAN004¤§M0A¡C ñ¤U¥þ²y°Ó·~¤Æ,·s¦X¬ù±ø¥ó¦p¤U: ¨È·à±d-KY ±N©ó ASLAN004 ¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥I CSL ºµ§´Ú¶µ 3,000 ¸U¬üª÷¡C CSL ±N¥i¦¬¨ú³Ì°ª¹F 9,500 ¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B ³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷¥H¤Î¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü 10%¤§Åv§Qª÷¡C (Áô§t³Ì°ª¾P°â31.2»õ¬ü¤¸)
10. 2019¦~Dupilumab ¦~¾P°â23»õ¬ü¤¸ 11. 2019¦~12¤ë REGN ªºCEO ¤½¶}«Å¥¬ Dupilumab ¦~¾P°â°ªÂI ¹F110»õ¬ü¤¸.
12 2019/12/05 ¤½¥¬ ASLAN004 ªvÀø ¤T¦ìAD ,200mg/¨C¶g¤@°w(4-6¶g)¡AEASI ¥§¡°´T71%, ¶W¶Vdupilumab 2a Á{§É ,300mg/¨C¶g¤@°w(600mg°_©l¶q)¡A²Ä¤¶g¥§¡EASI ¥§¡°´T67% .
13. LEO Pharma reveals positive top-line Phase III results for tralokinumab(¤T´ÁADÁ{§É¤w¸Ñª¼¦¨¥\,2019/12 ¤ë)
Tralokinumab ¤T´Á¥Dn«ü¼Ð»P¹ï·Ó组¤ñÈIGA,0/1¬°2
Dupilumab ¦P¼Ë¤ñÈ ¬°3.8/4.5 Àu©óTralokinumab100%
Lebrikizumab ¤G´Á¦P¼Ë¤ñÈ2.9 Dupilumab Àu©ó 3.8/2.9=131% 4.5/2.9=155%
14.2020¦~¤¸¤ë Dermira 11»õ¬ü¤¸³Q§¨Ó¨ÖÁÊ,¥t¶·©Ó±µDermira¤ä¥I¤W´åù¤óROCHE ,2017¦~ªº±ø¥ó: ¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A °£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù12.35»õ¬ü¤¸, ¥[¾P°â¤À¼í<= 10%. (§é²{È 29»õ¬ü¤¸)
15. 2020¦~ 7¤ë7¤éREGN ªñ6Ó¤ë ªÑ²¼¥«È¤jº¦300»õ¬ü¤¸.
16.2020/06/29 ªÑªF·|³ø§i : p¹º2022¦~ASLAN004 °µ§¹2b ´Á¤¤¤@««×ADÁ{§É¦A±ÂÅv . ¼ç¦b¶R®a¤w°Ñ»P2bÁ{§É¬ã°Q.(¦ô¬°¤jªÑªF/ݸ³¨Æ:Àq§J¤jÃļt.)¡B
17. 2020¦~ 7¤ë15 ¤é¡A¨È·à±d«Å¥¬ ²Ä¤@¤W¥«¦a¥Ñ¥xÆW§ï¬°¬ü°ê¯Ç´µ¹F§J¡A8¤ë25¤é~9¤ë25¤é¥xÆWªÑªÑªF¥i¥Ó½ÐÂà´«ADR,¹w´Á10¤ë©³«eÂà´«§¹²¦¡A
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X-
¥|AD¼Ð¹v·sÃľú¥v¡C
¤@¡BDupilumab---REGN ¤½¥q 2012-2014¦~ ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È7»õ¬ü¤¸. 2014 ¦~11¤ë Dupilumab ÀòB丅D(Breakthrough Therapy Designation ) in AD. 201/¦~9¤ë, ÀòFDA Ãĵý¥[³t䆺¬d(Priority review) .2017¦~ªì ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È50»õ¬ü¤¸.(¤T´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 380%~450%) 2017¦~3¤ëDupilumab ÀòÃĵý,¥þ²y²Ä¤@Ó¤¤-««×AD¼Ð¹vÃÄÃÒ¡C 3Ó¤º¤ëREGN ªÑ²¼¥«È¤jº¦140»õ¬ü¤¸. 2017¦~Q3 ¤W¥«¶}©l¾P°â/2017¦~ ¤U¥b¦~¾P°â2.3»õ¬ü¤¸.2019¦~¦~¾P°â23»õ¬ü¤¸ 2019¦~12¤ë REGN ªºCEO ¤½¶}«Å¥¬ Dupilumab ¦~¾P°â°ªÂI ¹F110»õ¬ü¤¸ 2020¦~ 7¤ë7¤éREGN ªñ6Ó¤ë ªÑ²¼¥«È¤jº¦300»õ¬ü¤¸. ---------------------- ¤G¡BLebrikizumab----§¨Ó¤½¥q 2017/8/8 Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv, «eª÷8000¸U¬ü¤¸¡A 2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C
±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A ¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A °£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸, ¥[¾P°â¤À¼í<= 10%.
2017¦~¦~©³¶}©l280¤H2b AD Á{§ÉÎcªG 2019¦~¤¸¤ë¤½§G2b AD Á{§É.(¤G´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 290%~380%) 2019¦~10¤ë ¶i¤J 2Ó400¤H,¦Xp800¤Hªº¤T´Á ¤¤-««×ADÁ{§É 2020¦~¤¸¤ë Dermira 11»õ¬ü¤¸³Q§¨Ó¨ÖÁÊ,¥t¶·©Ó±µDermira¤ä¥I¤W´åù¤óROCHE ,2017¦~ªº±ø¥ó: ¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A °£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù12.35»õ¬ü¤¸, ¥[¾P°â¤À¼í<= 10%.
------- ¤T¡BASLAN004-¨È·à±d 2014¦~ ¨È·à±d©MCSL ñ¬ù¦@¦P¶}µo°µ§¹·§©À©ÊÁ{§É«á¦A±ÂÅv ¥þ²y°Ó·~¤Æ,§Q¼í§¡¤À. 2019/05/31 ¨È·à±d ¡A½T»{M0A¡C ñ¤U¥þ²y°Ó·~¤Æ,·s¦X¬ù±ø¥ó¦p¤U: ¨È·à±d-KY ±N©ó ASLAN004 ¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥I CSL ºµ§´Ú¶µ 3,000 ¸U¬üª÷¡C CSL ±N¥i¦¬¨ú³Ì°ª¹F 9,500 ¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B ³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷¥H¤Î¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü 10%¤§Åv§Qª÷¡C
¦å²G¤¤ASLAN004 ÃĶq 1mg/L, ´N¥i¥H§¹¥þ§í¨î¡A60¤½¤çÅé«x8%=4.8 L ¦å²G , ²z½×¤W¦å²G¤¤ ¥§¡«O«ù4.8mg ,´N¥i§¹¥þ§í¨î ¬°¦P¯Å®t¤@Ó¶q¯Å(10¿)¥H¤W¥ÎÃĶq. Dupilumab ,¤¤¤å¥é³æ¡A600mg°_©l¶q¡A²Ä7¤Ñ¦å²G¤¤ ÃĶq ¥§¡70ug/ml=70mg/L, 70x4.8=326mg ¥¼¨Ó±j±À¥|¶g¤@°w¨Ó·m¥«³õ¡A¨ä¥L¤TÃĬҨâ¶g¤@针¡A
2019/12/05 ¤½¥¬ ASLAN004 ªvÀø ¤T¦ìAD ,200mg/¨C¶g¤@°w(4-6¶g)¡AEASI ¥§¡°´T71%, ¶W¶Vdupilumab 2a Á{§É ,300mg/¨C¶g¤@°w(600mg°_©l¶q)¡A²Ä¤¶g¥§¡EASI ¥§¡°´T67% . 2020/06/29 ªÑªF·|³ø§i : p¹º2022¦~ASLAN004 °µ§¹2b ´Á¤¤¤@««×ADÁ{§É¦A±ÂÅv . ¼ç¦b¶R®a¤w°Ñ»P2bÁ{§É¬ã°Q.(¦ô¬°¤jªÑªF/ݸ³¨Æ:Àq§J¤jÃļt.)¡B 2020¦~ 7¤ë15 ¤é¡A¨È·à±d«Å¥¬ ²Ä¤@¤W¥«¦a¥Ñ¥xÆW§ï¬°¬ü°ê¯Ç´µ¹F§J¡A8¤ë25¤é~9¤ë25¤é¥xÆWªÑªÑªF¥i¥Ó½ÐÂà´«ADR,¹w´Á10¤ë©³«eÂà´«§¹²¦¡A ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ¥|¡BTralokinumab 1.2016¦~,LEO Pharma©ó2016¦~±qªü´µ§Q±d¡]LSE¡GAZN¡^Àò±o¤F¥Ö½§¯e¯f¤¤ªºtralokinumabªºÅv§Q¡A¸Ó¥æ©ö¯A¤Î¦V^°ê-·ç¨å»sÃÄ¥¨ÀY¹w¥I1.15»õ¬ü¤¸¡A¥H¤Î°ª¹F10»õ¬ü¤¸ªº°Ó·~¬ÛÃö¨½µ{¸O©M²£«~¾P°âªº¯S³\Åv¨Ï¥Î¶O¤ñ¨Ò¤£¶W¹L¦Ê¤À¤§¤Q
LEO Pharma reveals positive top-line Phase III results for tralokinumab(¤T´ÁADÁ{§É¤w¸Ñª¼¦¨¥\,2019/12 ¤ë)
Tralokinumab ¤T´Á¥Dn«ü¼Ð»P¹ï·Ó组¤ñÈIGA,0/1¬°2
Dupilumab ¦P¼Ë¤ñÈ ¬°3.8/4.5 Àu©óTralokinumab100%
Lebrikizumab ¤G´Á¦P¼Ë¤ñÈ2.9 Dupilumab Àu©ó 3.8/2.9=131% 4.5/2.9=155% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤l®x10150074 |
µoªí®É¶¡:2020/7/22 ¤U¤È 02:35:13
²Ä 3179 ½g¦^À³
|
èè¬Ý½Æ©e°U¥æ©ö¶O¥Î»á°ª¡A¤£ª¾Âà´«·|¦¬¨ú¦h¤Ö¿ú¡H ½Ð°Ý¤j¤j¬O¶}¥ß°ê¤º½Æ©e°UÁÙ¬O°ê¥~Ãþ¦üetoroªº±b¤á©O?
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯Ë¢¦w10144680 |
µoªí®É¶¡:2020/7/22 ¤U¤È 02:12:27
²Ä 3178 ½g¦^À³
|
½u¤W¶}½Æ©e°U¥i¥H¡A¤£¹L¨é°ÓµLªk³q¹L¡A¦]¬°¤§«e¬O¥¼¦¨¦~¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2020/7/22 ¤W¤È 10:30:09
²Ä 3177 ½g¦^À³
|
¦pªG¤k¨à¤w¦³°ê¥~ªº¬üªÑ¥æ©ö±b¤á¤]¥i¥H¥Î ¤£¤@©wn¶}½Æ©e°U ¨ä¹ê²{¦b«Ü¦h½u¤W¶}¤á¥æ©ö³£«Ü¤è«K ¤£¥Î¾á¤ß¶ZÂ÷°ÝÃD |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2020/7/22 ¤W¤È 10:26:32
²Ä 3176 ½g¦^À³
|
³¯Ë¢¦w¤j¤j ²{¦b¨é°Ó½Æ©e°U¶}¤á´X¥G³£¥i¥H½u¤W¶}¤á §Ú¦Û¤v¥»¤H¤W¶g¤w½u¤W¶}½Æ©e°U±b¤á§¹¦¨ ½Ð±z¤k¨à§Q¥Î¨é°Ó½u¤W¶}¤á¶}½Æ©e°U±b¤á(¶}¦n·|¦³Ó±b¤á¸¹½X) ¨ì®ÉÔª½±µ¥Î³oÓ±b¤á´N¥i¥HÂà´«
¥u¬O±z¤´n½Ð±z¤k¨à¥h¨È·à±d©xºô¤U¸ü¨º¨â¤TÓÂà´«¥Îªºªí ¶ñ¦n¤§«á±H¦^¥xÆWµ¹±z ±z¦A¥h¿ì²zÂà´«§Y¥i |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2020/7/22 ¤W¤È 09:34:47
²Ä 3175 ½g¦^À³
|
Ë¢¦w¤j °Ý¤@¤U¥ÎÃØ»P¤è¦¡¡AÃØ»P¦^¨Ó |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/22 ¤W¤È 09:02:45
²Ä 3174 ½g¦^À³
|
www.berich.com.tw/dp/TalkTalk/Talk_Detail.asp?ii=204490&CNpg=1#
¥i½Ð¥²´Iºô ¥¼¤W¥«¥æ©ö°Ï¥[¤J
¨È·à±dªÑ¥÷¦³¤½¥q(¶}°Ò¤½¥q)----µLªk¤W¥«/µ¥¨ÖÁʩΤÀ¬õ¤§¥~°êªÑ²¼¥æ©ö°Ï
----¨p¤U¹L¤áµLÂà´«Åv¤§ªÑ²¼(¸Ô²Ä 3 ÂI©w¸q)¡A±z¤´¬°¨È·à±d ªÑ¥÷¦³¤½¥q(¶}°Ò¤½¥q)¤§ªÑªF----
¥xÆWµ|ªk: µ¥¦¹¥æ©öµ¥¦P¥~°ê¥æ©öªÑ²¼©Ò±o,¦p¨È·àADR¥æ©ö©Ò±o.(Ó¤H²z¸Ñ)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/22 ¤W¤È 08:50:57
²Ä 3173 ½g¦^À³
|
11. ¦pªÑªFµL·NÄ@±NªÑ²¼Âà´«¬°¬ü°ê¦s°U¾ÌÃÒ¤§³B¸m¬°¦ó? ¦p±zµL·NÄ@Âà´«¬°¬ü°ê¦s°U¾ÌÃÒ¡A±z±o¥H¦b¥Á°ê 109 ¦~ 8 ¤ë 25 ¤é¥»¤½¥q¦³»ùÃÒ¨é ²×¤îÃÒ¨éÂdÂi¶R½æ¤é«e¡A©ó¥xÆW¤½¶}¥«³õ±N±z©Ò«ù¦³¤§¥»¤½¥qªÑ¥÷¥X°â¡A¦b«ez¤é ´Á¤§«á¡A±z©Ò«ùªÑ²¼±NµLªk¦b¥xÆW©Î¨ä¥LÃÒ¨é¥æ©ö©Ò¤W¶i¦æ¤½¶}¶R½æ¡C
µM¦Ó¡A¦p±z¿ï¾Ü¤£Âà´«©Î¨p¤U¹L¤áµLÂà´«Åv¤§ªÑ²¼(¸Ô²Ä 3 ÂI©w¸q)¡A±z¤´¬°¨È·à±d ªÑ¥÷¦³¤½¥q(¶}°Ò¤½¥q)¤§ªÑªF¡A¤´¦³¸ê®æ©ó¥¼¨Ó°Ñ»P¥»¤½¥q°tµoªÑ®§©ÎªÑªF¤j ·|¡A¨Ã¨Ì¶}°Ò¸s®qªk«ßµ{§Ç¶i¦æ¨p¤H¹L¤á¥X°â¡C
¦p¥»¤½¥q©ó¥i¹w¨£¥¼¨Ó¶i¦æ¦X¨Ö¦¬ ÁÊ¡A«h±z¥i¥H¦b¨º®É¨Ì·Ó¥»¤½¥q¶}°Ò¸s®qªk¥O³¹µ{¥l¶°¤§ªÑªF¤j·|Àò±o¥b¼ÆªÑªF¦P ·N¡A¨Ì¬ÛÃön¬ù±ø´Ú¥X°â±zªº«ùªÑ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯Ë¢¦w10144680 |
µoªí®É¶¡:2020/7/22 ¤W¤È 08:46:13
²Ä 3172 ½g¦^À³
|
§ÚªºÃÒ¨é¤á¬O¤k¨àªº¡A¦]¬°¶}¤á®É¥¼¦¨¦~¡A²{¦bn¶}½Æ©e°Un¥»¤Hñ¦W¤w¦¨¦~¡A¥i¬O¥Ø«e¤H¦b°ê¥~9/25¤§«e³£µLªk¦^¨Ó¡A½Ð°Ý¦³¤j¤jª¾¹D¹L¤F9/25§Úªº¨È·à±d¬O§_Åܦ¨¾À¯È¡A¥ÃµL½¨©O¡H¨D±Ï¡CÁÂÁ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/22 ¤W¤È 07:42:16
²Ä 3171 ½g¦^À³
|
¥¼¨Ó AD/ý³ÝÃĤý¡X¡XASLAN004
¤@¡B¨È·à±d¤½¥q³Ìªñ²¤¶ 2020,05,26 ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ASLAN004¦³¼ç¤O¦¨¬°¦P¯e¯f³Ì¨ÎÀøªk
1. IL-13R£\1 §í¨î¾¯: ASLAN004¬O°ß¤@Âê©wIL-13R£\1ªº³æ®è§ÜÅé¡A¦³¼ç¤O¦¨¬°ªvÀø²§¦ì©Ê ¥Ö½§ª¢»P®ð³Ý¤§³Ì¨ÎÀøªk 2.¾÷Âà¤wÀòÃÒ¹ê :»PdupilumabÂê©w¬Û¦Pªº¸ô®|»P¨üÅé½Æ¦XÅé(·¥Àø®ÄÀ³¬Û·í) 3.Âê©w¥«³õ°Ï¹j®ÄªG:¨ãÀø®Ä¼W¶i¤§¼ç¤O¡B´î¤Ö¤£¨}¤ÏÀ³(µ²½¤ª¢) ¡B¨C¤ëµ¹ÃĤ@¦¸(«¤jªºÄvª§Àu¶Õ) §¹¦¨³æ¤@¾¯¶q»¼¼W¸ÕÅç. 4.¤w§¹¦¨°·±d¨ü¸ÕªÌªº¤@´Á³æ¤@¾¯¶q»¼¼W¸ÕÅç¡C¦Ü¤µ©|¥¼µo²{©ú Å㤣¨}¤ÏÀ³¡C¥ÎÃÄÀW²v¥i±æ¬°¨C¤ë¤@¦¸¡C ¦h¾¯¶q»¼¼W¸ÕÅç/·§©À ©ÊÅçÃÒ¶i¦æ¤¤ 5.¦h¾¯¶q»¼¼W¸ÕÅç/·§©À©ÊÅçÃÒªº²Ä¤G¾¯¶q±Ú¸s²{¥¿¦¬®×¤¤¡C ªì´ÁÀø®Ä¥O¤H®¶¾Ä¡C
aslanpharma.com/app/uploads/2020/05/20-05-19-ASLAN-CN.pdf
¤G¡BDupilumab ¾P°â¹w´Á110»õ¬ü¤¸/¦~°ªÂI¡C 2019/12 REGNªº CEO «Å¥¬Dupilumab ¥¼¨Ó¾P°â°ªÂI110»õ¬ü¤¸¡A¶W¥X¥«³õ¹w´Á50»õ¬ü¤¸¡Cªñ¥b¦~ªÑ»ù¥«È¤jº¦300»õ¬ü¤¸. 2017/Q3¤W¥« 2018¾P°â8»õ¬ü¤¸ 2019¾P°â23»õ¬ü¤¸ 2020¦ô ¾P°â40»õ¬ü¤¸ 2021¦ô ¾P°â60»õ¬ü¤¸ 2022¦ô ¾P°â80»õ¬ü¤¸ 2023¦ô ¾P°â100»õ¬ü¤¸
¤T¡B¹w´ÁASLAN004 ¾P°â°ªÂI70»õ¬ü¤¸¡A¬°Duilumab 100»õ¬ü¤¸64%.
1.Ävª§Àu¶Õ: A. IL-13R£\1 §í¨î¾¯: ASLAN004¬O°ß¤@Âê©wIL-13R£\1ªº³æ®è§ÜÅé¡A¦³¼ç¤O¦¨¬°ªvÀø²§¦ì©Ê ¥Ö½§ª¢»P®ð³Ý¤§³Ì¨ÎÀøªk
B.¾÷Âà(MOA)¤wÀòÃÒ¹ê :»PdupilumabÂê©w¬Û¦Pªº¸ô®|»P¨üÅé½Æ¦XÅé
C.¨C¥|¶g¥ÎÃĤ@¦¸¡A 16¶gÀøµ{¥ÎÃĶq¹wp¬°800mg~1600mg,¬°Dupilumab 2700mg ªº30%~60%ªº¼ç¤O.
D.. ASLAN004 1a Á{§Éµ²½× °w¹ï¤U´å¤¶½è©Ò¶i¦æ¤§¤ÀªRÅã¥Ü¡A ¦bIVµ¹ÃĪº¤@¤p®É¤º¡A¥]¬A¦b¹L±Ó©Êµoª¢¤ÏÀ³¤¤§êºt«n¨¤¦â¤§¤¶½è,¡§ÁC»Ä¤ÆSTAT6 (pSTAT6)¡¨§Y¨ü¨ì§¹¥þ§í¨î¡A¥B¤@ÃĪ«°Ê¤O¦±½u¹Ï(pharmacokinetic profile)Åã¥ÜASLAN004ªºµ¹ÃÄÀW²v¥i±æ¬°¨C¤ë¤@¦¸¡C
¯S§Oȱoª`·Nªº¬O¡A¸ÕÅç¼Æ¾Ú«ü¥XASLAN004§¹¥þ§í¨î¨ü¾¹°T¸¹¶Ç»¼©Ò»Ýªº³Ì§C¿@«× (trough level)¤ñ²{¦³ªvÀø¤è¦¡©Ò»Ýªº¿@«×§C¡A¿@«×®t¶Z¶W¹L¤@Ӽƶq¯Å(10~99¿)¡C
¥|¡BÄvª§µ¦²¤: ¥Ñ©óASLAN004 ¤W¥«®É¶¡¡A¹w¦ô¦b¤¦~«á¡A±Á{Dupilumab ±M§Q¨ì´Á¡A¨ä¥é¥ÍÃıN¥HDupilumab q»ù80%¶i¤JÉ]³õ¡A
1.§C¦¨¥»/(§C¥´°wÀW²v/§CÃĶq),§C°Æ§@¥Î ¥Ñ©óASLAN004,¥ÎÃĶq¬Û·í§C¡A ¦ôp¥H16¶g/¨C¥|¶g¤@°w, Àøµ{¥Î¶q1600mg vs Dupilumab ,2¶g¤@°w 2700mg, »â¥ý¥«³õ¡C (ASLAN004 800mg~1400mg ,³Æ¦Ó¤£¥Î)
DUPILUMAB ¥ÎªÌ 25%~50%µ²½¤ª¢¡AASLAN004 µL¦¹°Æ§@¥Î¡C
2.q»ùµ¦²¤: ¥HDUPILUMAB x64%(§C©ó¨ä¥é¥Í薬80%)¶i¤JÉ]³õ¡C
¬ü°êªk¥O³W©w: ¤½¡B¨p«O¡A¥ÎÃÄ¡A§CÃÄ»ù¥ý¥Î¡C
3.¾P°â¹Î¶¤; ¹w´Á¥@¬É²Ä¤G ªºÀq§JÃļt¹Î¶¤
¤¡B¥Ø¼Ð¾P°â : DUPILUMAB 110»õ¬ü¤¸x64%=70»õ¬ü¤¸. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/22 ¤W¤È 06:58:40
²Ä 3170 ½g¦^À³
|
¥xÁÞ¤j, www.accessdata.fda.gov/drugsatfda_docs/label/2018/761055s007lbl.pdf
Dupilumab FDA 䆺®Ö¹Lªº¾AÀ³¯g: ¤¤¤@««× AD¤Îý³Ý ¼ÐÅÒÀÉ¡C¦p¤W
P.15/ªí¤T¡A¦³µL¥[TCS (¥~¥ÎÃþ©T¾J³n»I)¤§«ü¼Ð ¹w«áÀø®Ä
¥Dn«ü¼ÐIGA,0/1 ¦³µL¡ÏTCS ¹w«áÀø®Ä¡A®t²§¤£¤j
TRIAL 1//TRIAL2//TRIAL 3 (¦³TCS) ¹êÅç²Õ¡þ¹ï·Ó²Õ
IGA,0/1¡C ***38%/10%//36%/9%//39%/12%(¥Dn«ü¼Ð ¦³µL¡ÏTCS®t²§¤£) ESAI 75% ***51%/15%//44%/12%//69%/23% ESAI 90% ***36%/8%//30%/7%//30%/11%
NRS ***41%/12%//36%/10%//59%/20% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2020/7/21 ¤U¤È 11:01:39
²Ä 3169 ½g¦^À³
|
nÁA¸ÑASLAN004¥¼¨ÓÀø®Ä»P¦w¥þ©Êªº¤ñ¹ï¥Ø¼ÐÃĪ«§ù¥²ª¢¥i¥H¬d¸ß§ù¥²ª¢¥é³æ©Î¥H¤UÀø®Ä¸ê°T¡C
www.dr-skin.com.tw/health/view/240
¬Ý§¹¸ê°T¡A¦A²z©Ê«ä¦Ò¤j®a·|µo²{¤Ñ©R¤jªº¼ÖÆ[¬O¦³©Ò¥»ªº¡A¤½¥q¥h¦~12¤ë¤½§iªº¤T¤H¼Æ¾Ú¡A¤¤««×²§¦ì©Ê¥Ö½§ª¢¤U°¦Ê¤À¤§50¬O¦Ê¤À¤§¦Ê¡A¤U°¦Ê¤À¤§75¡A¦pÆ[¹î¨ì6-8¶g¦³«Ü¤j¥i¯à¤T¤H¤¤¦Ü¤Ö¦³¤G¤H¬ù¦Ê¤À¤§66¡A¥H¤W¨âӼƾڳ£Àu©ó§ù¥²ª¢¡A§ù¥²ª¢¦³¤@²Õ¹êÅç¨Ö¥ÎÃþ©T¾J¤~¦³«Ü¦nÀø®Ä¡AASLAN004¨Ã¨S¦³¥ÎÃþ©T¾J¡A¤µ¦~²Ä¥|©u¦pªG¼Æ¾Ú»P¥h¦~¤Q¤G¤ë¤½§iªº¤@¼Ë¦nªº¸Ü¡A¨S¦³ªÑ²¼ªº¤H¥u¦n¨ì¨º´µ¹F§J¥h±¾³æ¤F¡C
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2020/7/21 ¤U¤È 10:18:01
²Ä 3168 ½g¦^À³
|
¥xÁÞ¤jÁ¿¨ì«ÂI ¨ì®ÉÔ¦pªG¤£¯à¥hÁ{®ÉªÑªF·|ªº¤pªÑªF ¤j®a¤@©wn°O±o½u¤W§ë²¼ ÅýADRÂà´«®×³q¹L |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2020/7/21 ¤U¤È 09:51:57
²Ä 3167 ½g¦^À³
|
¨È·à±dÂà´«¬ü°ê¨º´µ¹F§J¦s°U¾ÌÃÒ¿ìªk»P§ë¸ê¤H°Ý¹F «ÂI¥mÀ{
²Ä¤GÃD¤½¥q»{¬°Âà´«±N¥i¯à¹ïªÑªF³Ì¨Î§Q¯q ¡A§Æ±æªÑªF¿n·¥°Ñ¥[¤E¤ë¥|¤éÁ{®ÉªÑªF¤j·|°Ñ»Pªí¨M¡C ¤K¤ë¤G¤Q¤é¨ì¤E¤ë¤@¤é¥i¥H¦bªÑªF·|e²¼³q½u¤Wªí¨M¡C
²Ä¤TÃD¨ì²Ä¤QÃD Âà´«µ{§Ç®É¶¡¶O¥Î
²Ä¤Q¤@ÃD ´£¨ì¦p¥»¤½¥q¦b¥i¹J¨£¥¼¨Ó¶i¦æ¨ÖÁÊ¡AµL·NÂà´«ªºªÑªF¥i¨Ì¬ÛÃön¬ù±ø´Ú¥X°â«ùªÑ¡C¡]¬Ý°_¨Ó¤½¥q¬O¥H³Q¨ÖÁʬ°µo®i¥Dn¥Ø¼Ð¡^ ²Ä¤Q¤TÃD´£¨ì¼vÅT¥¼¨ÓªÑ²¼»ùȪº¦]¯À¦³´Á¤¤¼Æ¾Ú»P·§©À©ÊÅçÃҼƾڡA2021°_°Ê¤GBÁ{§É |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/21 ¤W¤È 07:47:19
²Ä 3166 ½g¦^À³
|
EASI-50 ¥i»¡¬O1bªº«ü¼Ð¤¤¡A³Ì«n¡C ¥Nªí¦³ÃĪ«¤ÏÀ³¡CÃþ¥ÜªvÀø¸~½FªºORR¡C
ASLAN004 2019/12/03 ,¤½¥¬3¦ì EASI-50,3/3=100% ¥t¥~¤T¦ì¡A¤w°µ§¹¡A²Ä¥|©u¤½¥¬¡C ¥t¥~¤T¦ì¡AEASI-50³Ì¤j¥i¯à¡A¤]¬O100%¡A
¦]¬°¨C¶g¤@°wx200mgSC ¨C¥|¶g800mg,¤w¶W¹LIV 10mg/kg,¥i§¹¥þ§í¨îªº¶q¡A§é¦X60kg SC 690mg
¨Ì¾ÚDupilumab 300mg/¨C¶g¤@°w¡A¦´ÁÁ{§É12¶g/8¶g¨£°ªûß°Ï¡A EASI-50 85% 预测ASLAN004«á¤T¦ì¡A100%ªº¾÷·|°ª¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K Dupilumab ¤T´ÁÁ{§É¡A¤j°约50%ªº°w¾¯¶q¡A¨â¶g¤@°w¡A ¨Ï±oEASI-50 µ²ªG¡A¤j°¬°65%-69%¡A
¤ñ85%¤@¶g¤@°w¡AÀø®Ä¤j°20%¥ª¥k¡C
³o´N¬OASLAN004Àø®ÄÀu©óDupilumabªº¼ç¦b¾÷·|¡C 2bÁ{§É³]p¡A¨ì¥iªñ§¹¥þ§í¨îªº°w¾¯¶q/¥|¶g¤@针¡C
¤é«áq»ù¥Ø¼Ð¬°Dupilumab 64%,(¨¾¤îDupilumab ¥¼¨Ó±M§Q¨ì´Á«á¤j¶q¥é¥ÍÃĶi¤J¥«Ô·) ²Å¦X¬ü°ê¤½¡B¨p«OÀI¡A«K©yÃÄ¥ý¥Îªk¥O¡C ¥[¤WÀq§J¾P°âºô¸ô
110»õ¬ü¤¸x64%=70»õ¬ü¤¸ªºAD/ý³Ý ¥Ø¼Ð¥«³õ
¤j¤jÌ »{¬°®e©öÁÙ¬O§xÃø¡H
¤½¥q²¤¶¡A´±¼g¥X ¡K¡K¦P¬Ì¯f(AD/ý³Ý)³Ì¨ÎÀøªk¡K¡K
¥²¦³Ävª§¥«³õMOA/Á{§É¼Æ¾Ú¦õÃÒ¡A¤£¬OÀH«K¼gªº¡C
Dupilumab ¤T´ÁÁ{§É,¤GÓÁ{§É (¤@).300 mg Q2W(¨â¶g¤@°w/16¶g) EASI-50 65%/69% ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ¹Ï1
ESAI-50 ,¨ì²Ä35¤Ñ(²Ä¤¶g), ¤w¹F°ª®p°Ï, 300mg/¨C¶g¤@°w*12¶g.(°_©l¶q600mg+300mg *3=1500mg) , www.nejm.org/doi/10.1056/NEJMoa1314768
2.ªí2
Dupilumab ¦´Á 12¶g--¨C¶g¤@°w*300mg(°_©l¶q600mg) N=55
EASI-50 ¦b²Ä29¤Ñ,¹F69% ¦b²Ä85¤Ñ,¹F85% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤U¤È 10:03:58
²Ä 3165 ½g¦^À³
|
¤½¥q²¤¶ ¤§«e ºÙASLAN004 ¦³¼ç¤O¦P¯Å³ÌÀu
¤w§ï¬° ¡X¡X¡X ASLAN004 ¦³¼ç¤O¦¨¬°¦P¯e¯f¡]AD¤Îý³Ý) ¤§³Ì¨ÎÀøªk¡X¡X¡X
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ASLAN004¦³¼ç¤O¦¨¬°¦P¯e¯f³Ì¨ÎÀøªk
1. IL-13R£\1 §í¨î¾¯: ASLAN004¬O°ß¤@Âê©wIL-13R£\1ªº³æ®è§ÜÅé¡A¦³¼ç¤O¦¨¬°ªvÀø²§¦ì©Ê ¥Ö½§ª¢»P®ð³Ý¤§³Ì¨ÎÀøªk 2.¾÷Âà¤wÀòÃÒ¹ê :»PdupilumabÂê©w¬Û¦Pªº¸ô®|»P¨üÅé½Æ¦XÅé 3.Âê©w¥«³õ°Ï¹j®ÄªG:¨ãÀø®Ä¼W¶i¤§¼ç¤O¡B´î¤Ö¤£¨}¤ÏÀ³(µ²½¤ª¢) ¡B¨C¤ëµ¹ÃĤ@¦¸ §¹¦¨³æ¤@¾¯¶q»¼¼W¸ÕÅç 4.¤w§¹¦¨°·±d¨ü¸ÕªÌªº¤@´Á³æ¤@¾¯¶q»¼¼W¸ÕÅç¡C¦Ü¤µ©|¥¼µo²{©ú Å㤣¨}¤ÏÀ³¡C¥ÎÃÄÀW²v¥i±æ¬°¨C¤ë¤@¦¸¡C ¦h¾¯¶q»¼¼W¸ÕÅç/·§©À ©ÊÅçÃÒ¶i¦æ¤¤ 5.¦h¾¯¶q»¼¼W¸ÕÅç/·§©À©ÊÅçÃÒªº²Ä¤G¾¯¶q±Ú¸s²{¥¿¦¬®×¤¤¡C ªì´ÁÀø®Ä¥O¤H®¶¾Ä¡C¹wp2021¦~¤W¥b§¹¦¨¡C
aslanpharma.com/app/uploads/2020/05/20-05-19-ASLAN-CN.pdf
p.7
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤U¤È 07:00:52
²Ä 3164 ½g¦^À³
|
¤jÃı¹ïÄvª§¬O±`ºA
MOA¿éĹ³Ì¤j.
¨È·à±dÀH®É·|¾D¨ÖÁÊ
¥¼¨ÓALAN004 ¤W¥«Ävª§¬O¨ÖÁʤjÃļtªº¨Æ.
¥Ø«e¥ÎÃĶq¤@Ӽƶq¯Å(10~70¿)§C©ó dupilumab,
¤W¥««á·íADÀsÀYªºÄvª§¤O¤wÂ\¥X.
110»õ¬ü¤¸*80%*80%=70»õ¬ü¤¸(Àøµ{q»ù¬ODupilumab ¥Ø«e64%)
¦]¬°ASLAN004 ¤w2019/05/31 °ê»Ú±ÂÅv¹L¤@¦¸,©MCSL ¤w¥æ¤â¹L¤@¦¸.
©M¼ç¦b¦X§@¥ë¦ñ½Í¥¼¨Ó±ÂÅv/¨ÖÁÊ , ¥u¶·§ó·s¥«³õ°ÊºA.
¨ä¥L©MCSL ½Í§P¼Ò¦¡¬[ºc¤£·|®t¤Ó¦h.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤U¤È 06:37:13
²Ä 3163 ½g¦^À³
|
Dupilumab ¥ÎÃĶq¤@©wASLAN004 °ªªºì¦],°£¤F©M¸ÑÂ÷¨t¼Æ¤ñ¦³Ãö¥~
¥t¤@Ó¦]¯À: ¦]¬°Dupilumab¦h¤@Óµ²¦X¸ô®|(A) , ¥h©M£^C ²Õ¦¨²Ä¤@«¬¨üÅé.¦ÓASLAN004¤£¥Î.
A.²Ä¤@«¬¨üÅé(Type I Recepter)¬O¥ÑIL-4R£\ ¤Î£^C ²Õ¦¨¡A¥u¯à©MIL-4 µ²¦X¡C
B.²Ä¤G«¬¨üÅé(Type II Recepter)¬O¥ÑIL-4R£\ ¤ÎIL-13R£\1 ²Õ¦¨¡A ¥i¥H©MIL-4 ©ÎIL-13µ²¦X¡C
Dupilumab MOA -¼v¤ù www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
§Ü¤¶¥Õ¯À-4 ¤Î§Ü¤¶¥Õ¯À-13 ¥Íª«»s¾¯¥Î©óÄY««¬®ð³Ý www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤U¤È 05:54:15
²Ä 3162 ½g¦^À³
|
¥xÁÞ¤j,
¤@.¬°¦ó»¡¤½¥q²³ø»¡ASLAN004Àø®Ä¦³¾÷·|Àu©óDupilumab.
¤ñ¹ï¥H¤Udupilumab Á{§É¸ê®Æ´Nª¾.
¨C¶g¤@°w¥i¯à§¹¥þ©Î±µªñ§¹¥þ§í¨îÀu©ó¨C¤G¶g¤@°wÀø®Ä
¤G.ASLAN004 2b ³]p
«e7¶gªº°w¾¯¶q(¦@9°w)Y¨¬, ¥§¡ESAI ¤ÏÀ³²Ä8¶gªñ°ªÂI(¦p2a). IGA, 0/1 ,»Ý®É¶¡¨Ï¨ä¤ÏÀ³¨ì³Ì°ª
(1)¦]¦¹ASLAN004 2b ³]p
4¶g¤@°w*4(16¶g) 0¶g /600mg+ 4¶g/600mg =1200mg (À³¨¬°÷.) 8¶g/200mg (ºû«ù¥Î) 12¶g/200mg(ºû«ù¥Î)
¦Xp16¶g4 °w
(2)200mg/¨C¤G¶g¤@°w 8*200mg=1600mg-----¤@©w·|³]p
(3)°_©l¶q600mg + 200mg /¨C4¶g¤@°w*3¦¸=1200mg----¤]¥i¯à³]p
(4)200mg/¨C¥|¶g¤@°w 4*200mg-----¤]¥i¯à³]p
1.¹Ï1
ESAI-50 ,¨ì²Ä35¤Ñ(²Ä¤¶g), ¤w¹F°ª®p°Ï, 300mg/¨C¶g¤@°w*12¶g.(°_©l¶q600mg+300mg *3=1500mg) , www.nejm.org/doi/10.1056/NEJMoa1314768
2.ªí2
Dupilumab ¦´Á 12¶g--¨C¶g¤@°w*300mg(°_©l¶q600mg) N=55
EASI-50 ¦b²Ä29¤Ñ,¹F69% ¦b²Ä85¤Ñ,¹F85%
EASI-75 ¦b²Ä29¤Ñ,¹F35% ¦b²Ä85¤Ñ,¹F62%
IGA, 0/1 ¦b²Ä29¤Ñ,¹F18% ¦b²Ä85¤Ñ,¹F40%
¥§¡EASI°´T ¦b²Ä29¤Ñ,¹F62.3% ¦b²Ä85¤Ñ,¹F74% **************** ¹ï·Ó²Õ:N=54
EASI-50 ¦b²Ä29¤Ñ,¹F20% ¦b²Ä85¤Ñ,¹F35%
EASI-75 ¦b²Ä29¤Ñ,¹F6% ¦b²Ä85¤Ñ,¹F15%
IGA, 0/1 ¦b²Ä29¤Ñ,¹F4% ¦b²Ä85¤Ñ,¹F7%
¥§¡EASI°´T ¦b²Ä29¤Ñ,¹F17.4% ¦b²Ä85¤Ñ,¹F23.3%
----------------------------------- Dupilumab ¤T´ÁÁ{§É,¤GÓÁ{§É (¤@).300 mg Q2W(¨â¶g¤@°w/16¶g) EASI-50 65%/69% EASI-75 51%/44% EASI-90 36%/30% IGA0/1 38%/36%
(¤T)¹ï·Ó²ÕPlacebo
EASI-50 25%/22% EASI-75 15%/12% EASI-90 8%/7% IGA0/1 10%/8%
www.nejm.org/doi/full/10.1056/nejmoa1610020
2. Dupilumab 2a/2b Á{§É ,2018/SEP
journals.lww.com/jaanp/Fulltext/2018/09000/Efficacy_and_safety_of_dupilumab_for_the_treatment.10.aspx
¹Ï¤@, 8 ¶g,EASI °´T¤wªñ73.6%12¶g¤§°ªÂI
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤U¤È 04:59:14
²Ä 3161 ½g¦^À³
|
ASLAN001 ±¹ï¶PÀù¥¤Îªñ10ºØ¥é¥ÍÃÄ,µLÄvª§¤O. ¦Ó©ñ±¼³Ì¦³Ävª§¤O¥i¦¨ORR ªºHER2/IHC+3 ¥«³õ. ¥i±¤«á¨Ó¨ä¥LHER1/HER3/HER4 §Ü·½¥«³õ¤Ó¤p.
ASLAN004 n¥´Ä¹ÀsÀYDupilumab ¤Î¨ä¥é¥ÍÃÄ¥«³õªº¦¨¬°¥¼¨ÓADÀsÀY.
´N¾a,
Àø®Ä¬Û·í §C¦¨¥» :ASLAN004004 800mg-1600mg vs Dupilumab ¥Î¶q2700mg/16¶g, 30%-60%(Ó¤H¦ôp) ·À¤Ö¥´°w¦¸¼Æ: ASLAN004 (¥|¶g¤@°w) vs Dupilumab (¨â¶g¤@°w) ·À¤@¥b
°Æ§@¥Î: µLDupilumab¥ÎªÌ 25~50% µ²½¤ª¢°Æ§@¥Î.
¤½¥q5/26 ¤¤¤å²³ø ½Ð¸ÔŪ¨Ã¿Ë¦Û«ä¦ÒÅçÃÒ. aslanpharma.com/app/uploads/2020/05/20-05-19-ASLAN-CN.pdf
¤è¯à©êªº¦í,¨ì³Q¨ÖÁÊ. ¤£²`¤J«Ü®e©ö³Q¬~¥X¥h.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2020/7/20 ¤U¤È 04:36:28
²Ä 3160 ½g¦^À³
|
To:¦Ñ·à¤ÍÌ
ÂনADR«áªº³o¤@¥M¤¿ÀI²§±`,²¦³º¹ð¾Ô¹ð±Ñªº¦Ñ·à,©|¥¼¨£¥ú©ú,n¦³¶À¸d¤@¹Úªº¥´ºâ...(§Úı±o¥Ø«e³Ì¤jªº§Q°ò¬O¬ü¥x¨â¦a»ù®t°÷¤j)
¦Ü©ó·s·à¤ÍÌ,n¦n¦n¿Å¶q¦Û¤vªº@¨ü«×,§@¦n§PÂ_,§ë¸ê¦Ût¬ÕÁ«.....
¥»ª©Åwªï¦hªÅ¨Ã³¯ªº¨¥½×,¦h¦h¥æ¬y....
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤U¤È 03:54:43
²Ä 3159 ½g¦^À³
|
·P°Ê¤j
ÁÂÁÂ!
¶Ô¦b¦]¦a¯Ñ ªG¬ÛÀH¦]½t ¦]¦³ªÅ¸q¬G ¸Uªk¬Ò¥i¦¨
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G·P°Ê£®10141081 |
µoªí®É¶¡:2020/7/20 ¤U¤È 03:42:14
²Ä 3158 ½g¦^À³
|
¤Ñ©R¤j
©êºp,§Ú¤£À´ÃÄÁÙ¬O§O¨Ó¶Ã¤F ¤£¹L³o¼Ë¬Ý¨Ó¤¦~«á³o¥«³õ¤]¬On¶i¤J¾Ô°ê®É¥N¤F ÁÙ¬O¯¬§AÁȤj¿ú°Õ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤U¤È 03:36:45
²Ä 3157 ½g¦^À³
|
§ó¥¿ ASLAN004 ¬O §@¥Î±µ¦X¦b IL-13R£\1 ¡A°ß¤@ªº·sÃÄ¡A©MDupilumab ±µ¦X¦b4R£\¤£¦P ¦ý¦P¼Ë¥iªýÂ_ «¬II¨üÅ骺²Õ¦¨¡AªýÂ_IL-4¤ÎIL13 ªº«H¸¹¶Ç»¼¡C
ASLAN004 ¤Î ¦X¤@FB825 ¦ôp 5¦~«á¤W¥«
±Á{Ävª§¥«³õ±N¬O Dupilumab ¦A¹L¤~¤C¦~ ¬ü°ê±M§Q¨ì´Á¡C
¤@¯ë¥é¥ÍÃı¹ï110»õ¬ü¤¸ªº¥«³õ¡A¤£·|©ñ¹L¡C ¥B·|¥HDupilumab q»ùx80% ·m¦û¥«³õ¡C
¦ÓASLAN004 ¥ÎÃħCDupilumab 90%¥i¯à(10¿¯Å)
¥i¥|¶g¤@°wÀ³¾Ô¡A ³Ì§C ¤]¥i¯à¥Î¥|¶g¤@°wx200mg =800mg ¾¯¶q¤@¤@
800mg/2700mg =¬ODupilumab 30% ¦¨¥»§C¨¬¥H±Á{¤é«áDupilumab ¥é¥ÍÃĪºq»ù¬D¾Ô¡C
Àøµ{¾¯¶q 1600mg ¡A ¨¬¥H¨¾¤îDupilumab ¨¾¥ÍÃĪº¤j¶q¶i¤JÉ]³õ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤U¤È 03:16:36
²Ä 3156 ½g¦^À³
|
ASLAN004 ¬O §@¥Î±µ¦X¦b IL-13R£\1 ¡A°ß¤@ªº·sÃÄ¡A©MDupilumab ±µ¦X¦b4R£\
ASLAN004 ¤Î ¦X¤@FB825 ¦ôp 5¦~«á¤W¥«
±Á{Ävª§¥«³õ±N¬O Dupilumab ¦A¹L¤~¤C¦~ ¬ü°ê±M§Q¨ì´Á¡C
¤@¯ë¥é¥ÍÃı¹ï110»õ¬ü¤¸ªº¥«³õ¡A¤£·|©ñ¹L¡C¥B·|¥HDupilumab q»ù·m¦û¥«³õ¡C ¦ÓASLAN004 ¥ÎÃħCDupilumab 90%¥i¯à(10¿¯Å)
¥i¥|¶g¤@°wÀ³¾Ô¡A¤]¥i¯à¥Î¥|¶g¤@°wx200mg =800mg ¾¯¶q¤@¤@
¦¨¥»§C¨¬¥H±Á{¤é«áDupilumab ¥é¥ÍÃĪºq»ù¬D¾Ô¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G·P°Ê£®10141081 |
µoªí®É¶¡:2020/7/20 ¤U¤È 02:55:26
²Ä 3155 ½g¦^À³
|
ì¨Ó¬O¥é¥ÍÃÄ Ãø©Ç¨SÅ¥¹L¦X¤@¦³´£¨ìÁÙ¦³¤@Ó³o»ò¼F®`ªº¹ï¤â
½ä«Ü¤j°Ú,¤Ñ©R¤j ÁÙ¬O¯¬§AÁȤj¿ú°Õ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤U¤È 02:01:20
²Ä 3154 ½g¦^À³
|
Dupilumab 110»õ¬ü¤¸¡A±M§Q¨ì´Á/¥é¥ÍÃÄq»ù80% x ASLAN004 ¦A¥´80%=64»õ¬ü¤¸ ¡]¬O¥¼¨ÓÃĤýASLAN004 ªº¥i¯à¦û»â¥«³õ)
Dupilumab 300mg ¤G¶g¤@°wx16¶g /°_©l¶q600mg =2700mg
ASLAN004 ¥|¶g¤@°w, «e¤G°wx600mg¡Ï«á¤G°wx200mg=1600mg¡]¦¹Á{§É³]p¨¬¤w)
°w¶q´î¤Ö¤@¥bx ¾¯¶q ´î¤Ö¬°Dupilumab 1600mg/2700mg=60% ¡A
¥H¤WÓ¤HÆ[¹î¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤U¤È 01:25:00
²Ä 3153 ½g¦^À³
|
Àq§J ±Mªù¦b¬D¾ÔÃĤý ! ·í·sÃĤý¡C
½Ð¥Î¥@¬É¯Å²´¥ú¨Ó¬Ý ¥¼¨ÓASLAN004 ¬D¾Ô DUPILUMAB ±M§Q¨ì´Á«áªº¥«³õ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤U¤È 01:10:57
²Ä 3152 ½g¦^À³
|
MOA ¬Æ¬°Â²³æ´N¬O§í¨îPD¤@ l ¼Ð¹vÃĪ«¡C
¤wÀò20ºØ¸~½F¾AÀ³¯gªºÃįg¡C
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X-
ÃĤý¥¼¨Ó¬O Àq§J¶°¹Îªº PD¤@1 §í¨î¾¯ Keytruda ,2025¦~±N¾P222»õ¬ü¤¸¡C 2018¦~¾P72»õ¬ü¤¸¡C
Keytruda±N¦¨ºZ¾PÃĤýªÌ ¹w´ú2025¦~¾P°âÃB±N¹F222»õ¬ü¤¸ 2019.10.07 Àô²y¥Í§ÞÂø»x°OªÌ/§õªLÀõ ½sĶ
¤é«e(4)¡A¬ã¨s¾÷ºcGlobalData¹w´ú¨ì¤F2023¦~¡AÀq¨FªF(MSD)ªºPD-1§í¨î¾¯Keytruda±N¦¨¬°¥@¬É¤W³ÌºZ¾PªºÃĪ«¡A¥B¨ì¤F2025¦~¨ä¦~¾P°âÃB±N¹F¨ì222»õ¬ü¤¸¡C
¥Ñ©óÄvª§¥[¼@©M±M§Q¨ì´Á¡Aì¥ý³ÌºZ¾PÃĪ«Humira¥¿¦b¨«¤U©Y¡A¦ã§Bºû¡]AbbVie¡^ªºHumira©ó2018¦~±a¨Ó¤F¶W¹L200»õ¬ü¤¸ªº¦¬¤J¡A¨Ï¨ä¦¨¬°¥þ²yÃÄ«~¾P°âªº¤ýªÌ¡C
¦ý¨ì¤F2023¦~¡AHumira±N¥¢¥h¬ü°êªº±M§Q«OÅ@¡A¥«³õ±N¥[¤J§ó¦hÄvª§ªÌ¡A¦p2018¦~11¤ë¡AFDA§åã¤FSandozªºHyrimoz¡A¸ÓÃĬO¤@ºØHumiraªº¥Íª«¬Û¦üÃÄ¡A¦ý¥Ñ©ó¥Ø«e¨ü¨ì±M§Q«OÅ@¡A¦]¦¹n¨ì2023¦~¤~¯à¦b¬ü°ê¤W¥«¡C
GlobalData ÂåÃÄ·~¤ÀªR®vKeshalini Sabaratnamªí¥Ü¡AKeytruda¦³±æ¶W¹L¦ã§BºûªºHumira¦¨¬°¥þ²y³ÌºZ¾PªºÃĪ«¡AKeytruda¤w¦b¬ü°êÀò±o¶W¹L20ºØ¸~½F¾Ç¾AÀ³¯gªº§åã¡A¨Ã¥B¥¿«ùÄò¦V¥þ²yÂX®i¨ì·sªº¾AÀ³¯g©M¥«³õ¡C
Àq¨FªF¥ý«eªº³ø§i«ü¥X¡A2018¦~¡AKeytrudaªº¾P°âÃB¬°72»õ¬ü¤¸¡A¥BªÑ»ù¤Wº¦¤F18%¡AµØº¸µó¤ÀªR®v¹wp2019¦~ªº¾P°âÃB¬°108»õ¬ü¤¸¡A¤µ¦~¨ì¥Ø«e¬°¤îªÑ»ù¤Wº¦¤F9.7¢H¡C
GlobalData¹wpKeytruda¨ì¤F2023¦~¾P°âÃB±N¹F¨ì199»õ¬ü¤¸¡A¤ñµØº¸µó¤ÀªR®vªº¹w¦ô§ó¬°¤jÁx¡C
GlobalData¹w´ú¡A¨ì2025¦~¡A¥²ªv§´¬I¶QÄ_¡]BMS¡^©M ½÷·ç¡]Pfizer¡^ªº§Ü¾®¦å¾¯Eliquis ±N¦¨¬°²Ä¤G¤jºZ¾PÃĪ«¡A²Ä¤T¦ì¬°¥²ªv§´¬I¶QÄ_¦¬ÁʪºCelgene¡A¨ä§ÜÀùÃĪ«Revlimid¡A¦Ó²Ä¥|¦ì¬°ª½±µ»PKeytrudaÄvª§ªº¥²ªv§´¬I¶QÄ_Opdivo¡C
www.gbimonthly.com/2019/10/54139/
Àq¨FªFªº¾ú¥v
§Ú̦b¬ü°ê³QºÙ¬° Merck & Co., Inc. (Merck)¡A¦b¬ü°ê¤Î¥[®³¤j¥H¥~ªº¦a°Ï¥HÀq¨FªFÃļt (Merck Sharp & Dohme¡AMSD) ¬°¦W¡CÀq¨FªFÃļtªº¥ø·~Á`³¡¦ì©ó¬ü°ê¯Ã¿A¦è¦{ (Kenilworth, New Jersey, United States)¡A«e¨¬°¤@®a¦ì©ó¼w°ê¹F©i¬I¶ð¯S (Darmstadt) ªº¤Æ¾Ç²£«~¤½¥q¡C¦è¤¸1891¦~®É¥Ñ³ìªv¡DÀq§J (George Merck) ©ó¬ü°ê¯Ã¬ù³Ð¥ß¤À¤½¥q¡A¨Ã¥Ñ¼w°ê¶i¤f¤Æ¾Çª««~°â¤©·í¦aªºÃľ¯®v¡C
ÀHµÛ·~°È¤é¯q¦¨ªø¡A¦è¤¸1902¦~®É George Merck ©ó¬ü°ê¯Ã¿A¦è¦{¦¨¥ß Merck & Co.¡A¶}©l¥H»s³y¨ú¥N¶i¤f·~°È¡A³v¨B¼W¥[²£¯à¤Î©Ý®i¥«³õ¡A¨Ã©ó¦è¤¸1917¦~²Ä¤@¦¸¥@¬É¤j¾Ô´Á¶¡¡A¥¿¦¡µ²§ô»P¼w°ê¥À¤½¥q¤§¶¡ªºÃö«Y¡C
¦è¤¸1930¦~¥Nªì´Á¡AMerck & Co., Inc. ¶}©l±NÀç¹B½dÃ¥ÂX¤j¦ÜÃĪ«¬ã¨s¡A¨Ã±N·~°ÈIJ¨¤©µ¦ù¦Ü®ü¥~¥«³õ¡C¦è¤¸1953¦~¡A»PSharp & Dohme ¦X¨Ö¡A¥¿¦¡¦¨¥ßÀq¨FªFÃļt (Merck Sharp & Dohme¡AMSD)¡A«Ø¥ß°_¬ãµo¡B»s³y»P¾P°â¤@Åé¤Æªº¸ó°êÃÄ«~¥ø·~¶°¹Î¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤W¤È 11:46:26
²Ä 3151 ½g¦^À³
|
finance.yahoo.com/quote/arql?ltr=1
ArQule 2020¤¸¤ë ¦~³QÀq§J 27»õ¬ü¤¸¨ÖÁÊ/20¬ü¤¸¤U¥«
2018¦~¤¸ªÑ»ù1.7¬ü¤¸/ªÑ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤W¤È 11:39:37
²Ä 3150 ½g¦^À³
|
norway.twsthr.info/StockHolders.aspx?stock=6497
´²¤á¼W¥[¥u¦³¤W¶g.
400±i¥H¤W«ùªÑ, ¦b¥h¦~12¤ë11¤é149,245±i(¼W¸ê«á) ¥Ø«e150,573±i |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤W¤È 11:25:24
²Ä 3149 ½g¦^À³
|
¶È¶·4Ó¦h¤ë,¨Ó½×Â_
¥Í§ÞªÑ§ë¸ê¦b
·sÃĪº¥¼¨Ó¾P°â!
µL½t¦X´x¥OÅw³ß! ------------------------------------ ¤£¤ñ¸ûREGN Dupilumab ! ¤£¤ñ¦X¤@ Fb825 !
¤£½×MOA !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G·P°Ê£®10141081 |
µoªí®É¶¡:2020/7/20 ¤W¤È 11:18:24
²Ä 3148 ½g¦^À³
|
¤½¥qªv²z¶W°ª¤ô·Ç?
¤£n»¡¶W°ª¤ô·Ç¤F,¥un¤½¥qªv²z¦³¤ô·Ç,´N¤£·|§â¤½¥q²bÈ·d¦¨tªº,·d¦¨n¤U¥«¤F ¨Ó¥xÆW²Ä¤@¤W¥«,«o¤£¤F¸Ñ¥xÆWªk¥O,©Î»¡¤F¸Ñ«o¤£·Q¿í¦u¥xÆWªk¥O,·d¦¨¤½¥q¥²¶·¤U¥«¤F,ÁÙ»¡¥xÆWªk¥O¤ÓÄY®æ ¤W¥««e¤£ª¾¹D¹CÀ¸³W«h¶Ü?¤W¥««á¦Û¤vª±¨ìn¤U¥«¤F,¦A¨Ó©Ç¹CÀ¸³W«h ³o¬O¤°»ò¤½¥qªv²z? ¨Ó¥xÆW¦h¤Ö¿ú±¾µP?²{¦b¦h¤Ö¿ú?¦³·ÓÅU¨ì¤pªÑªF¶Ü? ¥H«e¬O«ç¼Ë?¥H«á·|¤£¤@¼Ë¶Ü?
¨C©P³£¬O1¦Ü5±iªº´²¤á¼W¥[³Ì¦h ª©¤W¤j¦Ñ¨C¤Ñ¹ª§j¤½¥q¦h¦³»ùÈ µ²ªG§l¤Þ¨ìªº³£¬O¤p´²¤á «ô°UºNºN¨}¤ß ¤£n¦A®`¤p´²¤á¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤W¤È 11:12:04
²Ä 3147 ½g¦^À³
|
17»õ¥x¹ô¸êª÷»Ý¨D¡A Y¶È¨Ì8¬ü¤¸(¥xªÑ47.2¤¸/ªÑ)¡AADR¶Ò¸ê¡A¶È»Ý3.6¸U±i¡A¸ê¥»ÃBÂX¦Ü19¡Ï3.6=22.6 »õ¥x¹ô.
·|§C»ù¨p¶Ò¯uªº´X¥G¤£¥i¯à¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤W¤È 11:04:37
²Ä 3146 ½g¦^À³
|
ª¼ÂI¤T¡B
¥¼¨Ó°µ§¹2b Á{§É13»õ¥x¹ô¡Ï1¦~Àç¹B¨ì2023¦~6¤ë¡A4»õ¥x¹ô¡C=17»õ¥x¹ô»Ý¨D¡C
¥h¦~12¤ë/3¤ê¤½¥¬ASLAN004 3¦ì ªºESAI °´T 71%(4-6¶g), ¤½¶}¶Ò¸ê»ù¤w 2.5 ¬ü¤¸/ªÑ
¤µ¦~¦~©³¤½§G24¤H(18+6) ,¥i¤§«e¹w´ú¦P¤ô凖¡A¦PDupilumab 2a ¤ô凖¡C
¤§«e³Ì°ª¬ü°ê¤À§é®vµ¹¤©8¬ü¤¸ªº¥Ø¼Ð»ù¡C
¶È¨Ì1a ¨ì1b ªº·s¼W»ùȦô¡A
¦A±ÂÅv±o§Q¥¼¦ô,³o¦¸¬O§_ª½±µ¤ÏÀ³¡H ¦³«Ý¤½¥q¥h¬ü°ê¥«³õ¦h¿ìªk»¡¡A·¾³q¥«³õ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤W¤È 10:42:26
²Ä 3145 ½g¦^À³
|
ª¼ÂI¤G¡C
2019¦~05/31 ¨È·à±d¦@¦P¬ãµo1A ±ÂÅv¤w¦³10»õ¬ü¤¸ªº§é²{»ùÈ¡A
2020/08/08 ¤°»ò³£¤£°µ, ÀH¬ü°ê¥«³õ»{¦P Dupilumab °ªÂX°ª¥¼¨Ó¾P°â¨ì110»õ¬ü¤¸¡C(¥»¨Ó¥«³õ»{¦P50»õ¬ü¤¸) ¦ÓASLAN004 §é²{»ùÈÀH¤§¼W¥[¨ì21»õ¬ü¤¸¡C
¤½¥qªv²z¬O¶W°ª¤ô·Ç¡AÀ´±o1a´Nñ¤U ¥þ²y°Ó·~¤Æ¦X¬ù¡C
¦pªG¥h¦~±ÂÅvµ¹²Ä¤T¤è¡A³o¥s°µ¨S¤ô·Çªº¸gÀç¹Î¶¤¡C
¦h°µ 1b&2b Á{§É¦hÁÈ15»õ¬ü¤¸¡C
Y¥¼¨Ó2022¦~¡AREGN «Å¥¬ DUPILUMAB ±N¦A´£°ª¾P°â¨ì180»õ¬ü¤¸¡C ²{¦b½æASLAN004 ¤£¬On¸¨¤U駡¦W¡C
¬ü°ê1000¸U¤H ¤¤¡B««× AD, 43»õ¬ü¤¸¡X¡X18¸U¤H¦~¥Î¹L.
¥«³õÂX¥R©Ê«D±`°ª¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤W¤È 10:27:13
²Ä 3144 ½g¦^À³
|
ª¼ÂI¤§¤@
²H°¨¿ü ¬O¸³¨Æ¡A«ùªÑ¶W¹LÀq§J¬°³Ì¤jªÑªF. CEO ³Å«i °õªÑ3340±i
¤½¥q³Ì¤jªÑªF§Q¯q¬O¤½¶}¶Ò¸ê¡A¤w«Å¥¬¡C
¨p¶Ò¾÷·|«Ü¤p«Ü¤p¡C
¥@¬É«e¤¤j¬Ò¦b·mAD¤jÃÄ¡C FB825 ¤§«e´N¦³«e5¤j¤¤¤G¤jÃļt¥X»ù. ©Ò¥H ASLAN004 ³Ì²×¥²¤ÏÀ³»ùÈ¡A ¦Ó¥B¸³¨Æ·|ªk³W³W©w¡A«¤j¨Æ¥ó¡A¦p±ÂÅv©Î¨ÖÁÊ ¡AYÀq§J¶°¹Î¬°·í¨Æ¤H¡A¨ä¸³¨Æ¥Nªí¡A¤£±o°Ñ»P§ë²¼¡C
³o®a¤½¥qªv²z¶W±j¡Aµ´«D¤@¯ë¤@Ó¤jªÑªF¥D¾Éªº¤½¥q¥i¤ñ¡C
·P°Ê¤j¡AÁÂÁ§A ´£¿ô! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤W¤È 10:13:49
²Ä 3143 ½g¦^À³
|
youtu.be/Gye2MM7RlsI
¦òªk¬O³Ì²z©Ê¡A¬Ò¨Ì¤£¥i±À½ªº¯u²z ¨Óªv¤ß
¯ëY´¼¼z:½t°_¡B©ÊªÅ ½t°_: ½t¥Í¦Ó»E¡A½t·À¦Ó´² ©ÊªÅ: ¦b§i¶D§Ú̲³¦]½t¥µ¥ , ªÅ¦b§_©w¤£ÅÜ©Ê¡B§_©w¥D®_©Ê¡B§_©w³æ¤@©Ê ªÅ¤£¬O¤°»ò³£¨S¦³. ¦]ªGÃö«Y
§ë¸ênÀò§Q (ªG) ²Ä¤@¦]: ¬°MOA¬O§_¥i¨ú±oÃĵý ²Ä¤G¦]:¬°MOAÄvª§¤O ²Ä¤T¦]: ¬°销°âºô¸ô
µÐ蕯¬È¦]¡A©Ò¥H¶Ô¬ã¨s¦U¦]¡C ·sÃĦ³¸ê°T¤£¹ïºÙ¤§¦]¡C»ùȥѤ¤¦Ó顕¡C
²³¥Í¬ÈªG¡AªÑ»ù¬O¤ÏÀ³¥¼¨Ó, ªÑ»ù¥ç¨ü·sÃĸê°T¤£¹ïºÙÄY«¼vÅT¡C ¤£¯Ñ¦]¦Ó²r¨DªG! ¦X²z¶Ü?
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G·P°Ê£®10141081 |
µoªí®É¶¡:2020/7/20 ¤W¤È 10:00:52
²Ä 3142 ½g¦^À³
|
²z½×¤W³o®a¤½¥q¥H°]°È¨¤«×¦Ó¨¥¤w¸g˳¬ ¨ì²{¦b¨S¦³Ë³¬ªºì¦]¬O¦]¬°É´Úµ¹¤½¥qªºª÷¥D¨S¦³©â»È®Ú,¥i¯à¦]¬°¬O¤jªÑªF ¦pªGÃīܦ³®Ä,¦pªG¤jªÑªF¤£·QÅý¤½¥q¤U¥«,¨ºÀ³¸Ó²{¦b´N§âÃıÂÅv¥X¥h ¤½¥q·íªì·|¨Ó¥xÆW±¾µP,À³¸Ó¬O¦]¬°¥xÆWªº¥Í§ÞªÑªÑ»ù«Ü®e©ö¶WÃB¤ÏÀ³ ¦p·íªìªº´¼Àº©M²{¦bªº¦X¤@,¦Ü¤Ö³£¦³¶W¹L¤T¨ì¥|¿ªº»ùȺ¦´T
¦pªG²{¦b³oÃÄ´NȤQ»õ¬ü¤¸,¨º²{¦b±ÂÅv¥X¥h ¤£¥u¤£¥Î¤U¥«,¦Ó¥B¦b³oªi¥Í§Þ¼ö¼é¤§¤U,¦b¥xªÑªº¤ÏÀ³µ´¹ï¤£¥u30»õ¬ü¤¸ ¤£¥²µ¥¨ì¨â¦~«á¥h¬ü°ê¥u¯à¤ÏÀ³21»õ¬ü¤¸
¬JµM¤jªÑªF½T©wn¤U¥«,¨ºªí¥Ü¥¼¨Ó¥u¯à¦b¬ü°ê¯u¤M¹êºjªºªí²{ °]°È¤W¦]¬°¤½¥q²bȤw¸g¬OtÈ,©Ò¥H²{¦bªºªÑ¥»¤w¸g¨S¦³·N¸q ¥¼¨Ó¤½¥qnÄ~Äò¸gÀ禳¥i¯à¨«¨âºØ¤è¦¡ ¤j´T´î¸ê«á¦A¤j´T¼W¸ê,©Î¬O¨p¶Ò ¦pªG¬OÀq§JnÁʨÖ,¨º¥i¯à´N¥ÑÀq§J¥D¾É§a,³»¦h·|Åý¦³Ãö«Yªº¤jªÑªF°Ñ»P °Ó·~¤WÁ¿¨Dªº¬O§Q¯q©M§Q®`Ãö«Y «e±ªº¹êÅç¤w¸g¥¢±Ñ,¤jÆs¨S¦³¥²n¦]¬°nÅU¤Î¤pªÑªF§Q¯q¦Ó¶Ë®`¦Û¤vÅv¯q ²¦³º«e±¤w¸g¥ý½ä¿é¤F,¤½¥q²bȤw¬Ot¼Æ,·sªº½ä§½¬O«¨Óªº,¹D¸q¤W¤]¨S¦³¹ï¤£°_½Ö ¦Ó¥B¦pªG¤£³o¼Ë°µ,¤Ï¦Ó·|©ÛPÀq§J¤jªÑªFªº¤Ï¹ï,¦]¬°¨S¦³¦bªk¥O³\¥i¤U´M¨D¤½¥qªº³Ì¤j§Q¯q
ÃĦ³¨S¦³®Ä§Ú¤£²M·¡,¦ý´NºâÃīܦ³®Ä,À³¸Ó¤]©M²{¦bªºªÑªFÃö«Y¤£¤j¤F ©Ò¥H²{¦b«ù¦³¥xÆW¨È·à¦h¤ÖªÑ¨ä¹ê·N¸q³£¤£¤j ¦pªG¬O쥻®M¨cªºªÑªF¤£·Q»{½ß,·íµM¬O¥i¥H¤j¶O©P³¹¥hÂà´«¦¨¬üªÑ,¤£¹L¥i¯à³Ì²×¤£¨£±o·|¦³¤°»ò®ÄªG ¦Ó²{¦b¤~·Q°Ñ»Pªº,§Ú¬O±j¯P«Øij¤£n,¦pªG·Qn½ä³o¤¤Q¿ªºÀò§Q,µ²ªG«Ü¥i¯à¬O¦×¥]¤l¥´ª¯
¥H¤W¶È¬OÓ¤H·Qªk,¤d¸U¤£n·í¦¨§ë¸ê¨Ì¾Ú
©êºp,¨S¦³n¾×¤H°]¸ôªº·N«ä ¥u¬O§Æ±æ¤£¤Ó²M·¡ª¬ªpªº´²¤á¤£n¦A¶TµM¶i¤J¤F ¨¯WÁÈ¿ú¤£®e©ö,§ë¸ê«e¦h¤T«ä ¨S¦³¯u¥¿¤F¸Ñª¬ªpªº¤½¥q¤£n¶Ã§ë,¤×¨ä¬On¤U¥«ªº¤½¥q |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤W¤È 09:09:03
²Ä 3141 ½g¦^À³
|
CE〇 ³ÅÁ`»¡
2021/06¡V¤§«e, ¤½¥q¥|»õ¥x¹ô¥i¥H¤äÀ³1bÁ{§É, ©Ò¥H¤µ¦~²Ä¥|©un¼W¸ê°µASLAN004 2b Á{§É. (2020/06/17 ªk»¡) 2021/07~2022/08 ¥¼¨ÓASLAN004 ¤G´Á¡Ï¤½¥qºÞ¾P¤ä¥X¡A¦ô约¦~12»õ¥x¹ô(2019/12¤ëªk説),< 13Ó¤ë 2b Á{§É¦ô/13»õ¥x¹ô
¦A¥[4»õ¡A¥i¤äÀ³¨ì 2023¦~06¤ë.
¦ôp¥»¦¸¼W¸ê¡A±N¶Ò17»õ¥x¹ô(5800¸U¬ü¤¸).¡X¡X¡X¥i¯à³Ì«á¤@¦¸.
2020¦~ 10¤ë¥÷±NADR§ï¬° ²Ä¤@¦a¤W¥« ¸ê¥»ÃB19»õ¬ü¤¸¡C
¼W¸ê¸ê¥»¬O§_¥u¼W3»õ¡A¨Ó¶Ò17»õ, 17/3 =5.6 ????ÁÙ¬O§ó¦h©Î¤Ö¡A¬Ò¦³¥i¯à¡A¤£¥i´ú.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤W¤È 08:05:27
²Ä 3140 ½g¦^À³
|
¥xÆW¦n¼F®`¡I
¥xÆWªk¥O ¨Ì¤½¥q²bȬ°t¼Æn¨D ¨È·à¤UÂd¡A¢¨Ï§ï¬ü°ê¯Ç´µ¹F§J¬°²Ä¤@±¾µP¦a¡C¡]¬ü°ê¥Í§Þ¥«È¶W¹L¥xÆW60¿) ¥xÆWªk¥O ¨Ï¨È·à±d ASLAN004, MOA¤w½T»{,¤wÀò°ê»Ú±ÂÅvªº¼ç¦b§é²{ §Q¯q ¹F10»õ¬ü¤¸¡A¦Ó¦A±ÂÅv±N¼W¦Ü21»õ¬ü¤¸¡AÄvª§¤OÀu©ó¥¼¨Ó¦~¾P°â110»õ¬ü¤¸ ¤jÃÄ Dupilumab. Â÷¶}»OÆW¡C
¥xÆWªk¥O ¨Ï Àq§J¶°¹Î ¡Ï ²H°¨¿ü ¨â¤j¸³¨Æ ¥«È/²b値 12 ¥ü¥x¹ôªº¤l¤½¥q²V¥X»OÆW¡A
¥xÆW¦n´Î¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤W¤È 07:06:52
²Ä 3139 ½g¦^À³
|
21»õ¬ü¤¸ªº¨ÖÁÊ»ù¦ôp¯uªº¶W«O¦u¡C
¤jªÑªFÀq§J 27»õ¬ü¤¸¤µ¦~ªì¨ÖÁÊArQle. ¥u¬°¦åÀù¤G½u10»õ¬ü¤¸¥ª¥k 10/11 ORR¡A 11¤Hªº1bÁ{§É¡C
Ävª§¤O¶W¯ÅüLªºASLAN004¡A¥ÑÀq§J¶°¹Î¨Óµo®i¡A§Jµo´§¨ä¨»ù©MDupilumab ÀsÀYÄvª§¤~n¶}©l¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤W¤È 06:11:29
²Ä 3138 ½g¦^À³
|
MOA www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ³o½g¤¤¤å¬ã¨s¤å³¹¤@ ´N¬O§e²{¤TÃĪºý³Ý ¤T´ÁÁ{§É¼Æ¾Ú
¥u¦³Dupilumab ¹LÃö¡A¨ä¥LLebrikizumab¤ÎTralokinumab¬Ò¥¢±Ñ¡C
Lebrikizumab & Tralokinumab MÆâA , ¥u¯àªýÂ_IL13 °T¸¹¶Ç»¼¡AµLªk§¹¥þªýÂ_IL4 °T¸¹¶Ç»¼¡A¥\¯à¤j´î75%~50%¡C
µLªkªýÂ_ A¸ô®| (2): IL4 & IL-4R£\ ¦A±µ¦XIL-13R£\1 , ²Õ¦¨ªºII«¬¨üÅé, ¦]¦Ó±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼¡A¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (signal transducer and activator of transcription 6, STAT6) ¶Ç¾É¸ô®|,¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C
¥u¯àªýÂ_B¸ô®| : Lebrikizumab ±µ¦X IL13 ªºB¡BCÁ³±Û , ¦ýIL13 & IL-13R£\1 ¤´¥i±µ¦X¡A¥u¬OµLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II«¬ ¨üÅé Tralokinumab ±µ¦XIL13 ªºA¡BDÁ³±Û ¨Ï IL13 & IL-13R£\1 µLªk±µ¦X¡A¤]µLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II «¬¨üÅé
¥H¤W¸ÑÄÀ Tralokinumab ¤T´ÁÁ{§É¹w«á«ü¼Ð¡AÀø®Ä´X¥G¥u¦³Dupilumab 50%¡C¡Aý³Ý¤T´Á¸Ñª¼¥¢±Ñ¡C
¦]Lebrikizumab , IL13 & IL-13R£\1 ¤´¥i±µ¦X¦û¾Ú IL-13R £\1, ¼vÅT0~50% IL4 °T¸¹¶Ç»¼¡C ¤]¸ÑÄÀ Lebrikizumab ¤G´ÁÁ{§É¹w«á¥Dn«ü¼Ð»P¹ï·Ó²Õ¤ñ È ¥u¦³Dupilumab 50%~75%¡C¡C ý³Ý¤T´ÁÁ{§É¸Ñª¼¡A¤GÁ{§É¡A¥u¦³¤@Á{§É¦¨¥\¡A¥t¥~¤@Ó¥¢±Ñ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/20 ¤W¤È 05:51:16
²Ä 3137 ½g¦^À³
|
Development History and FDA Approval Process for Dupixent Date Article Jun 19, 2020 Approval FDA Approves New Dupixent (dupilumab) Pre-Filled Pen Designed to Support More Convenient Self-Administration May 26, 2020 Approval FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis Jun 26, 2019 Approval FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis Mar 11, 2019 Approval FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents Oct 19, 2018 Approval FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma Mar 28, 2017 Approval FDA Approves Dupixent (dupilumab) for Eczema
www.drugs.com/history/dupixent.html
¦P¤@ÃĦhºØ¾AÀ³¯g¡AIL-4/il-13 Âù¼ÐªýÂ_´N¬O¼F®`¡A ¥þ¥@¬É°ß¤G¡CASLAN04¡ÏDupilumab (Dupixent¡^ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2020/7/19 ¤U¤È 10:51:25
²Ä 3136 ½g¦^À³
|
·PÁ¤ѩR¤j¾ã²zªºÄ_¶Q¸ê°T ¹L±Ó®ð³ÝÃĪ«¬ãµo¦¨¥\¾÷²v¤ñÀù¯gÃĪ«°ª«Ü¦h¡AASLAN004¦³¯S©w¹vÂI¤S¬O¥þ¤H·½³æ®è§ÜÅéÃĪ«¡]ASLAN004¬°Âê©wIL-13¨üÅé£\1¦¸³æ¦ì (¥çºÙ¬°IL-13R£\1) ¤§¥þ¤H·½³æ®è§ÜÅé¡^¡A¥[¤W¤w¸gª¾¹DªvÀø¯e¯fªº¾÷¨îMOA³o¤TÓ±ø¥ó¤S·|©Ô°ªASLAN004ªº¦¨¥\¾÷²v¡A§ë¸ê¥Í§ÞÂåÃĪѨä¹ê¬O¦b»PÁ{§É¸ÕÅ禨¥\¾÷²v¹ï½ä¡A¥h¦~¤Q¤G¤ë¤½§iªº¼Æ¾ÚÅý¤½¥q«H¤ß¤j¼WÅý²Ä¥|©uªº¼Æ¾Ú¥O¤H´Á«Ý ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2020/7/19 ¤U¤È 07:20:16
²Ä 3135 ½g¦^À³
|
·PÁ¤j®aºëÅPªº°T®§¤À¨É¡AÀò¯q¨}¦h |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/19 ¤U¤È 04:39:12
²Ä 3134 ½g¦^À³
|
¬ÝÀ´ ©³¤U ¼Æ¤ÀÁé MOA ¼v¤ù , ¤~¯àÁA¸Ñ ASLAN004 »ùÈ. ¤~¯à©êASLN ADR ¨ì 55¬ü¤¸/ªÑªº³Q¨ÖÁÊ»ùÈ
·íDupilumab n½æ110»õ¬ü¤¸,¬°¦óASLAN004¥i³Q¦ô½æ50~65»õ¬ü¤¸?
¤@Ãijq,¥|Ãĺɳqª¾
1.ASLAN004 MOA -¼v¤ù aslanpharma.com/drug/aslan004/
2.Dupilumab MOA -¼v¤ù
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
MOA www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¤@¡BII«¬¨üÅé(TYPE II RECEPTER): ¡X¡X¹L±Ó©Êµoª¢¤ÏÀ³ ¸ô®|:
¤»Ó¥D¨¤: °tÅé : (1)IL-4(¤¶¥Õ¯À4¸¹) ,(2)IL-13 (¤¶¥Õ¯À13¸¹) ¨ü¾¹ : (3)IL-4R£\ , (4)IL-13 R£\1 (5)II«¬¨üÅé (TYPE II RECEPTER): (²Õ¦¨ A : IL4 ±µ¦XIL-4R£\ ¦A±µ¦X IL-13 R£\1) (²Õ¦¨ B : IL13 ±µ¦XIL-13R£\1 ¦A±µ¦X IL-4 R£\)
(6)pSTAT6
1. IL-4¤ÎIL-13 ¬Ò¥i ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³ , ¦³¥H¤UA¡BB¨â±ø¸ô®|
A: ¥ÑIL-4 ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¸ô®|
¸ô®|(1). IL-4 ±µ¦X IL-4R£\ = IL4& IL-4R£\ (2). IL4& IL-4R£\ ¦A±µ¦X IL-13 R£\1=II «¬¨üÅé (²Õ¦¨II«¬ ¨üÅé) (3). II «¬¨üÅé±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼ (4). ¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6) (signal transducer and activator of transcription 6, pSTAT6) ¶Ç¾É¸ô®|, (5) ¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C
B: ¥ÑIL-13 ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¸ô®|
¸ô®|(1). IL-13 ±µ¦X IL-13R£\1 = IL13& IL-13R£\1 (2). IL13 & IL-13R£\1 ¦A±µ¦X IL-4 R£\= II«¬ ¨üÅé (²Õ¦¨II «¬¨üÅé) (3). II «¬¨üÅé ±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼ (4). ¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6) (signal transducer and activator of transcription 6, pSTAT6) ¶Ç¾É¸ô®|, (5) ¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¤G .Dupilumab¤ÎASLAN004 ¬Ò¥i¦P®ÉªýÂ_IL4¤ÎIL13 °T®§¶Ç¾É¸ô®|
Dupilumab µ²¦XIL-4R£\ & ASLAN004 µ²¦XIL-13 R£\1¤§¾÷Âà(MOA) ¬Ò¥i¦P®ÉªýÂ_ II«¬¨üÅ餧²Õ¦¨¦ÓÁקKÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6)¤§¬¡¤Æ¡A¤]ÁקK¹L±Ó©Êµoª¢¤ÏÀ³. ¨Ï±oA&B ¸ô®|¤¤¤£²£¥Í(2)~(5)¸ô®|¡C
¤T¡BLebrikizumab & Tralokinumab M〇A , ¥u¯àªýÂ_IL13 °T¸¹¶Ç»¼¡AµLªk§¹¥þªýÂ_IL4 °T¸¹¶Ç»¼¡A¥\¯à¤j´î75%~50%¡C
µLªkªýÂ_ A¸ô®| (2): IL4 & IL-4R£\ ¦A±µ¦XIL-13R£\1 , ²Õ¦¨ªºII«¬¨üÅé, ¦]¦Ó±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼¡A¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (signal transducer and activator of transcription 6, STAT6) ¶Ç¾É¸ô®|,¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C
¥u¯àªýÂ_B¸ô®| : Lebrikizumab ±µ¦X IL13 ªºB¡BCÁ³±Û , ¦ýIL13 & IL-13R£\1 ¤´¥i±µ¦X¡A¥u¬OµLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II«¬ ¨üÅé Tralokinumab ±µ¦XIL13 ªºA¡BDÁ³±Û ¨Ï IL13 & IL-13R£\1 µLªk±µ¦X¡A¤]µLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II «¬¨üÅé
¥H¤W¸ÑÄÀ Tralokinumab ¤T´ÁÁ{§É¹w«á«ü¼Ð¡AÀø®Ä´X¥G¥u¦³Dupilumab 50%¡C
¦]Lebrikizumab , IL13 & IL-13R£\1 ¤´¥i±µ¦X¦û¾Ú IL-13R £\1, ¼vÅT0~50% IL4 °T¸¹¶Ç»¼¡C ¤]¸ÑÄÀ Lebrikizumab ¤G´ÁÁ{§É¹w«á¥Dn«ü¼Ð»P¹ï·Ó²Õ¤ñ È ¥u¦³Dupilumab 50%~75%¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/19 ¤W¤È 10:36:22
²Ä 3133 ½g¦^À³
|
4ºØAD¼Ð¹v·sÃľú¥v¡C
¤@¡BDupilumab---REGN ¤½¥q 2012-2014¦~ ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È7»õ¬ü¤¸. 2017¦~ªì ¥«³õ¤ÀªR®v¦ôDupilumab ¦~¾P°â°ªÂI È50»õ¬ü¤¸.(¤T´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 380%~450%) 2017¦~3¤ëÀòÃĵý,3Ó¤ëREGN ªÑ²¼¥«È¤jº¦140»õ¬ü¤¸. 2019¦~¦~¾P°â23»õ¬ü¤¸ 2019¦~12¤ë REGN ªºCEO ¤½¶}«Å¥¬ Dupilumab ¦~¾P°â°ªÂI ¹F110»õ¬ü¤¸ 2020¦~ 7¤ë7¤éREGN ªñ6Ó¤ë ªÑ²¼¥«È¤jº¦300»õ¬ü¤¸. ---------------------- ¤G¡BLebrikizumab----§¨Ó¤½¥q 2017/8/8 Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv, «eª÷8000¸U¬ü¤¸¡A 2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C
±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A ¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A °£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸, ¥[¾P°â¤À¼í<= 10%.
2017¦~¦~©³¶}©l280¤H2b AD Á{§ÉÎcªG 2019¦~¤¸¤ë¤½§G2b AD Á{§É.(¤G´Á¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ 290%~380%) 2019¦~10¤ë ¶i¤J 2Ó400¤H,¦Xp800¤Hªº¤T´Á ¤¤-««×ADÁ{§É 2020¦~¤¸¤ë Dermira 11»õ¬ü¤¸³Q§¨Ó¨ÖÁÊ,¥t¶·©Ó±µDermira¤ä¥I¤W´åù¤óROCHE ,2017¦~ªº±ø¥ó: ¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A °£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù12.35»õ¬ü¤¸, ¥[¾P°â¤À¼í<= 10%.
------- ¤T¡BASLAN004-¨È·à±d 2014¦~ ¨È·à±d©MCSL ñ¬ù¦@¦P¶}µo°µ§¹·§©À©ÊÁ{§É«á¦A±ÂÅv ¥þ²y°Ó·~¤Æ,§Q¼í§¡¤À. 2019/05/31 ¨È·à±d ¡A½T»{M0A¡C ñ¤U¥þ²y°Ó·~¤Æ,·s¦X¬ù±ø¥ó¦p¤U: ¨È·à±d-KY ±N©ó ASLAN004 ¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥I CSL ºµ§´Ú¶µ 3,000 ¸U¬üª÷¡C CSL ±N¥i¦¬¨ú³Ì°ª¹F 9,500 ¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B ³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷¥H¤Î¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü 10%¤§Åv§Qª÷¡C
¦å²G¤¤ASLAN004 ÃĶq 1mg/L, ´N¥i¥H§¹¥þ§í¨î¡A60¤½¤çÅé«x8%=4.8 L ¦å²G , ²z½×¤W¦å²G¤¤ ¥§¡«O«ù4.8mg ,´N¥i§¹¥þ§í¨î ¬°¦P¯Å®t¤@Ó¶q¯Å(10¿)¥H¤W¥ÎÃĶq. Dupilumab ,¤¤¤å¥é³æ¡A600mg°_©l¶q¡A²Ä7¤Ñ¦å²G¤¤ ÃĶq ¥§¡70ug/ml=70mg/L, 70x4.8=326mg ¥¼¨Ó±j±À¥|¶g¤@°w¨Ó·m¥«³õ¡A¨ä¥L¤TÃĬҨâ¶g¤@针¡A
2019/12/05 ¤½¥¬ ASLAN004 ªvÀø ¤T¦ìAD ,200mg/¨C¶g¤@°w(4-6¶g)¡AEASI ¥§¡°´T71%, ¶W¶Vdupilumab 2a Á{§É ,300mg/¨C¶g¤@°w(600mg°_©l¶q)¡A²Ä¤¶g¥§¡EASI ¥§¡°´T67% .
------- ------------ 2020/06/29 ªÑªF·|³ø§i : p¹º2022¦~ASLAN004 °µ§¹2b ´Á¤¤¤@««×ADÁ{§É¦A±ÂÅv . ¼ç¦b¶R®a¤w°Ñ»P2bÁ{§É¬ã°Q.(¦ô¬°¤jªÑªF/ݸ³¨Æ:Àq§J¤jÃļt.)¡B ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ¥|¡BTralokinumab 1.2016¦~,LEO Pharma©ó2016¦~±qªü´µ§Q±d¡]LSE¡GAZN¡^Àò±o¤F¥Ö½§¯e¯f¤¤ªºtralokinumabªºÅv§Q¡A¸Ó¥æ©ö¯A¤Î¦V^°ê-·ç¨å»sÃÄ¥¨ÀY¹w¥I1.15»õ¬ü¤¸¡A¥H¤Î°ª¹F10»õ¬ü¤¸ªº°Ó·~¬ÛÃö¨½µ{¸O©M²£«~¾P°âªº¯S³\Åv¨Ï¥Î¶O¤ñ¨Ò¤£¶W¹L¦Ê¤À¤§¤Q
LEO Pharma reveals positive top-line Phase III results for tralokinumab(¤T´ÁADÁ{§É¤w¸Ñª¼¦¨¥\,2019/12 ¤ë)
Tralokinumab ¤T´Á¥Dn«ü¼Ð»P¹ï·Ó组¤ñÈIGA,0/1¬°2
Dupilumab ¦P¼Ë¤ñÈ ¬°3.8/4.5 Àu©óTralokinumab100%
Lebrikizumab ¤G´Á¦P¼Ë¤ñÈ2.9 Dupilumab Àu©ó 3.8/2.9=131% 4.5/2.9=155% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/19 ¤W¤È 09:06:55
²Ä 3132 ½g¦^À³
|
«ÂI¦b ¦U¦ì¤j¤j ¦³µL¼W¥[ ¦Û¤v§ë¸ê·sÃÄ¥\¤O¡C
½Ñ¦æµL±`¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2020/7/19 ¤W¤È 08:45:25
²Ä 3131 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j¤j¡A¤é«áÂà¬üªÑ«á¡A½Ñ¦ì¤j¤j¬O§_ÁÙ·|¦b¦¹µoªíµû½×©M«n¸ê°T¡AÁÙ¬O·|Â੹¥L³B°Q½×©O¡H·PÁ¤j®a´£¨ÑÄ_¶Q·N¨£ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/19 ¤W¤È 07:48:20
²Ä 3130 ½g¦^À³
|
¡B¨úµý¤G¤j¼Ð·Ç 1.¦w¥þ©Ê 2.¥Ø«e¨Ì¤@/¤G´ÁÁ{§É资®Æ¡A¤w¥i¨ú±o«¤j¯e¯fªºÁ{®ÉÃĵý¡C ¦ý¤´须°µ¤T´ÁÁ{§É¡C
¤T´ÁÁ{§É
³q±`PÈ<0.001 ¤ñ¸û¦³¥«³õ»¡ªA¤O¡C ¥Dn«ü¼Ð ¹êÅç组/¹ï·Ó¤ñ>1.8¿¥ª¥k¡AN>300 PÈ<0.001
Dupilumab ¤T´ÁÁ{§É AD¥D§ó«ü¼Ð IGA,0/1 ¤ñÈ3.8-4¿¡AN>400 P<0.0001
ASLAN004 ¦³Àu©óDupilumabªº¾÷·|¡C ¦]¬°Dupilumab 16 ¶gx8¦¸¡A9°wx300mg=2700mg ©|¥¼§¹¥þ§í¨î¡C 2a¤@¶g针¡AÀu©ó2b¨â¶g¤@针¡A10%-14%¥§¡«ü¼ÐÀø®Ä¡C
¤G¡BASLAN004Ävª§¤O 1¡AM0A¤w³Q½T»{ MOA¦PDupilumab ¥i¦P®É§í¨îIL-4¤ÎIL-13°T¸¹¶Ç¾É¡C 2.Á{§ÉÀø®Ä ASLAN004¦³Àu©óDupilumab¾÷·| ¤G/¤T´ÁÀø®Ä¥Dn«ü¼ÐIGA¡A0/1¤ñÈ Dupilumab 1 >Lebrikiumab 0.75> 0.5Tralokinumab
2.1 2019.12.03¤½§G1b200mg «e¤T¦ìAD4-6¶g¥§¡EASI°´T71%,²Ä8¶g¦ô°¨ì77%-78% ¦ÛµM±µªñDupilumab 2a ¥§¡ ESAI°´T73.6%
3.¥´°w频²v16¶gÀøµ{ ASLAN004¥|¶g¤@°wªº预´Á Dupilumab ¤G¶g¤@°w 4¡A°Æ§@¥Î Dupilumab ±wªÌ25%-50%¦³µ²½¤ª¢ ASLAN004µL
¤T¡B¨È·à¦~³ø¤w°O载2022¦~°µ§¹2bADÁ{§É´N±ÂÅv¥X¥h¡A 2019¦~1O¤ë¡A¼ç¦b¦X§@¥ë¦ñ°Ñ¥[«áÄòÁ{§É¤Î±ÂÅv¬ã°Q¡C
2019¦~©³¤@ªi资遗 员¤u쥻56¤H¡A¥Ø«e23¤H¡C
²Ä¥|©u¤½§G´Á¤¤¸Ñª¼«á¼W资¡C°µ2bÁ{§É ¥i¯à³Ì«á¤@¦¸¡C-
¬ãµo¨â¤j°ÆÁ`¡A¤@°h¡A¤@¨óijÂ÷¾¡C
n³Q¨ÖÁʾ÷·|¤j¡C ¤£»Ýn°ª额©w资¥»¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ¦n©_°ÝÓ°ÝÃD¡A³q±`ÃB©w¸ê¥»ÃB³]©w¸û°ª¡A¬O¬°¤F¤é«áµo¦æ·sªÑªº¤è«K¡F¤§«á¤w½T©w¤@©w·|¶Ò¸ê¥H¤ä«ù«áÄòÁ{§É¸ÕÅ窺¶i¦æ¡A¬°¦óÁÙn´î¸ê?
YÀq§J¶°¹Î±µ¤âASLAN004¤T´ÁÁ{§É¤Î¥þ²y¾P°â
n½æASLAN004¡A50-65»õ¬ü¤¸¡A«ÜÃø/ÁÙ¬O«Ü²³æ¡H
¬ü°êÀq§J+¼w°êÀq§J ¶°¹ÎÀ禬380»õ¬ü¤¸¡C ¥«È2000»õ¬ü¤¸¡C
¬D¾ÔDupilumab ADÀsÀY¡A«Üºë±m¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/19 ¤W¤È 05:42:00
²Ä 3129 ½g¦^À³
|
·sÃĪѤô«Ü²` 1.¥i¨úÃĵý§_¡HADÃĵý100%¥i¨ú±o¡C 2.ÃÄ«~Ävª§¤O?AD¼Ð¹v¤¤¡A¦P级³ÌÀu 3.¥þ²y°Ó·~¤Æ¹Î¶¤¬O§_û{üL¡H¥@¬É²Ä¤GÀq§J¨Ó销ASLAN004¾÷·|¤j¡C
4¡AªÑ»ùÂ÷À³¦³»ùÈ40-50¿¡C
¥H¤W4ÂI¡A¥R¥÷²z¸Ñ¡A¤~¯à©êªº¦í¡C ¦Ê¦~¤£©ö¨£ªº¥Í§Þ¶Â°¨¡C
Y¦U¦ì¤j¤j ¦³¦p¦¹¦nªº¼Ðªº¡A ¤£ªø§ë¡A¬Û«HÀ³¸Ó¦³§ó¦nªº¡C
¯¬ºÖ ¦U¦ì¤jÁÈ¿ú¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gtimchan51610148760 |
µoªí®É¶¡:2020/7/19 ¤W¤È 02:04:25
²Ä 3128 ½g¦^À³
|
§Ú¤W°ê¥~ºô¯¸¬d¸ßadrªº«OºÞ¶O aslnºÞ²z¶O¦¨¥ß¤T¦~¨ì²{¦b³£¬O0.03 usd ©Ò¥H§A¦³6497 1000ªÑªº¸Ü´N¬Oadr 200ªÑ * 0.03 = 6 usd = 180 ¥x¹ô §A¦³1±i´N¬O 180¥x¹ô §A¦³10±i´N¬O 1800¥x¹ô §A¦³100±i´N¬O 18000¥x¹ô |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gtimchan51610148760 |
µoªí®É¶¡:2020/7/19 ¤W¤È 12:31:36
²Ä 3127 ½g¦^À³
|
§Ú¦b³oÓª©¦Ñ¦¹ï¥xªÑ¨È·à±d6497¬Ý±o«ÜªÅ «Ü¦hª©¤ÍÀ³¸Ó«Ü°Q¹½§Úªº¨¥½× ! ®ð±o¤úÄoÄo... ¤£¥i§_»{§Ú¤§«eµo¨¥¹Lªº¨¥½×³£¤@¤@ÅçÃÒ ¬Æ¦Üaslan001¸Ñª¼«e´Nn¤j®a½æ±¼....¨ºÓ®ÉÔª©¤Í³£¤£¥H¬°µM ..... µM«á¨È·à±d6497ªÑ»ù¯}©³¦A¯}©³ µM«á·Ç³Æ¤U¥« ..... ¦ý±µ¤U¨Ó§Ú±N¦ø¾÷¶R¶i6497µ¥Âà´«adr aslnªÑ¥»´Nºâ¼W¥[¨ä¹ê¦b¬üªÑ¥«³õÁÙºâ¬O¤pªÑ¥»ªº¤½¥q ! ¦³¨Ç¥Í§Þ¤½¥qªÑ¥»¤ñ¨È·à±d¤j¤Q´X¿ µM«át¶Å¤ñ¨È·à±d§ó¦h ªÑ»ù¦b8~¯}¦Ê³£¦³...Á`¤§¨È·à±d6497ªÑ»ù¤w¸g¤£«n ! ¦ý¦pªG¦³§ó§C»ù §Ú·|«i´±·m¶i ! ¤£µu½u ´N©é¤@Óq4¼Æ¾Ú ! ¤U©P±Nºò¨n6497·|¶^´X®Ú°±ªO ¶^¶V¦h®Ú°±ªO¶V¦n ¥un¶^°±Ãz¶q·Ç³Æ¥´¶}...§Ú´N·|¥ß¨è¶}©l·m¶i ! ²¦³º«ù¦³Ó¦ì¼ÆªÑ²¼§ë¸êªÌ¤£¥i¯àªá¨º¨Ç®É¶¡¸ò¤âÄò¶O¥h¿ì²z¤¾ªøªº¤å¥ó¬yµ{ ! ©Ò¥H½æÀ£¤@©w·|¥XÅ¢ ... n¶X³o¾÷·|¨Ó·mµu ! ¦ý§ë¸ê·|¦³·ÀI ¤£¬OÃĹªº ©Ò¥H½Ð¿Å¶q¦Û¤vªº¯à¤O¦A¥h¶R !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2020/7/18 ¤U¤È 11:49:33
²Ä 3126 ½g¦^À³
|
¦A¥[¤@½g¡A
²z½×¤W·íµM¬O¥i¦æªº¡A°ÝÃD¬O¶O¥Î½Ö¥X¡H·sªºadr¤@ªÑ¯àȦh¤Ö¿ú¡H¨å«¬ªºµo¦æadr¬O¤½¥qµo¥xÆW·sªÑ²¼¡A¦V¬ü°êSEC¡]ÃÒºÞ·|¡^¥Ó½ÐÂন¬ü°êªºadr¡A½æadrµ¹§ë¸ê¤H¡]¬ü°ê¤H©Î¥xÆW¤H©Î¨ä¥¦¤H¡A¦b¬ü°ê¦³ÃÒ¨é±b¤áªÌ¡^¡C¦Vsec¥Ó½Ð¬On¿úªº¡A¬ü°ê°UºÞ»È¦æ«OºÞ¥xÆWªÑ²¼»P¥X¨ãadr¤]¬On¿úªº¡Aµo¦æ·sªÑ¤½¥q¦¬¨ì¿ú¥i¥h¤ä¥Iµo¦æadrªº¬ÛÃö¶O¥Î¡C¨È·à±dªº®×¨ÒÅܦ¨¦¬¦^¥xÆWªÑ²¼¡A¦Aµoadrµ¹ìªÑªF¡A¨º¤¤¶¡²£¥Íªº¶O¥Î³£¥ÑìªÑªF¤ä¥I¡C§Ú±j¯PÃhºÃµo¦æadr¶O¥Îµ¥¡A¥i¯à³£¤ñ²{¦b¥xÆWªÑ»ùÁÙn°ª¡F¦A»¡¨È·à±d¬ü°êadrªÑ¼Æ¤@¤U¤l¼W¥[¨º»ò¦h¡A¤½¥q²bȤS¬Otªº¡AadrªÑ»ù¯à¦³¦h°ª¡H´«¦¨adtÁÙ¤£¬O¤@¼Ë¤£È¿ú¡I¨ºªá¿ú¥hÂà´«¦³·N¸q¶Ü¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2020/7/18 ¤U¤È 11:43:04
²Ä 3125 ½g¦^À³
|
¥tÃþ¬Ýªk¡A¤À¨É¦U¦ì¤j¤j¡A©|¬è¦U¦ì¤j¤j¤À¨É¬Ýªk¡A
³o®a¤½¥q«Ü¤£±o¤F¡I¦P¤@¤Ñ¥i¥H¥xÆW¶^10%¡A¬ü°êº¦10%¡F¤½¥q²bȬOtªº¡A«o¦³²{ª÷¥x¹ô¥|»õ¡Aªí¥Ü¤jªÑªF¹çÄ@É¿úµ¹¤½¥q¡A¤£Ä@²{ª÷¼W¸ê¡]¯}²£©Î¤½¥q½æ±¼¡A¶·¥ýÁٶš^¡C²Ä¤@ÓÃÄ«~°µ¥¢±Ñ¤F¡A²Ä¤GÓÃÄ«~³s²Ä¤@´Á³£ÁÙ¨S°µ§¹¡A¤½¥q¥«ÈÁÙ¤¤d¸U¬ü¤¸¥ª¥k¡A¬Û¸û¦]µØ¥«È¬O¤C¤d¤»¦Ê¸U¬ü¤¸¡C©Ò¥H§Úµ´¤£¶RKY¤½¥qªÑ²¼¡A¶R¤F¥i¯à¥ý³Q¢Ù¤@¹y¡A¿ú¦A³Q¢ç¨«¡A«ç»ò¦ºªº³£¤£ª¾¹D¡A«¢¡I«¢¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/18 ¤U¤È 08:43:15
²Ä 3124 ½g¦^À³
|
¤p资¤j¡A
²Ä¥|©u¤½§G´Á¤¤¸Ñª¼«á¼W资¡C°µ2bÁ{§É ¥i¯à³Ì«á¤@¦¸¡C-
¬ãµo¨â¤j°ÆÁ`¡A¤@°h¡A¤@¨óijÂ÷¾¡C
n³Q¨ÖÁʾ÷·|¤j¡C ¤£»Ýn°ª额©w资¥»¡C
¥H¤WÓ¤H²q´ú¡C
¡G¤p¸ê¦V«e½Ä10149354 µoªí®É¶¡:2020/7/17 ¤U¤È 10:55:33²Ä 3106 ½g¦^À³ ÁÂÁ ¤Ñ©R¤jªº¦^ÂСC
¦n©_°ÝÓ°ÝÃD¡A³q±`ÃB©w¸ê¥»ÃB³]©w¸û°ª¡A¬O¬°¤F¤é«áµo¦æ·sªÑªº¤è«K¡F¤§«á¤w½T©w¤@©w·|¶Ò¸ê¥H¤ä«ù«áÄòÁ{§É¸ÕÅ窺¶i¦æ¡A¬°¦óÁÙn´î¸ê?
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/18 ¤U¤È 03:27:04
²Ä 3123 ½g¦^À³
|
The company expects to announce interim, unblinded data from the study in the fourth quarter of 2020. ½Ķ§ó¥¿-2
¸Ó¤½¥q¹wp±N¦b2020¦~²Ä¥|©u«×¤½§G¸Ó¬ã¨sªº´Á¤¤¸Ñª¼¼Æ¾Ú¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/18 ¤U¤È 03:20:32
²Ä 3122 ½g¦^À³
|
This move is also in line with the shift in our commercial focus towards the U.S. market as we prepare to initiate a Phase 2b study of ASLAN004 in atopic dermatitis in 2021.¡¨
½Ķ§ó¥¿
¦¹Á|¤]»P§Ú̷dzƦb2021¦~±Ò°ÊASLAN004¦b¯SÀ³©Ê¥Öª¢ªº2b´ÁÁ{§É¬ã¨s¤¤ªº°Ó·~«ÂIÂà¦V¬ü°ê¥«³õ¬Û¤@P¡C¡¨ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/18 ¤U¤È 03:15:37
²Ä 3121 ½g¦^À³
|
GOOGLE ½Ķ¤§ ·s»D½Z
¨È·à±d»sÃÄ«Å¥¬±N¨ä¥DnªÑ²¼¤W¥«¦Ü¯Ç´µ¹F§J¡A¨Ã±q¥x¥_¥æ©ö©Ò°£µP 2020¦~7¤ë17¤é¡A·s¥[©Y¡V±Mª`©óÁ{§É¶¥¬q§K¬Ì¾Ç©M¸~½F¾Çªº¥Íª«»sÃĤ½¥qASLAN Pharmaceuticals¡]Nasdaq¡GASLN¡ATPEx¡G6497¡^¤µ¤Ñ«Å¥¬«Å¥¬¶i¤@¨B¦b¯Ç´µ¹F§Jº¦¸¤½¶}µo¦æªº¶i®i¥þ²y¥«³õ¡]¡§ Nasdaq¡¨¡^¨Ã¦¬¨ì¥x¥_¥æ©ö©Ò¡]TPEX¡^ªº°h¥«³qª¾¡A³o¬OTPEx°h¥«¹Lµ{¤¤ªº¹w´Á¨BÆJ¡C¸Ó¤½¥q±N«O¯d¨ä¦b¬ü°ê¯Ç´µ¹F§J¦b¬ü°ê¯Ç´µ¹F§J¤W¥«ªº¬ü°ê¦s°UªÑ²¼¡]ADS¡^¡A¨Ã¥B¥»¤½§iªº²{¦³«ù¦³¤HµL»Ý±Ä¨ú¥ô¦ó¦æ°Ê¡C ASLAN Pharmaceuticalsº®u°õ¦æ©xCarl Firth³Õ¤h»¡¡G¡§Å²©ó§Ṳ́£¦A¨üTPExªk³Wªº¬ù§ô¡A§Ú֦̾³§ó¤jªºÆF¬¡©Ê¡A¦]¦¹±N¤½¥q¦b¯Ç´µ¹F§Jªº¥Dn¤W¥«Åܧ󬰯Ǵµ¹F§J¡A±N¼W±j§ÚÌÄw¶°¸êª÷ªº¯à¤O¡C¹L¥h¤»Ó¤ë¤¤¡A§ÚÌ90¢HªºÃÒ¨é¥æ©ö³£¦b¯Ç´µ¹F§J¶i¦æ¡A¦Û2017¦~¥H¨Ó§Ú̦b¥xÆW¥¼Äw¶°¥ô¦ó¸êª÷¡C¦¹Á|¤]²Å¦X§Ú̷dzƶ}©l¦V¬ü°ê¥«³õÂಾ°Ó·~«¤ß¦b2021¦~§¹¦¨¤FASLAN004¦b¯SÀ³©Ê¥Öª¢¤¤ªº2b´Á¬ã¨s¡¨¡C ASLAN¹wp¨ä´¶³qªÑ±N©ó2020¦~8¤ë25¤é°±¤î¦bTPEx¤W¥æ©ö¡A¨Ã¥BTPExªk³W±N¦b¦¹«á¤£¤[°±¤î¾A¥Î¡C¸Ó¤½¥q´¶³qªÑªº«ù¦³¤H¥i¥H¦b2020¦~9¤ë25¤é¤§«e¥Ó½Ð±N¨äªÑ²¼Âà´«¬°¬ü°ê¦s°U¾ÌÃÒ¡A¹wpÂà´«±N¦b10¤ë©³¤§«e§¹¦¨¡C ASLAN¥Ø«e¥¿¦b©Û¶Ò±wªÌ°Ñ¥[ASLAN004¦b¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢ªº1´ÁÀH¾÷¡AÂùª¼¡A¦w¼¢¾¯¹ï·Ó¦h¾¯¶q»¼¼W¬ã¨sªº¤TÓ¾¯¶q²Õ¤¤ªº²Ä¤GÓ¡CÀHµÛ·s¥[©Y¬F©²¹ï¹K¨îCOVID-19¶Ç¼½ªº¨î³v¨B¨ú®ø¡A¹wp±N©ó8¤ë«·s¶}©l©Û¶Ò±wªÌ¡C¿D¤j§Q¨È©M¬ü°êªººô¯¸¤]·Ç³Æ¤W½u¥H¥[§Ö©Û¸u³t«×¡C¸Ó¤½¥q¹wp±N¦b2020¦~²Ä¥|©u«×¤½§G¸Ó¬ã¨sªºÁ{®É«Dª¼¼Æ¾Ú¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/18 ¤U¤È 03:06:34
²Ä 3120 ½g¦^À³
|
¥xÁÞ¤j, 2020/07/17 ·s»D½Z
¦p¤U¡G 2021¦~ ±N啓°Ê ASAN004 2b ADÁ{§É¡C
PRESS RELEASE
ASLAN PHARMACEUTICALS ANNOUNCES THE MOVE OF ITS PRIMARY LISTING TO NASDAQ AND DELISTING FROM TAIPEI EXCHANGE Singapore, July 17, 2020 ¡V ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced further progress towards a primary listing on the Nasdaq Global Market (¡§Nasdaq¡¨) and receipt of a Notice of Delisting from the Taipei Exchange (¡§TPEx¡¨), an expected step in the TPEx delisting process. The company will retain its listing of American Depositary Shares (¡§ADS¡¨) on Nasdaq in the United States and existing holders of ADS do not need to take any action as a result of this announcement. Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: ¡§Changing the company¡¦s primary listing to Nasdaq will enhance our ability to raise capital given the greater flexibility afforded to us when we are no longer subject to TPEx regulations. 90 percent of trading in our securities the last six months has taken place on Nasdaq and we have not raised any capital in Taiwan since 2017. This move is also in line with the shift in our commercial focus towards the U.S. market as we prepare to initiate a Phase 2b study of ASLAN004 in atopic dermatitis in 2021.¡¨ ASLAN expects its ordinary shares to cease trading on TPEx on August 25, 2020, and TPEx regulations will cease to apply shortly thereafter. Holders of the company¡¦s ordinary shares can apply before September 25, 2020, to convert their shares into ADS and it is anticipated that the conversion will be completed before the end of October. ASLAN is currently recruiting patients into the second of three dose cohorts of its Phase 1 randomised, double-blind, placebo-controlled multiple ascending dose study of ASLAN004 in moderate to severe atopic dermatitis. Recruitment of patients into the study is expected to restart in August as restrictions put in place by the Singapore government to contain the spread of COVID-19 are gradually lifted. Sites in Australia and the U.S. are also preparing to come online to accelerate recruitment. The company expects to announce interim, unblinded data from the study in the fourth quarter of 2020. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/18 ¤U¤È 02:51:06
²Ä 3119 ½g¦^À³
|
¹ï, ¦]¬°¤Ó¦³§â´¤¡A¥¼¨ÓASAN004 ¼Æ¾Ú·|¡Ö¡× Dupilumab
¦X¤@¡AFB825 ¤´¶·°µ 2a IV90¤HÁ{§É¡C
¥¼¨Ó2b SC ,¥ÑLEO±µ¤â ¥i¯à¶·¦p ¥Lªº¬Û¦üÃÄ Xolair/³ß·ç¼Ö ¡]¦P¼Ë ±i¤l¤å³Õ¤h©Ò¬ãµo) IgE ¼Ð¹vÃĪ« ¨Ì¥Íª««ü¼ÐIgE ¡AÅé«¡A¦³¤£¦P°w¾¯¶q¡C¤Î¥´°wÀW²v¡C
³ß·ç¼Ö ª`®g²G¾¯ 150 ²@§J/²@¤É(¹w¥R¶ñª`®g°wµ© )¤@¤@¤@¤¤¤å¥é³æ
Xolair R ¥»ÃÄ¥ÑÂå®v¨Ï¥Î ¾AÀ³¯g ¹L±Ó©Ê®ð³Ý Solution for injection, 150mg/ml in pre-filled syringe |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2020/7/18 ¤U¤È 01:10:48
²Ä 3118 ½g¦^À³
|
¤Ñ©R¤j ¨Ì¾Ú°Ý¹F½g13 CEO´£¨ì¹wp©ó 2020 ¦~²Ä¥|©uµo¥¬ ASLAN004 ¦h¾¯¶q»¼¼WÃĪ«¸ÕÅç(MAD)´Á¤¤¼Æ¾Ú¤Î·§©À©Ê¸ÕÅç¼Æ¾Ú¨Ã©ó 2021 ¦~®i¶}²Ä 2b ´ÁÁ{§É¸ÕÅç¡C
Ó¤H»{¬°¤@´Á´N·|§¹¦¨¤@¯ë¤G´Á¤~·|§¹¦¨ªº·§©À©ÊÅçÃÒ¡A³t«×ºâ«D±`§Ö¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/18 ¤U¤È 12:36:50
²Ä 3117 ½g¦^À³
|
¬ÝÀ´MOA ,ª¾¹DASLAN004¤ÎDupilumab ¦³¬Û¦P¸ô®|ªÌ
------------------------------------- 1.ASLAN004 MOA -¼v¤ù aslanpharma.com/drug/aslan004/
2.Dupilumab MOA -¼v¤ù
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
MOA www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M
------------------------------------------------ ¤£¥Îµ¥¤½§G¼Æ¾Ú, §Y¥i¨Ìdupilumab 2a Á{§É¸ê®Æ, ¥i ¹w´ú ASLAN004
2019/12/03 ¤½¥¬3¦ì ASLAN004 200mg /¨C¶g¤@°w 1bÁ{§É , EASI¥§¡°´T71% (4-6¶g) ¦ôp EASI¥§¡°´T ,²Ä8¶g¦b77~78% -----------------------------------
¦ÛµM±µªñDupilumab ¨C¶g¤@°w 2a Á{§É ªº²Ä¤¶gEASI °´T67%¡B²Ä¤»¶g¥§¡°EASI 70% ²Ä12¶g¥§¡°EASI 73.6%
Dupilumab 2a/2b Á{§É ,2018/SEP
journals.lww.com/jaanp/Fulltext/2018/09000/Efficacy_and_safety_of_dupilumab_for_the_treatment.10.aspx |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/18 ¤U¤È 12:18:41
²Ä 3116 ½g¦^À³
|
¤½¥q¤â¤W¤w¦³ ASLAN004 200mg/¨C¶g¤@°w+ 6¤H*8¶g ¹ï·Ó²Õ 2¤H +12¶gÆ[¹î¸ê®Æ ¥¼¸Ñª¼¼Æ¾Ú.
------------------------------------------------------ ³Å«iªí¥Ü¡A·sÃĹwp¤µ¦~²Ä 4 ©u¤½¥¬Á{§É¼Æ¾Ú¡A¼ÖÆ[¬Ý«Ý¼Æ¾Úµ²ªG¡A
¹wp¤µ¦~²Ä 4 ©u±N¿ì²z¼W¸ê¡A¸êª÷±N¹B¥Î©óÁ{§É¤G´Á¡C
news.cnyes.com/news/id/4507222 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/18 ¤W¤È 11:59:14
²Ä 3115 ½g¦^À³
|
·sÃĬãµo¤è±¡A¨È·à±d¥¿¦b¶i¦æ²§¦ì©Ê¥Ö½§ª¢ÃĪ« ASLAN004 ¤@´ÁÁ{§É¸ÕÅç¡A³Å«iªí¥Ü¡A¹wp¤µ¦~©³«e¤½¥¬Á{§É¤@´Á¼Æ¾Ú¡A2021 ¦~±Ò°ÊÁ{§É¤G´Á¡B³Ì§Ö¥i¦b 2023 ¦~§¹¦¨¡C
³Å«iªí¥Ü¡A·sÃĹwp¤µ¦~²Ä 4 ©u¤½¥¬Á{§É¼Æ¾Ú¡A¼ÖÆ[¬Ý«Ý¼Æ¾Úµ²ªG¡A ¤£¹L¦]¥Ø«e±b¤W²{ª÷¬ù¦³ 4 »õ¤¸¡A¥B¨C©u¬ãµo¶O¥Î¬ù 1 »õ¤¸¡A¥u¯à¤ä¼µ¨ì·sÃÄÁ{§É¤@´Á¡A¦]¦¹¡A¹wp¤µ¦~²Ä 4 ©u±N¿ì²z¼W¸ê¡A¸êª÷±N¹B¥Î©óÁ{§É¤G´Á¡C
news.cnyes.com/news/id/4507222 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gonly10135877 |
µoªí®É¶¡:2020/7/18 ¤W¤È 10:42:08
²Ä 3114 ½g¦^À³
|
adr ªº«OºÞ¶O¤£¾å±on¦p¦óú¬O½æ¥X®É³Q©â¨ú«OºÞ¶O,©Î¬O©w®É¶×¿ú¥hú,Y§Ñ¤Fú«OºÞ¶O¤£ª¾·|«ç¼Ë? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/18 ¤W¤È 09:51:56
²Ä 3113 ½g¦^À³
|
8. Âà´«µ{§Ç¤j¬ù¦h¤[¥i¥H§¹¦¨? ¦pªÑªF¤w³Æ§´©Ò¦³¤Wz¤å¥ó¡B¸g¸s¯qÃÒ¨é½T»{¸ê°TµL»~¥B¬ÛÃö¶O¥Î¦p¼Æú¥I¡A¼¯®Ú ¤j³q»È¦æ J.P. Morgan ©ó¦¬¨ì©Ò¦³¥¿¥»¥Ó½Ð¤å¥ó«á±N©ó 1 ¦Ü 2 Ӥ뤺§¹¦¨¥»¤½¥qªÑ ²¼Âà´«¬°¬ü°ê¦s°U¾ÌÃÒ¡B¨Ã¼·¥I¸Ó¬ü°ê¦s°U¾ÌÃҦܱz«ü©w¤§¬üªÑ¥æ©ö±b¤á¤§¬yµ{¡C ±©¥»¤½¥q¤£¾á«O¶W¥X¨ä±±¨î½d³ò¤§®É¶¡ªí¡C
9¤ë25 ¤é ¥Ó½ÐºI¤î¤é ¡Ï30~60 ¤Ñ¨ú±oªÑ²¼
¹wp10¤ë25¤é~11¤ë25¤é ¤§¶¡¨ú±oADR¡A¥i¦b¬ü°ê¯Ç´µ¹F§J¥æ©ö©Ò¡A¦Û¥Ñ½æ¥X¡C
13. ¤½¥q²×¤î¦³»ùÃÒ¨éÂdÂi¶R½æ«á¥i¯àµo¥Íþ¨Ç·|¼vÅTªÑ²¼»ùȪºÃöÁä¨Æ¶µ? ¥»¤½¥q©ó²×¤î¦³»ùÃÒ¨éÂdÂi¶R½æ¥H¤Î°±¤î¦b¥xÆW¦³»ùÃҨ餽¶}µo¦æ«á¡A±NÂಾ²Ä¤@ ¤W¥«¥«³õ«¤ß¦Ü¨º´µ¹F§J¥æ©ö©Ò¡C§Ú̱N«ùÄòÂX¤j²£«~²Õ¦X¨Ã»EµJµo®i¤Î¨ã¼ç¤O¤§ ASLAN004 À³¥Î©ó²§¦ì©Ê¥Ö½§ª¢¡A¨Ã¹wp©ó 2020 ¦~²Ä¥|©uµo¥¬ ASLAN004 ¦h¾¯¶q»¼ ¼WÃĪ«¸ÕÅç(MAD)´Á¤¤¼Æ¾Ú¤Î·§©À©Ê¸ÕÅç¼Æ¾Ú¨Ã©ó 2021 ¦~®i¶}²Ä 2b ´ÁÁ{§É¸ÕÅç¡C ³o¨Ç³£¬O¥i¯à¼vÅT¥¼¨ÓªÑ²¼»ùȤ§ÃöÁä¨Æ¶µ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/18 ¤W¤È 09:45:34
²Ä 3112 ½g¦^À³
|
¬Q¤Ñ¨È·à±dµo§G°ê»Ú·s»D½Z¡C
±N¯Ç´µ¹F§J¥«³õ§ï¬°²Ä¤@¤W¥«¦aÂI¡C
ASLAN Pharmaceuticals Announces the Move of its Primary Listing to Nasdaq and Delisting From Taipei Exchange
finance.yahoo.com/news/aslan-pharmaceuticals-announces-move-primary-100838247.html
ASLN ADR ¤Wº¦10% ¼y¯¬¡C 2.04 ¬ü¤¸/ªÑ¦¬½L¡C
368(¤dªÑ)=¬ù1800±i¥xªÑ¦¨¥æ¶q |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/18 ¤W¤È 07:57:04
²Ä 3111 ½g¦^À³
|
¥xÁÞ¤j ,
Dupilumab AD ,¦U´ÁÁ{§É¸ê®Æ¡A¦p¤U´Á¥Z¡A
1. Dupilumab ¦´Á¥|Ó AD Á{§É 4¶g/12¶g , 2014/07/10
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
www.nejm.org/doi/10.1056/NEJMoa1314768
2. Dupilumab 2a/2b Á{§É ,2018/SEP
journals.lww.com/jaanp/Fulltext/2018/09000/Efficacy_and_safety_of_dupilumab_for_the_treatment.10.aspx
3.Dupilumab AD 2Ó¤T´ÁÁ{§É, 300mg/¨C¶g¤@°w/300mg/¨C¤G¶g¤@°w 2016/12/15
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis www.nejm.org/doi/full/10.1056/nejmoa1610020 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/18 ¤W¤È 07:21:27
²Ä 3110 ½g¦^À³
|
n¬Ý¼Æ¾Úªº¤j¤j,
DUPILUMAB ¦´Á¥|ÓÁ{§É¸ÕÅçµ²ªG¡A¦³³\¦h¹Ïªí ¡G¦p¤U www.nejm.org/doi/10.1056/NEJMoa1314768 Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
2014/07/10
µ²ªG ¦b¬°´Á4¶gªº³æÃĪvÀø¬ã¨s¤¤¡Adupilumab¾ÉPÁ{§É«ü¼Ð¡A¥Íª«¼Ð»xª«¤ô¥©MÂà¿ý²Õªº§Ö³t¥B¾¯¶q¨Ì¿à©Ê§ïµ½¡C
dupilumab³æÃĪvÀø12¶g¬ã¨sªºµ²ªG«²{¨Ã©µªø¤F4¶gªº¬ã¨sµ²ªG¡Gdupilumab²Õ±wªÌ¤¤85¢Hªº±wªÌEASI±o¤À°§C¤F50¢H¡A¦Ó¦w¼¢¾¯²Õ±wªÌ¤¤³o¤@¤ñ¨Ò¬°35¢H ¡]EASI-50¡A¦bEASI¤¤±o¤À¸û°ªªí¥ÜÀã¯lÄY«µ{«×§ó°ª¡^¡]P <0.001¡^
¡F¦b¬ã¨sªÌªºÁ`Åéµû¦ô¤¤¡A dupilumab²Õ¤¤40¢Hªº±wªÌ»P¦w¼¢¾¯²Õ¤¤ªº7¢H¬Û¤ñ¸û¡A±o¤À¬°0¡G1¡]ªí©ú¥Ö½§¯fÅܤw²M°£©Î±µªñ²M°£¡^¡]P <0.001¡^¡F dupilumab²Õªºæ±Äoµû¤À°§C¤F55.7¢H¡]ªí©úæ±Äo´î¤Ö¡^¡A¦Ó¦w¼¢¾¯²Õ°§C¤F15.1¢H¡]P <0.001¡^¡C
¦b³o¶µÁp¦X¬ã¨s¤¤¡A¾¨ºÞ±µ¨ü¤F¦w¼¢¾¯ª`®gªº±wªÌ¤¤¡Adupilumab²Õªº±wªÌ¤¤¦³100¢H²Å¦XEASI-50ªº¼Ð·Ç¡]P = 0.002¡^¡A¦Ó±µ¨ü¦w¼¢¾¯ª`®gªº§½³¡¿}¥Ö½è¿E¯Àªº±wªÌ¬°50¢H¡C dupilumab¥[¿}¥Ö½è¿E¯Àªº¨Ï¥Î¶q¤Ö©ó±µ¨ü¦w¼¢¾¯¥[§½³¡ÃĪ«ªº±wªÌ©Ò¥Î§½³¡¿}¥Ö½è¿E¯Àªº¤@¥b¡]P = 0.16¡^¡C¦w¼¢¾¯µ¥¤£¨}¨Æ¥ó¦p¥Ö½§·P¬Vªºµo¥ÍÀW²v§ó°ª¡C»ó«|ª¢©MÀYµh¬Odupilumab³Ì±`¨£ªº¤£¨}¨Æ¥ó¡C µ²½× ¥ÎdupilumabªvÀøªº±wªÌ¦b©Ò¦³µû¦ôªº¯SÀ³©Ê¥Öª¢¯e¯f¬¡°Ê©Ê«ü¼Ð¤¤§¡¨ã¦³©úÅã¥B§Ö³tªº§ïµ½¡C°Æ§@¥Î¨S¦³¾¯¶q¨î¡C
Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers, NCT01259323. opens in new tab, NCT01385657. opens in new tab, NCT01639040. opens in new tab, and NCT01548404. opens in new tab.)
RESULTS In the 4-week monotherapy studies, dupilumab resulted in rapid and dose-dependent improvements in clinical indexes, biomarker levels, and the transcriptome. The results of the 12-week study of dupilumab monotherapy reproduced and extended the 4-week findings: 85% of patients in the dupilumab group, as compared with 35% of those in the placebo group, had a 50% reduction in the EASI score (EASI-50, with higher scores in the EASI indicating greater severity of eczema) (P<0.001); 40% of patients in the dupilumab group, as compared with 7% in the placebo group, had a score of 0 to 1 (indicating clearing or near-clearing of skin lesions) on the investigator¡¦s global assessment (P<0.001); and pruritus scores decreased (indicating a reduction in itch) by 55.7% in the dupilumab group versus 15.1% in the placebo group (P<0.001). In the combination study, 100% of the patients in the dupilumab group, as compared with 50% of those who received topical glucocorticoids with placebo injection, met the criterion for EASI-50 (P=0.002), despite the fact that patients who received dupilumab plus glucocorticoids used less than half the amount of topical glucocorticoids used by those who received placebo plus the topical medication (P=0.16). Adverse events, such as skin infection, occurred more frequently with placebo; nasopharyngitis and headache were the most frequent adverse events with dupilumab. CONCLUSIONS Patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity. Side-effect profiles were not dose-limiting. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers, NCT01259323. opens in new tab, NCT01385657. opens in new tab, NCT01639040. opens in new tab, and NCT01548404. opens in new tab.) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2020/7/18 ¤W¤È 12:16:29
²Ä 3109 ½g¦^À³
|
¤½¥q«¤j°T®§»¡©ú·|±`¨£°ÝÃD¦b©xºô aslanpharma.com/zh/investors/
ªÑªFªA°È¤U¤è¡A¥H©xºô»¡©ú¬°·Ç
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2020/7/18 ¤W¤È 12:04:18
²Ä 3108 ½g¦^À³
|
§ó¥¿»P¸É¥R («e«h§@¼o¡^
¤Wµ¦ ¤¤µ¦ ¤Uµ¦
1§C»ù½æ¥X¬O¤Uµ¦¡A³o·|²£¥Í¥ß§Yªº¤j´TÁ«·l¡C
2Âà´«¦¨ADR³Ì¬O¤Wµ¦¡A¦pªO¤Í©Òpºâ100±i¥xªÑÂà´«¤âÄò¶O¬ù30000¤¸¥x¹ô¡A«OºÞ¶O¦p¥H¨CªÑ0.01¬ü¤¸pºâ¥b¦~¬ù6000¤¸¥x¹ô¡A©ú¦~¨S¦³Âà´«¤âÄò¶Oªº°ÝÃD¡A¥u³Ñ«OºÞ¶O¡AASLAN004²§¦ì©Ê¥Ö½§ª¢±ÂÅv¥i§Ö¥iºC¡AÓ¤H²q´ú¥i¯à¤¶©ó§¹¦¨¤@´Á¨ì§¹¦¨¤GB«á¤§¶¡¡A¼Æ¾ÚÀu²§¤£¦ý¯à¸Ñ®M§ó¥i¯à¤jÀò§Q¡A©¡®É¨º¨Ç«OºÞ¶O¡AÂà´«¤âÄò¶O¦^·Q°_¨Ó³£¬OȦ^²¼»ù¡C2021¦~¶}©l¤GBÁ{§É¹êÅç¡A2022¦~´N§¹¦¨¤GB´ÁÁ{§É¸Õ¡A¥h¦~3¤Hªº¼Æ¾ÚADR´¿º¦¶W¹L8¤¸¡A24¤Hªº¼Æ¾Ú©Î±ÂÅv·|º¦¨ì¦h¤Ö¨S¤Hª¾¹D¡H¡A¤W¤Ñ¤~ª¾¹D¡H¦³¨ºÓ©R»P¹B¦ÛµM·|¤jÀò§Q¡A¥bÂI¤£¥Ñ¤H¡C
3¤£·QÂà´«¬O¤¤µ¦¡A¨Ì¾Ú¤µ¤Ñ«°T°Ýµª²Ä¤Q¤T¥i¥H«O¦³¶}°Ò¨È·à±dªºªÑªF¡A¨É¦³À³¸Ó¦³ªºÅv§Q¡A¸Ô²Ó»¡©ú½Ð°Ñ¦Ò²Ä¤Q¤TÂI¡C
4¦³Ãö§ë¸ê°ê¥~Àò§Q¥xÆW¦©µ|ªº°ÝÃD¡A¯à¦©¨ìµ|ªí¥Ü¤w¸g¸Ñ®M¨Ã¥BÀò§Q¡Aµ|²v¦h¤Ö¤w¸g¤£«n¤F¡C
¥H¤U¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2020/7/17 ¤U¤È 11:15:41
²Ä 3107 ½g¦^À³
|
¤Wµ¦ ¤¤µ¦ ¤Uµ¦
1§C»ù½æ¥X¬O¤Uµ¦¡A¬°¤F¸`¬ÙÂà´«¤âÄò¶O»P«OºÞ¶O½æ¥X«ùªÑ¬O¤Uµ¦¡A³o·|²£¥Í¥ß§Yªº¤j´TÁ«·l¡C
2Âà´«¦¨ADR³Ì¤Wµ¦¡A¦pªO¤Í©Òpºâ100±i¥xªÑÂà´«¤âÄò¶O¬ù30000¤¸¥x¹ô¡A«OºÞ¶O¦p¥H¨CªÑ0.01¬ü¤¸pºâ¥b¦~¬ù6000¤¸¥x¹ô¡A©ú¦~¨S¦³Âà´«¤âÄò¶Oªº°ÝÃD¡A¥u³Ñ«OºÞ¶O¡AASLAN00±ÂÅv¥i§Ö¥iºC¡A¤¶©ó§¹¦¨¤@´Á¨ì§¹¦¨¤GB¤§¶¡¡A¼Æ¾ÚÀu²§¤£¦ý¯à¸Ñ®M§ó¥i¯à¤jÀò§Q¡A©¡®É¨º¨Ç¶O¥Î¦^·Q°_¨Ó³£¬O¤p¿ú¡A 2022¦~´N§¹¦¨¤GB´ÁÁ{§É¸Õ¡A¥æªº«OºÞ¶O³Ì¦h¤]¬O¨â¦~¡A¥h¦~3¤Hªº¼Æ¾ÚADR´¿º¦¶W¹L8¤¸¡A24¤Hªº¼Æ¾Ú©Î±ÂÅv·|º¦¨ì¦h¤Ö¡H¨S¤Hª¾¹D¡A¤W¤Ñ¤~ª¾¹D¡H¦³¨ºÓ©R»P¹B¦ÛµM·|¤jÀò§Q¡A¥bÂI¤£¥Ñ¤H¡C
3¤£·QÂà´«¤£·Q½æ¥X¬O¤¤µ¦¡A¤]¥i¥H«O¦³¶}°Ò¨È·à±dªºªÑªF¡A³Q¨ÖÁʤ]¥i«ö«ùªÑ¤À¿ú¡C
¥H¤U¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¸ê¦V«e½Ä10149354 |
µoªí®É¶¡:2020/7/17 ¤U¤È 10:55:33
²Ä 3106 ½g¦^À³
|
ÁÂÁ ¤Ñ©R¤jªº¦^ÂСC
¦n©_°ÝÓ°ÝÃD¡A³q±`ÃB©w¸ê¥»ÃB³]©w¸û°ª¡A¬O¬°¤F¤é«áµo¦æ·sªÑªº¤è«K¡F¤§«á¤w½T©w¤@©w·|¶Ò¸ê¥H¤ä«ù«áÄòÁ{§É¸ÕÅ窺¶i¦æ¡A¬°¦óÁÙn´î¸ê? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/17 ¤U¤È 09:50:29
²Ä 3105 ½g¦^À³
|
(4) ÀÀ´î¤Ö¥»¤½¥qÃB©w¸ê¥»®×(¯S§O¨Mij)-conditional approval©óºM¾P¤½¶}µo¦æ«á ¥BÀò±o¶}°Ò¸s®q¤jªk°|®Öã´î¸ê©R¥O«á¤§±ø¥ó«¬¨Mij
ÃB©w¸ê¥» : ¥Ø«e 50»õ¥x¹ô. ¦ý¥uµo¦æ¬ù19»õ¥x¹ô.(¸Ô¨£ªÑªF·|¤â¥U) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¸ê¦V«e½Ä10149354 |
µoªí®É¶¡:2020/7/17 ¤U¤È 09:38:51
²Ä 3104 ½g¦^À³
|
³o¬O³W¹ºn¦A´î¸ê?
-------------------------------------------------------------------------------------------- ¥»¸ê®Æ¥Ñ¡@(¤WÂd¤½¥q) ¨È·à±d-KY ¡@¤½¥q´£¨Ñ §Ç¸¹ 7 µo¨¥¤é´Á 109/07/17 µo¨¥®É¶¡ 19:54:35 µo¨¥¤H ³Å«i µo¨¥¤H¾ºÙ °õ¦æªø µo¨¥¤H¹q¸Ü +65 6222 4235 ¥D¦® ¥»¤½¥q¸³¨Æ·|¨Mij¥l¶}109¦~²Ä2¦¸ªÑªFÁ{®É·|¬ÛÃö¨Æ©y ²Å¦X±ø´Ú ¡@²Ä 17 ´Ú ¨Æ¹êµo¥Í¤é 109/07/17 »¡©ú 1.¸³¨Æ·|¨Mij¤é´Á:109/07/17 2.ªÑªFÁ{®É·|¥l¶}¤é´Á:109/09/04 3.ªÑªFÁ{®É·|¥l¶}¦aÂI:¥x¥_°ê»Ú·|ij¤¤¤ß105·|ij«Ç(¥x¥_¥««H¸q¸ô¤¬q1¸¹) 4.¥l¶°¨Æ¥Ñ¤@¡B³ø§i¨Æ¶µ: ¨È·à±d-KY´¶³qªÑªÑ¥÷Âà´«¦Ü¨º´µ¹F§J¤W¥«¤§¬ü°ê¦s°U¾ÌÃÒÂà´«¿ìªkº[§ë¸ê¤H°Ýµª¨Ã ±N²Ä¤@¤W¥«¥«³õÂಾ¦Ü¬ü°ê¨º´µ¹F§J³ø§i¡C 5.¥l¶°¨Æ¥Ñ¤G¡B©Ó»{¨Æ¶µ:µL¡C 6.¥l¶°¨Æ¥Ñ¤T¡B°Q½×¨Æ¶µ: (1) ÀÀ²×¤î¥»¤½¥q¦b¥x¤½¶}µo¦æ®×(««×¨Mij) (2) ÀÀ×q¥»¤½¥q¤½¥q³¹µ{®×(¯S§O¨Mij)-conditional approval©óºM¾P¤½¶}µo¦æ«á ¤§±ø¥ó«¬¨Mij (3) ÀÀ«·s¦W¥Ø¥»¤½¥qÃB©w¸ê¥»®×(´¶³q¨Mij)-conditional approval©óºM¾P¤½¶}µo ¦æ«á¤§±ø¥ó«¬¨Mij (4) ÀÀ´î¤Ö¥»¤½¥qÃB©w¸ê¥»®×(¯S§O¨Mij)-conditional approval©óºM¾P¤½¶}µo¦æ«á ¥BÀò±o¶}°Ò¸s®q¤jªk°|®Öã´î¸ê©R¥O«á¤§±ø¥ó«¬¨Mij (5) ÀÀ©óÀò±o¶}°Ò¸s®q¤jªk°|®Öã´î¸ê©R¥O«á¡A¥H°Æ¥»§Î¦¡¥¿¦¡¨ú¥N¤Wz×q«á¤§ ¥»¤½¥q¤½¥q³¹µ{®×(¯S§O¨Mij)-conditional approval©óºM¾P¤½¶}µo¦æ«á¥BÀò±o ¶}°Ò¸s®q¤jªk°|®Öã´î¸ê©R¥O«á¤§±ø¥ó«¬¨Mij (6) ¥»¤½¥q¤WÂd¦³»ùÃÒ¨é²×¤î¦bÃÒ¨é°ÓÀç·~³B©Ò¶R½æ«á¡AÀÀ½Ð¨D»OÆW¶°¤¤«OºÞµ²ºâ ©Ò¨ó§U¡A±NªÑªFÃÒ¨é±b¤á¤¤¨È·à±d-KY´¶³qªÑªÑ¼Æ¥þ¼ÆÂà¦ÜªÑªFµn¿ý±b¤U¡A¥H§Q ¨È·à±d-KY¦b¥xÆW°õ¦æ³æ¦ì¡A«áÄò¥Nªí¥»¤½¥q¶i¦æªÑªF¦W¥U¤§ºûÅ@¤ÎºÞ²z¡C 7.¥l¶°¨Æ¥Ñ¥|¡B¿ïÁ|¨Æ¶µ:µL¡C 8.¥l¶°¨Æ¥Ñ¤¡B¨ä¥Lij®×:µL¡C 9.¥l¶°¨Æ¥Ñ¤»¡BÁ{®É°Êij:µL¡C 10.°±¤î¹L¤á°_©l¤é´Á:109/08/06 11.°±¤î¹L¤áºI¤î¤é´Á:109/09/04 12.¬O§_¤w©óªÑ§Q¤À¬£±¡§Î¤½§i¬Õ¾l¤À¬£©ÎÁ«·l¼·¸Éij®×¤º®e(¬O/§_/¤£¾A¥Î):¤£¾A¥Î¡C 13.©|¥¼©óªÑ§Q¤À¬£±¡§Î¤½§i¬Õ¾l¤À¬£©ÎÁ«·l¼·¸Éij®×¤º®eªÌ¡A½Ð±Ô©úì¦]:¤£¾A¥Î¡C 14.¨ä¥LÀ³±Ô©ú¨Æ¶µ: ¥»¦¸ªÑªF·|ªÑªF±o¥H¹q¤l¤è¦¡¦æ¨Ïªí¨MÅv¡A¦æ¨Ï´Á¶¡¬°¡G¦Û109¦~08¤ë20¤é¦Ü109 ¦~09¤ë01¤é¤î¡A½ÐªÑªF³wµn¤J»OÆW¶°¤¤«OºÞµ²ºâ©ÒªÑ¥÷¦³¤½¥q¡uªÑªF·|e²¼³q¡v (ºô§}¡Gwww.stockvote.com.tw)¡A¨Ì¬ÛÃö»¡©ú§ë²¼ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2020/7/17 ¤U¤È 09:15:54
²Ä 3103 ½g¦^À³
|
¤å¤¤¦³´£¨ì¡AADR¦³¥i¯à·|¦¬¨ú«OºÞ¶O ²Ä¤Q±ø³Ì«á¡G
• ¬ü°ê¦s°U¾ÌÃÒ¸g¬ö°Ó«OºÞ¶O¡G ¶R¶i¬ü°ê¦s°U¾ÌÃÒ¦p©ó«OºÞ¶O¥Î¦¬¨ú°ò·Ç¤é®É©|¦³«ùªÑ¡A±N·|³Q¬ü°ê«OºÞ¾÷ºc ¦¬¨ú«OºÞ¶O¥Î¡C¬ü°ê¦s°U¾ÌÃÒ«OºÞ¶O¬ù¨CªÑ 0.01 ¬ü¤¸¦Ü 0.05 ¬ü¤¸¤£µ¥¡A¨C¥b ¦~¡B¤@¦~©Î©w´Á¦V«ù¦³¤H¦¬¨ú¤@¦¸¡A¨ãÅé¶O¥Î¨ú¨M©ó±zªºÃÒ¨é¸g¬ö°Ó¡C ¤Wz¶O¥Î«Y°ò©ó¥»¤½¥q»s§@¥»§ë¸ê¤H°Ýµª®É¡A¥»¤½¥q¨ú±o¤§«H®§¡AµLªk«OÃÒ¤Wz¶O ¥Îªº·Ç½T©Ê¤Î§¹¾ã©Ê¡C ½ÐÁpô±zÓ¤Hªºµ|°È¿Ô¸ßÅU°Ý¥HÀò¨ú¦³Ãö¦b¬ü°ê¨º´µ¹F§J¥æ©ö©Ò¶R½æ¬ü°ê¦s°U¾ÌÃÒ ¥i¯à²£¥Íªº¦U¶µµ|°È³W¹º«Øij¡A¥»¤½¥q·§¤£´£¨ÑªÑªFÓ¤H°]°È³W¹º¿Ô¸ß¡C 11. ¦pªÑªFµL·NÄ@±NªÑ²¼Âà´«¬°¬ü°ê¦s°U¾ÌÃÒ¤§³B¸m¬°¦ó? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§_¨ì©³°Õ10148994 |
µoªí®É¶¡:2020/7/17 ¤U¤È 08:05:30
²Ä 3102 ½g¦^À³
|
°²¨Ï¥»¤½¥q¦b¥xÆW¤´¬O¤½¶}µo¦æ¤½¥q¡A«hªÑªFªºªÑ¥÷±NµLªkÂà´«¬°¬ü°ê¦s°U¾ÌÃÒ¡A ¥çµLªk©ó¥Á°ê 109 ¦~ 8 ¤ë 25 ¤é²×¤î¦³»ùÃÒ¨éÂdÂi¶R½æ«á«á¦b¥ô¦ó¤½¶}ÃҨ饫³õ¤W ¶i¦æ¥æ©ö¡C
ºâ¬Oµ¹¥xÆW©x¤èªº³Ì«á¾÷·|¶Ü¡H«¢«¢¡]§ÚÁÙ¬OÄ~Äòµ¥adr¦n¤F¡^ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gtimchan51610148760 |
µoªí®É¶¡:2020/7/17 ¤U¤È 06:11:27
²Ä 3101 ½g¦^À³
|
ºâ¿ù¤F ! 100±i¨È·à±d = (20000ªÑASLN * 0.05) + 20 = 1020¬üª÷ = 30600¥x¹ô |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gtimchan51610148760 |
µoªí®É¶¡:2020/7/17 ¤U¤È 06:07:50
²Ä 3100 ½g¦^À³
|
ÁÙnÂà´«ªº¤âÄò¶O 1000ªÑ ´«¦¨ ADR 200ªÑ * 0.05USD + 20USD ¤]´N¬O§A¤â¤W¦³¤@±i¨È·à±d nú 900¶ôªº¤âÄò¶O 100±i½Ð§A·Ç³Æ 9¸U |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gtimchan51610148760 |
µoªí®É¶¡:2020/7/17 ¤U¤È 05:53:54
²Ä 3099 ½g¦^À³
|
¨È·à±dªÑ¥÷¦³¤½¥q ²×¤î¦³»ùÃÒ¨é©ó°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ß¥æ©ö ªÑ¥÷Âà´«¦Ü¨º´µ¹F§J(NASDAQ)¤W¥«¤§¬ü°ê¦s°U¾ÌÃÒ(ADS) Âà´«¿ìªkº[§ë¸ê¤H°Ýµª ¨È·à±dªÑ¥÷¦³¤½¥q(ASLAN Pharmaceuticals Limited¡AªÑ²¼¥N½X 6497)¡]¤UºÙ¡u¥»¤½ ¥q¡v©Î¡u¨È·à±d¡v¡^©ó¥Á°ê 109 ¦~ 7 ¤ë 16 ¤é±µÀò°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ß ¡]¤UºÙ¡uÂd¶R¤¤¤ß¡v¡^¥¿¦¡³qª¾¡A¦]¤£²Å¦X°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ßÃÒ¨é °ÓÀç·~³B©Ò¶R½æ¦³»ùÃÒ¨é·~°È³W«h²Ä¤Q¤G±ø¤§¤G¡A¹wp±N©ó¥Á°ê 109 ¦~ 8 ¤ë 25 ¤é°_²× ¤î¦³»ùÃÒ¨éÂdÂi¶R½æ¡C ¥»¤½¥qªÑ²¼±N«ùÄò¥H¬ü°ê¦s°U¾ÌÃÒ American Depositary Shares (ADS)§Î¦¡©ó¬ü°ê¨º´µ¹F §JÃÒ¨é¥æ©ö©Ò±¾µP¡C¥»¤½¥q¦³»ùÃÒ¨é²×¤îÂdÂi¶R½æ¨Ã¤£·|¼vÅT¥»¤½¥q¤§¦³»ùÃÒ¨é«ùÄò ©ó¨º´µ¹F§JÃÒ¨é¥æ©ö©Ò±¾µP¤Î¥æ©ö¡A¥B¬ü°ê¨º´µ¹F§J±N¦¨¬°¥»¤½¥q¦³»ùÃҨ餧¥Dn¥æ ©ö¥«³õ¡A¦Ó쥻«ù¦³¬ü°ê¦s°U¾ÌÃÒ¤§ªÑªF¹ï¦¹µL¶·±Ä¨ú¥ô¦ó¦æ°Ê¡C ¥»¤½¥q±N¨ó§U¥xÆWªÑªF¶i¦æªÑ¥÷Âà´«¬°¬ü°ê¦s°U¾ÌÃҦܨº´µ¹F§JÃÒ¨é¥æ©ö©Ò«ùÄò¦sÄò ¤Î¥æ©ö¡C¥»¤½¥q¤§ªÑªF¨ÃµL¸q°È°Ñ»P¥»¦¸Âà´«¡AYµL·NÄ@Âà´«¤§ªÑªF«h¥i¥H¦b²×¤î¦³ »ùÃÒ¨éÂdÂi¶R½æ¤é«e±N©Ò«ùªÑ¥÷©ó¥xÆW¥«³õ¥X°â¡A©Î«ùÄò«ù¦³¥»¤½¥q¶}°ÒªÑ¥÷¡C¯S§O ª`·N¡A¤@¥¹¥»¤½¥q¦³»ùÃÒ¨é²×¤îÂdÂi¶R½æ¡A¥»¤½¥q¦³»ùÃÒ¨é°ß¤@¤½¶}¥æ©ö¥«³õ±N·|¬O ³z¹L¬ü°ê¦s°U¾ÌÃҩ󨺴µ¹F§JÃÒ¨é¥æ©ö©Ò¶i¦æ¥æ©ö¡C ¥H¤U°w¹ïªÑ²¼Âà´«¿ìªk¤ÎªÑªF±`¨£°ÝÃD»¡©ú¡G 1. ¦ó¿×¬ü°ê¦s°U¾ÌÃÒ(ADS)? ¬ü°ê¦s°U¾ÌÃÒ«Y¥~°ê¤½¥q©ó¬ü°êÃҨ饫³õ¥æ©öªÑ²¼ªº¤@ºØ§Î¦¡¡C¤j¦h¼Æªº¥~°ê¤½¥q ¦b¬ü°êÃҨ饫³õ³z¹L¦s°U¾ÌÃҧΦ¡¶i¦æ¥æ©ö¨Ã´£¤É°ê»Úª¾¦W«×¡C´N¨È·à±d®×¨Ò¦Ó ¨¥¡A§Ú̪º¦s°U¾÷ºc«Y¬°¥@¬É»â¥ý»È¦æ¤§¤@ªº¼¯®Ú¤j³q»È¦æ J.P. Morgan Chase Bank, N.A.( J.P. Morgan)¡A¥Ø«e¨C³æ¦ì¬ü°ê¦s°U¾ÌÃÒªí¹ü¥»¤½¥q´¶³qªÑ 5 ªÑ (¦¹©ÒºÙ ´¶³qªÑ»P¥Ø«e¦b¥xÆWÃÒ¨éÂdÂi¶R½æ¤¤¤ß¤WÂd¤§ªÑ¥÷Ãþ§O¬Û¦P)¡C¥»¤½¥q¤§¬ü°ê¦s°U ¾ÌÃÒ¦b¨º´µ¹F§JÃÒ¨é¥æ©ö©Ò±¾µP¤§ªÑ²¼¥N½X¬° ¡¨ASLN¡¨¡C °£¨ü¨ì¤@¨ÇÁŧK©M¨î¤§¬ù§ô¡A¥»¤½¥q¬ü°ê¦s°U¾ÌÃҩ󨺴µ¹F§J¤W¥«À³¿í´`¤§ªk³W ¥H¤ÎÀ³¤½§i¨Æ¶µ¤§¿¦±K©Ên¨D¡A»P¦b¬ü°ê·í¦a²Ä¤@¤W¥«ªº¤½¥q¼Ð·Ç¤@P¡C¦Û¨È·à±d ©ó 2018 ¦~ 5 ¤ë¦b¨º´µ¹F§J¤W¥«¥H¨Ó§¡²Å¦X¬ü°ê·í¦aÃÒºÞªk¥O³W½d¡CÂǥѬü°ê¦s°U ¾ÌÃÒ¦b¬ü°êÃҨ饫³õªº¤½¶}µo¦æ¡A¨È·à±d¦b¬ü°êÃҨ饫³õÀò±o²³¦h¥B¹ï©ó¥Í§Þ·sÃÄ ·¥¨ã¸gÅ窺§ë¸ê¤H°ò¦Àu¶Õ¡A¦P®É¤]¬°¥~°ê¥Í§Þ·sÃĤ½¥qªÑ²¼¦b¬ü°êÃҨ饫³õ®i¶} ¤F¸û¨ã°ª«×ªº¬y³q©Ê¡C 2. ªÑªF¬O§_¯à±N¥xÆWªºªÑ²¼Âà´«¬°¬ü°ê¦s°U¾ÌÃÒ? ¥»¤½¥q»{¬°±N¥xÆWªºªÑ²¼Âà´«¬°¬ü°ê¦s°U¾ÌÃÒ±N¥i¯à¹F¨ìªÑªF̪º³Ì¨Î§Q¯q¡A«Y¦] ¬ü°ê¦s°U¾ÌÃÒªº¾ú¥v»ù®æ¤Î¥æ©ö¬y³q©Ê»·°ª©ó¥»¤½¥qªÑ²¼¦bÂd¶R¤¤¤ß¥æ©ö¡C¥»¤½¥q ¦³»ùÃÒ¨é©ó¥xÆW°±¤î¤½¶}µo¦æ«á¡A¤~¯à¨Ì¾Ú¥»§ë¸ê¤H°Ýµª·§zªºÂà´«¿ìªk¤Î¬yµ{¡A ¨ó§UªÑªF±N©Ò«ù¦³¤§¥»¤½¥qªÑ¥÷Âà´«¬°¬ü°ê¦s°U¾ÌÃÒ¡C¥B«ez©ó¥xÆW°±¤î¤½¶}µo ¦æ¡A¤´»Ý¨ú±oª÷¿ÄºÊ·þºÞ²z©eû·|ÃÒ¨é´Á³f§½(¤UºÙ¡uª÷ºÞ·|ÃÒ´Á§½¡v)¤§®Öã¡C ¥»¤½¥q¹w©w©ó¥Á°ê 109 ¦~ 9 ¤ë 4 ¤é¤§ªÑªFÁ{®É·|¤W¨Mij°±¤î©ó¥xÆW¤½¶}µo¦æ®×¨Ã´£ ½Ðª÷ºÞ·|ÃÒ´Á§½°±¤î¥»¤½¥q©ó¥xÆW¤½¶}µo¦æ¡A¨äµô¶qÅv¤§¦æ¨Ï±N¦Ò¶qªÑªF·|§ë²¼µ² ªG¡A¬G¥»¤½¥qÀµ½ÐªÑªF¿n·¥°Ñ»P¥Á°ê 109 ¦~ 9 ¤ë 4 ¤é¤§ªÑªFÁ{®É·|¤§¬ÛÃö«n¨M ij¡C °²¨Ï¥»¤½¥q¦b¥xÆW¤´¬O¤½¶}µo¦æ¤½¥q¡A«hªÑªFªºªÑ¥÷±NµLªkÂà´«¬°¬ü°ê¦s°U¾ÌÃÒ¡A ¥çµLªk©ó¥Á°ê 109 ¦~ 8 ¤ë 25 ¤é²×¤î¦³»ùÃÒ¨éÂdÂi¶R½æ«á«á¦b¥ô¦ó¤½¶}ÃҨ饫³õ¤W ¶i¦æ¥æ©ö¡C 3. ½Ö¥i¥H±N¨äªÑ²¼Âà´«¬°¬ü°ê¦s°U¾ÌÃÒ? ¨Ì¥»¤½¥q¸³¨Æ·|¨Mij³q¹L¤§ªÑ¥÷Âà´«¿ìªk¡A©Ò¦³¨È·à±dªÑªF§¡¦³Åv§Q±N¨äºI¦Ü¥Á°ê 109 ¦~ 8 ¤ë 25 ¤é(¦³»ùÃÒ¨é²×¤îÂdÂi¶R½æ¤é)¤î¡B©Ò«ù¦³¤§¥»¤½¥qªÑ¥÷¨Ì¥»¤½¥q¬ü°ê ¦s°U¾ÌÃÒªí¹ü¤§ªÑ¼Æ¡A¥þ¼ÆÂà´«¬°¬ü°ê¦s°U¾ÌÃÒ¡C¬°ÁקK²£¥Íª§Ä³¡A¥»¤½¥q¸³¨Æ·| ¤w¨Mij¥ô¦ó©ó¥Á°ê 109 ¦~ 8 ¤ë 25 ¤é«á¨p¤U¹L¤áÂàÅý¤§ªÑ¥÷§¡¤£¨ã¦³Âà´«¬ü°ê¦s°U ¾ÌÃÒ¤§Åv§Q¡C 4. ¦ó®É¯à¶}©l¥Ó½Ð±N¨äªÑ²¼Âà´«¬°¬ü°ê¦s°U¾ÌÃÒ? ¥»¤½¥qªÑ²¼±N©ó¥Á°ê 109 ¦~ 8 ¤ë 25 ¤é¦Û²×¤î¦³»ùÃÒ¨éÂdÂi¶R½æ¡C¦³·NÄ@±N¨ä©Ò«ù ¦³¤§¥»¤½¥qªÑ¥÷Âà´«¬°¬ü°ê¦s°U¾ÌÃÒ¡A¥B²Å¦X¸ê®æ¤§ªÑªF¥²¶·©ó¥Á°ê 109 ¦~ 9 ¤ë 25 ¤é«e´£¥æ¥Ó½Ð¡A¥H¾A¥Î¥»Âà´«¿ìªk©Òz¬yµ{¡C ±z¥i±q¥»¤½¥qºô¯¸ªÑªFªA°È±M°Ï¤U¸ü¬ü°ê¦s°U¾ÌÃÒÂà´«¥Ó½Ðªí®æ©Î¬¢·í¦a°õ¦æ³æ¦ì ¸s¯qª÷¹©ÃÒ¨éªÑ¥÷¦³¤½¥q¡]¤UºÙ¡u¸s¯qÃÒ¨é¡v¡^¿Ë¦Û¯Á¨ú¥Ó½Ðªí®æ (½Ð°Ñ¾\²Ä 7 ÂI)¶}©lÂà´«¤å¥ó·Ç³Æ¡C¥Ó½Ðªí®æ»Ý«Ý¥»¤½¥q©ó¥xÆW°±¤î¤½¶}µo¦æ«á¤~¯à¥Í®Ä¡C¥» ¤½¥q¹w¦ô¦¹¹Lµ{¤j¬ù»Ý 1 ¦Ü 2 Ӥ맹¦¨¡C 5. ¬O§_¦³¥ô¦óÂà´«®É¶¡¨î? ¥»¤½¥q±N©ó¥Á°ê 109 ¦~ 8 ¤ë 25 ¤é°_¨ü²zªÑªFÂà´«¥Ó½Ð¡A¥Bº§å¬ü°ê¦s°U¾ÌÃÒÂà´« ¥Ó½ÐºI¤î¤é¬°¥Á°ê 109 ¦~ 9 ¤ë 25 ¤é¡C¥ô¦ó©ó 109 ¦~ 9 ¤ë 25 ¤é«á¦¬¨ìªºªÑªF¥Ó½Ð ¥i¯àµLªk¥H¥»Âà´«¿ìªk©Òz¬yµ{¿ì²z¡C 6. ªÑªF¥²¶··Ç³Æ¤°»ò¥ý¨M±ø¥ó¤~¯à¶i¦æªÑ¥÷Âà´«? ¬°¤F¶¶§Q¨ú±o¬ü°ê¦s°U¾ÌÃÒ¡A±z¥²¶·¥ý¾Ö¦³¥i¨Ñ¥æ©ö¤§¬ü°êÃÒ¨é¤á©Î³z¹L°ê¤º¨é°Ó ¶}¥ßªº½Æ©e°U±b¤á¡CY±z¨ÃµL¨ã³Æ«ez¤§±ø¥ó¡A±z±NµLªk±N¨È·à±dªÑ²¼Âà´«¬°¨È·à ±d¬ü°ê¦s°U¾ÌÃÒ¡C 7. ¬ÛÃöµ{§Ç©M¥Ó½Ðªí³æ¬°¦ó? ±z¥²¶·¥ý»P±zªº¶}¤áÃÒ¨é¸g¬ö°ÓÁpô¥H«ü¥Ü±N±zªºµL¹êÅéªÑ²¼¦Û¶°¤¤«OºÞ±b¤á²¾Âà ¦Üµn¿ý±b¤á 3DP8-5555555¡A¥H¨Ñ¸s¯qÃÒ¨é¶i¦æÂà´«µ{§Ç¡C ¶à«á½Ð¬¢¸s¯qÃÒ¨é©Î¥»¤½¥q©x¤èºô¯¸¨ú±o¤U¦C¤å¥ó¡C¤å¥ó±N©ó¥Á°ê 109 ¦~ 7 ¤ë 25 ¤é«á¶}©ñ¤U¸ü¡C (aslanpharma.com/zh/investors/shareholder-services/ §ë¸êªÌ Ãö«Y - ªÑªFªA°È±M°Ï) • ªÑ¥÷ÂàÅý®Ñ Instrument of Transfer: ³o¥÷¤å¥ó±N¥æ¥Iµ¹¥»¤½¥q¶}°Òµn°O¥N²z¤H¡A¨¬¯÷ÃÒ©ú«ù¦³¤H¦P·N±N©Ò«ù¶}°Ò ªÑ¥÷³z¹L¦s°U¾÷ºc±N±z«ù¦³ªº¥»¤½¥qªÑ¥÷Âà´«¬°¬ü°ê¦s°U¾ÌÃҨä©¥Hµn°O¦b JPMorgan Chase Bank N.A.¼¯®Ú¤j³q¦W¤U¡]³s¦P¨ä¥L¬ü°ê¦s°U¾ÌÃÒ«ù¦³¤H¡^¡C ½Ð»P¸s¯qÃÒ¨é½T»{¥i¨ÑÂà´«¤§´¶³qªÑ¼Æ¶q¨Ãñ¸pªÑ¥÷ÂàÅý®Ñ¡F • ªÑ¥÷°e¹F®Ñ Letter of Transmittal: ³o¥÷¤å¥ó±N¥æ¥Iµ¹¥»¤½¥q¦s°U¾÷ºc¼¯®Ú¤j³q»È¦æ J.P. Morgan¡A¨Ó¤¹³\¼¯®Ú¤j ³q»È¦æ J.P. Morgan ±NÂà´««áªº¬ü°ê¦s°U¾ÌÃÒ¥æ¥Iµ¹±zªºÃÒ¨é¸g¬ö°Ó¡Cªí®æ ¤º®e½Ð¯d¤UªÅ¥Õ¡A½T©w¤§¥iÂà´«ªÑ¼Æ¡BªÑ²¼½s¸¹¡BªÑ²¼¤é´Á±N¥Ñ¶}°Ò/¤À¤ä µn°O³B¥N±z½T»{¤Î¶ñ¼g¡C°£ªÑªF±b¤á¸ê°T´£¨Ñ¥~¡A¦¹¥÷¤å¥ó¶È»Ý±zªºÃ±¦r§Y ¥iÂàµoµ¹¼¯®Ú¤j³q»È¦æ J.P. Morgan ¶i¦æ¨Ï¥Î¡C ¤@¥¹§¹¦¨¤Wz¥Ó½Ðªí®æ¡A½Ð©ó¥Á°ê 109 ¦~ 9 ¤ë 25 ¤é«eºÉ³t±N¥¿¥»¥H±¾¸¹¶l±H/¿Ë °e¦Ü¸s¯qÃÒ¨é¨Ãú¥æ¬ÛÃö¶O¥Î(½Ð°Ñ¾\²Ä 10 ÂI)¡C ½Ðª`·N¡A¸s¯qÃÒ¨é¶È©ó¥»¤½¥q¦³»ùÃÒ¨é²×¤îÂdÂi¶R½æ¥æ©ö¤é¡]§Y¥Á°ê 109 ¦~ 8 ¤ë 25 ¤é¡^«á¶}©l¦¬¨ü¿ì²z¡A¸s¯qÃҨ馳Åv¨Ì¥»¤½¥q¿ìªk¶i¦æªí³æ½T»{¤ÎÀˬd¡A¥H¨Ñ ¥»¤½¥q¤§¶}°Òµn°O¥N²z¤H¤Î¼¯®Ú¤j³q»È¦æ J.P. Morgan ¶¶§Qµo¦æ¬ü°ê¦s°U¾ÌÃÒ¡C 8. Âà´«µ{§Ç¤j¬ù¦h¤[¥i¥H§¹¦¨? ¦pªÑªF¤w³Æ§´©Ò¦³¤Wz¤å¥ó¡B¸g¸s¯qÃÒ¨é½T»{¸ê°TµL»~¥B¬ÛÃö¶O¥Î¦p¼Æú¥I¡A¼¯®Ú ¤j³q»È¦æ J.P. Morgan ©ó¦¬¨ì©Ò¦³¥¿¥»¥Ó½Ð¤å¥ó«á±N©ó 1 ¦Ü 2 Ӥ뤺§¹¦¨¥»¤½¥qªÑ ²¼Âà´«¬°¬ü°ê¦s°U¾ÌÃÒ¡B¨Ã¼·¥I¸Ó¬ü°ê¦s°U¾ÌÃҦܱz«ü©w¤§¬üªÑ¥æ©ö±b¤á¤§¬yµ{¡C ±©¥»¤½¥q¤£¾á«O¶W¥X¨ä±±¨î½d³ò¤§®É¶¡ªí¡C 9. ¦ó®É¥i¥H¦b¨º´µ¹F§J¥«³õ¤W¥æ©ö¨È·à±d¦s°U¾ÌÃÒ? ±z¥²¶·«ü¥Ü±zªºÃÒ¨é¸g¬ö°Ó±µ¦¬¥»¤½¥q¦s°U»È¦æ J.P. Morgan ¥æ¥I¬ü°ê¦s°U¾ÌÃÒ¤§ «ü¥O¡A±zªº¬ü°êÃÒ¨é¸g¬ö¤H©Î¥xÆW½Æ©e°UÃÒ¨é¸g¬ö¤H±N§iª¾±z¬O§_¦³¨ä¥L»Ý¨D§Y¯à §¹¦¨¬ü°ê¦s°U¾ÌÃÒ¼·¥I¡AÀH«á¡A±z¥ß§Y¥i¥H¦b¨º´µ¹F§JÃÒ¨é¥æ©ö©Ò¶i¦æ¥æ©ö¡C 10. ¦ôp¦¨¥»¬°¦ó? ¥H¤U¶O¥Î«Y±N¤ä¥I¤©²Ä¤T¤èªºµo¦æ¶O¥Î¤Î¦æ¬F§@·~¶O¡AµLÀ³¤ä¥I¤©¤½¥q¤§¶O¥Î¡G • ¬ü°ê¦s°U¾ÌÃÒµo¦æ¶O¥Î: ¨C¦ìªÑªF§¡»Ýt¾á©Ò«ùªÑ¥÷Âà´«¦Ü¬ü°ê¦s°U¾ÌÃÒ¤§¨CªÑµo¦æ¦¨¥»¡C¨C³æ¦ì¬ü°ê ¦s°U¾ÌÃÒÂà´«/µo¦æ¦¨¥»¬° 5 ¬ü¤À(¬üª÷$0.05 ¤¸)¡A¦¹¶µµo¦æ¦¨¥»«Y¥Ñ¼¯®Ú¤j³q»È ¦æ J.P. Morgan ¦¬¨ú¡A¤£¥]§t¨ä¥Lµ|®½©Î±z©Ò¦b¦aÃÒ¨é¸g¬ö¤HÃB¥~¦¬¨ú¤§¤âÄò ¶O¡C • ¦æ¬F§@·~¶O¡G ¨C¦ìªÑªF§¡»Ýt¾á¬üª÷ 20 ¤¸¤§¦æ¬F§@·~¶O¡C¦¹«Y¤@¦¸©Ê¥B±NÂà¤ä¥I¤©¬ÛÃö²Ä¤T ¤è¶i¦æªÑ¥÷Âà´«¤§¬ÛÃö¶O¥Î¡C ¨Ò¦p¡G±z«ù¦³ 1,000 ªÑ´¶³qªÑªÑ²¼(¬Û·í©ó 200 ªÑ¬ü°ê¦s°U¾ÌÃÒ)¡A±z»Ýn©óú¥æÂà ´«¤å¥ó®É¦P®É¤ä¥I¦@p¬üª÷$30 ¤¸(200 ªÑ¬ü°ê¦s°U¾ÌÃÒ*¬üª÷ 0.05 ¤¸+¬üª÷ 20 ¤¸) µ¹¸s¯qª÷¹©«ü©w±b¤á¡C¬ÛÃö¸ê°T±N©óÂà´«¥Ó½Ð¤å¥ó¤¤¥i¨ú±o¡C ¥t¡A¥»§ë¸ê¤H°Ýµª·§z¤U¦C¥i¯àµo¥Í¤§¨ä¥L¦¨¥»¶È¨Ñ§ë¸ê¤H°Ñ¦Ò (µøªÑªF/ÃÒ¨é°Ó±¡ ªp¦Ó¦³©Ò¤£¦P): • ¶}¤á¤âÄò¶O¡G ¦p±z§Æ±æ¶}¥ß¬ü°êªÑ²¼¥æ©ö±b¤á¥i¯à²£¥Í¶}¤á¤âÄò¶O¡A½Ð¬¢¦UÃÒ¨é°Ó¸g¬ö°Ó¡C • ¥æ©ö¬¡°Ê¶O (TAF) / ¥æ©ö¼x¶O¡G ·í±z¶R½æ¬ü°ê¦s°U¾ÌÃҮɡA±zªºÃÒ¨é¸g¬ö°Ó±N¥H¦¨¥æªÑ¼Æpºâ¦V±z¦¬¨ü¥æ©ö¬¡ °Ê¶O¡A½æ¥X®É¦¬¨ú¬ù¦¨¥æª÷ÃB¤§ 0.00221%¡A³Ì§C¦¬¨ú 0.01 ¬ü¤¸¡A³Ì°ª¬ü¤¸ 5.95 ¬ü¤¸¡C¦¹¶µ¶O¥Î±N¨Ì¾Ú±zªºÃÒ¨é¸g¬ö°Ó¤Î¬ü°ê·í§½¤£©w´Á½Õ¾ã¡C • ¬ü°ê¦s°U¾ÌÃÒ¸g¬ö°Ó«OºÞ¶O¡G ¶R¶i¬ü°ê¦s°U¾ÌÃÒ¦p©ó«OºÞ¶O¥Î¦¬¨ú°ò·Ç¤é®É©|¦³«ùªÑ¡A±N·|³Q¬ü°ê«OºÞ¾÷ºc ¦¬¨ú«OºÞ¶O¥Î¡C¬ü°ê¦s°U¾ÌÃÒ«OºÞ¶O¬ù¨CªÑ 0.01 ¬ü¤¸¦Ü 0.05 ¬ü¤¸¤£µ¥¡A¨C¥b ¦~¡B¤@¦~©Î©w´Á¦V«ù¦³¤H¦¬¨ú¤@¦¸¡A¨ãÅé¶O¥Î¨ú¨M©ó±zªºÃÒ¨é¸g¬ö°Ó¡C ¤Wz¶O¥Î«Y°ò©ó¥»¤½¥q»s§@¥»§ë¸ê¤H°Ýµª®É¡A¥»¤½¥q¨ú±o¤§«H®§¡AµLªk«OÃÒ¤Wz¶O ¥Îªº·Ç½T©Ê¤Î§¹¾ã©Ê¡C ½ÐÁpô±zÓ¤Hªºµ|°È¿Ô¸ßÅU°Ý¥HÀò¨ú¦³Ãö¦b¬ü°ê¨º´µ¹F§J¥æ©ö©Ò¶R½æ¬ü°ê¦s°U¾ÌÃÒ ¥i¯à²£¥Íªº¦U¶µµ|°È³W¹º«Øij¡A¥»¤½¥q·§¤£´£¨ÑªÑªFÓ¤H°]°È³W¹º¿Ô¸ß¡C 11. ¦pªÑªFµL·NÄ@±NªÑ²¼Âà´«¬°¬ü°ê¦s°U¾ÌÃÒ¤§³B¸m¬°¦ó? ¦p±zµL·NÄ@Âà´«¬°¬ü°ê¦s°U¾ÌÃÒ¡A±z±o¥H¦b¥Á°ê 109 ¦~ 8 ¤ë 25 ¤é¥»¤½¥q¦³»ùÃÒ¨é ²×¤îÃÒ¨éÂdÂi¶R½æ¤é«e¡A©ó¥xÆW¤½¶}¥«³õ±N±z©Ò«ù¦³¤§¥»¤½¥qªÑ¥÷¥X°â¡A¦b«ez¤é ´Á¤§«á¡A±z©Ò«ùªÑ²¼±NµLªk¦b¥xÆW©Î¨ä¥LÃÒ¨é¥æ©ö©Ò¤W¶i¦æ¤½¶}¶R½æ¡C µM¦Ó¡A¦p±z¿ï¾Ü¤£Âà´«©Î¨p¤U¹L¤áµLÂà´«Åv¤§ªÑ²¼(¸Ô²Ä 3 ÂI©w¸q)¡A±z¤´¬°¨È·à±d ªÑ¥÷¦³¤½¥q(¶}°Ò¤½¥q)¤§ªÑªF¡A¤´¦³¸ê®æ©ó¥¼¨Ó°Ñ»P¥»¤½¥q°tµoªÑ®§©ÎªÑªF¤j ·|¡A¨Ã¨Ì¶}°Ò¸s®qªk«ßµ{§Ç¶i¦æ¨p¤H¹L¤á¥X°â¡C¦p¥»¤½¥q©ó¥i¹w¨£¥¼¨Ó¶i¦æ¦X¨Ö¦¬ ÁÊ¡A«h±z¥i¥H¦b¨º®É¨Ì·Ó¥»¤½¥q¶}°Ò¸s®qªk¥O³¹µ{¥l¶°¤§ªÑªF¤j·|Àò±o¥b¼ÆªÑªF¦P ·N¡A¨Ì¬ÛÃön¬ù±ø´Ú¥X°â±zªº«ùªÑ¡C 12. §Ú¥i¥H¥uÂà´«³¡¤ÀªÑ¼Æ¶Ü? §_¡C¦p±z§Æ±æ°Ñ»P¥»¦¸Âà´«¡A½Ð¨Ì¤Wz¬ü°ê¦s°U¾ÌÃÒªí¹ü´¶³qªÑ¼Æ¶q(1:5)¡A±N±z©Ò «ù¦³¤§¥»¤½¥qªÑ¥÷¤@¦¸¥þ¼ÆÂà´«¡C 13. ¤½¥q²×¤î¦³»ùÃÒ¨éÂdÂi¶R½æ«á¥i¯àµo¥Íþ¨Ç·|¼vÅTªÑ²¼»ùȪºÃöÁä¨Æ¶µ? ¥»¤½¥q©ó²×¤î¦³»ùÃÒ¨éÂdÂi¶R½æ¥H¤Î°±¤î¦b¥xÆW¦³»ùÃҨ餽¶}µo¦æ«á¡A±NÂಾ²Ä¤@ ¤W¥«¥«³õ«¤ß¦Ü¨º´µ¹F§J¥æ©ö©Ò¡C§Ú̱N«ùÄòÂX¤j²£«~²Õ¦X¨Ã»EµJµo®i¤Î¨ã¼ç¤O¤§ ASLAN004 À³¥Î©ó²§¦ì©Ê¥Ö½§ª¢¡A¨Ã¹wp©ó 2020 ¦~²Ä¥|©uµo¥¬ ASLAN004 ¦h¾¯¶q»¼ ¼WÃĪ«¸ÕÅç(MAD)´Á¤¤¼Æ¾Ú¤Î·§©À©Ê¸ÕÅç¼Æ¾Ú¨Ã©ó 2021 ¦~®i¶}²Ä 2b ´ÁÁ{§É¸ÕÅç¡C ³o¨Ç³£¬O¥i¯à¼vÅT¥¼¨ÓªÑ²¼»ùȤ§ÃöÁä¨Æ¶µ¡C Ápµ¸¸ê°T ·í¦a°õ¦æ³æ¦ì: ¸s¯qª÷¹©ÃÒ¨éªÑ¥÷¦³¤½¥q ¹q¸Ü: +886 2 2702 3999 ¶Ç¯u: +886 2 2706 3300 ¹q¤l«H½c: A33424@capital.com.tw ¥»¤½¥q: ¨È·à±dªÑ¥÷¦³¤½¥q Tel: +65 6222 4235 Fax: +65 6225 2419 ¹q¤l«H½c: sharetransfer@aslanpharma.com §K³dÁn©ú ¤WzÂà´«¿ìªkº[§ë¸ê¤H°Ýµª¦p¦³¤£ºÉ¤§³B¤@¤Á¥H¥»¤½¥q¸³¨Æ·|¨Mij¡B¥»¤½¥qÀ³¾A¥Î¤§ªk¥O¤Î¥»¤½¥q³¹ µ{³W©w¿ì²z¡C½Ð°Ñ¾\¥»¤½¥q©xºô¤w¨ú±o³Ì·s°T®§¡C¹ï©ó¥ô¦ó¥¼¿í´`µ{§Ç¤§²§Ä³ªÑªF¥»¤½¥q«O¯d¨äÂà´« Åv¥B¥»¤½¥q¤£t¾á¥ô¦ó¦¹Ãþ¥¼Âà´«¤§³d¥ô¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gtimchan51610148760 |
µoªí®É¶¡:2020/7/17 ¤U¤È 05:27:41
²Ä 3098 ½g¦^À³
|
nÂà´«ADRªº§ë¸êªÌ ±j¯P«ØijÁÙ¬O¥Î°ê¤º¨÷°Óªº½Æ©e°U¤ñ¸û¦n ! ¦w¥þ«×¤ñfirstrade µ¥®ü¥~¨é°Ó°ª«Ü¦h ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GJCY10146705 |
µoªí®É¶¡:2020/7/17 ¤U¤È 05:14:14
²Ä 3097 ½g¦^À³
|
½Ð°Ýtimchan¤j«e´X½g»¡ªº¨È·à±d©xºôªºªÑªF°Ý»Pµª ¦³¤H¥i¥H¤U¸ü¤F¶Ü? ÂI¤Fµ²ªG¸õ¦P¤@Ó¶±¥X¨Ó
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2020/7/17 ¤U¤È 04:58:21
²Ä 3096 ½g¦^À³
|
«Ü¦h¬ü°ê¥Í§Þ¤½¥q¦´ÁªÑ»ù¥u¦³Ó¦ì¼Æ¡A ¨Ò¦pRegn ³Ì§C¨Ó¨ì3¬ü¤¸¡A·í¦³¦¨¥\ÃĪ«¬ãµo¦¨¥\¡A´N·|»P²{¦bªÑ»ù632¤¸¤£¥i¦P¤é¦Ó»y¡C
www.google.com/search?q=regn+stock&oq=Re&aqs=chrome.1.69i57j35i39j69i60l3.2972j0j4&client=ms-android-htc&sourceid=chrome-mobile&ie=UTF-8 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/17 ¤U¤È 04:26:57
²Ä 3095 ½g¦^À³
|
²Ä¤@¤W¥«¦a¤è¥Ñ¥xÆW(¥Í§Þ¥«È1¥ü¥x¹ô)´«¬ü°ê(«e20¤j»sÃĤ½¥q¥«È60¥ü) !
8/25 «á «ù¥xªÑ¥½´«ADR¤§¥xªÑ6497 ¥¼¤W¥«¦æ±¡¡A¸òµÛµLº¦¶^´T. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2020/7/17 ¤U¤È 04:15:35
²Ä 3094 ½g¦^À³
|
»¡¥y¹ê¦b¸Ü ¨È·à±dÄ@·NÀ°¥xÆW§ë¸êªÌÂà´«¦¨ADR §Ú¯uªºÄ±±o¤w¸g¸Û·N¤Q¨¬
·sÃĤ½¥q¥»¨Ó´N¬O¤@½¨âÀü²´ ÃĦ¨¥\©Î¥¢±Ñ¤]¤£¬O100%¯à´x´¤ ¤j®a¤@©w·|«Ü®ð´X¦¸¸Ñª¼¥¢±ÑªÑ»ù¼É¶^
¦ý¦Ü¤Ö¤½¥qÄ@·NºÉ¤OºûÅ@ªÑªFÅv¯q ¦h¤Ö¤½¥q¤U¥«´N¤U¥«¤F¡AÁÙºÞ§A¥h¦º ¨ó§UÂàADR³oÂI§Úµ¹¤½¥q¤@ÓÆg ¨ä¹êÂàADR¯uªº¨S¤£¦n ¥ú¬O¨Sº¦¶^´T¨î³oÂI´N¤ñ¥xªÑ±j¦h¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2020/7/17 ¤U¤È 04:08:06
²Ä 3093 ½g¦^À³
|
¦³¤H»¡Âà´«ADR¡A·|ÅýADRªÑ¥»±i¼Æ¤j¼W ³o¬O¿ùªº ¥xªÑÂàADRªÑ¥»®Ú¥»´N¤£ÅÜ ¥\½Ò°µ¨¬¦A¨Ó°Õ ¤£¹L´N¬O¦³«Ü¦h¤£À´ªº¤H¡A¤~·|¦³¦n»ù®æ¥i¥H¾ß ¤j®aÄ~Äò¬å¨SÃö«Y¡A§Úµ¥µÛ±µ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/17 ¤U¤È 03:56:48
²Ä 3092 ½g¦^À³
|
¥xÁÞ¤j ,
www2.deloitte.com/tw/tc/pages/tax/articles/tax-overseas-income.html
ª`·N¨Æ¶µ¤@¡n¨Ã¤£¬O¦³®ü¥~©Ò±o´Nn½Òµ|
Ó¤H®ü¥~©Ò±o¬O³z¹L¡u³Ì§Cµ|t¨î¡v¨Ó½Òµ|¡A¦]¦¹¡Aúµ|»P§_¥²¶·³q¹L¡u¼h¼hÃö¥d¡v¡C
²Ä¤@¡A¥Ó³øªÌÀ³À˵ø¥Ó³ø¤á¡u¥þ¦~®ü¥~©Ò±o¡v¬O§_¹F100¸U¤¸¡A¥¼¹F¼ÐªÌ®ü¥~©Ò±oµL¶·¯Ç¤Jpºâ¡F
²Ä¤G¡A¡u¥þ¦~®ü¥~©Ò±o¡v¶W¹L100¸U¤¸¡AÀ³¦A¥[p¨ä¥L¡uÀ³p¤J°ò¥»©Ò±oÃB¤§¶µ¥Ø¡v«á¡]¨Ò¦p¨ü¯q¤H»Pn«O¤H¤£¦Pªº¤H¹Ø«OÀI¤Î¦~ª÷«OÀIµ¹¥I¡A©Î«D²{ª÷®½Ãت÷ÃB¤Îºî¦X©Ò±o²bÃB¡^¡A¦Apºâ¡u°ò¥»©Ò±oÃB¡v¡C¡u°ò¥»©Ò±oÃB¡v¥¼¹F670¸U¤¸ªÌ¡A¨S¦³Ãº¯Ç°ò¥»µ|ÃBªº°ÝÃD¡C
²Ä¤T¡AY¡u°ò¥»©Ò±oÃB¡v¶W¹L670¸U¤¸¡An¥ý¦©°£670¸U¤¸¡A¦A±N¾lÃB¥H20%µ|²vpºâ¡u°ò¥»µ|ÃB¡v¡C¨Ã±N¡u°ò¥»µ|ÃB¡v«á»P¡u¤@¯ë©Ò±oµ|ÃB¡v¤ñ¸û¡AY°ò¥»µ|ÃB¤p©ó¤@¯ë©Ò±oµ|ÃB¡A¤@¼Ë¨S¦³Ãº¯Ç°ò¥»µ|ÃBªº°ÝÃD¡C
³Ì«á¡AY¡u°ò¥»µ|ÃB¡v¶W¹L¡u¤@¯ë©Ò±oµ|ÃB¡v¡AÁÙn½T»{¬O§_¦³¡u®ü¥~¤w¯Çµ|ÃB¡v¥i¦©©è¡CY®ü¥~¤w¯Çµ|ÃB¦©©èª÷ÃB¤p©ó¤Wz®tÃB¡A¤~¶·«ö¤£¨¬¦©©è¼Æú¯Ç°ò¥»µ|ÃB¡C
¦]¦¹¡A²³æ¨Ó»¡¡A·í°ê¤º©Ò±o¶V°ªªÌ¡A¨ä®ü¥~©Ò±oµL¶·½Òµ|ªº¾÷·|´N·|¶V°ª¡AÁ|¨Ò»¡©ú¦p¤U¡]¨£ªí¤@¡^¡CÁöµM¦P¼Ë¬O700¸Uªº®ü¥~©Ò±o¡A¦ý¦]¬°°ê¤ºªº©Ò±o¾A¥Îµ|²v¤£¦P¡A¾ÉP©Ò±o²bÃB¸û°ªªº±¡ªp¨ä®ü¥~©Ò±oµL¶·½Òµ|¡A¦Ó©Ò±o²bÃB¸û§CªÌ¨ä®ü¥~©Ò±o¶·½Òµ|¡C
ª`·N¨Æ¶µ¤G¡n¤¤°ê¤j³°¦a°Ï©Ò±o«D®ü¥~©Ò±o
¨Ì¾Ú¡m»OÆW¦a°Ï»P¤j³°¦a°Ï¤H¥ÁÃö«Y±ø¨Ò¡n¡A¤¤°ê¤j³°¦a°Ï©Ò±o¨Ã«D®ü¥~©Ò±o¡A©Ò¥HÓ¤H¨ú¦Û¤j³°¦a°Ï¤§©Ò±oÄÝ©óºî©Òµ|ªº½Òµ|½d³ò¡A¶·p¤J©Ò±oÁ`ÃB¾A¥Î²Ö¶iµ|²v¡C¤£¹L¡A¬°¤FÁקK«½Æ½Òµ|¡A¦b¤¤°ê¤j³°¦a°Ï¤wú¯Çªº©Ò±oµ|¡A¦b¥xÆW¥i¥H©èúµ|ÃB¡A¦ý¥i¦©©èª÷ÃB¤£±o¶W¹L¦]¥[¤J¤¤°ê¤j³°©Ò±o«á¡A©Ò¼W¥[ªº¦b¥xÀ³¯Çµ|ÃB¡C
ª`·N¨Æ¶µ¤T¡n¨Ã«D¹Ò¥~¸êª÷¶×¤J¤~¬O®ü¥~©Ò±o
¯Çµ|¸q°È¤H¸g±`»~¥H¬°¡u¶×¤J¤§¹Ò¥~¸êª÷¡vÄÝ®ü¥~©Ò±o¡C¨Æ¹ê¤W¡A®ü¥~©Ò±o»P¸êª÷¶×¤JµL¥²µMÃö«Y¡C¤ý·çÂE«ü¥X¡A¨ä¥]§t¤GºØ²[¸q¡G²Ä¤@¡A¶×¤J¤§¸êª÷¦³¥i¯à¬Oì©l¶×¥X®ü¥~¤§¸êª÷ªðÁÙ¡B¤w¸g¥Ó³ø¹L¥H«e¦~«×®ü¥~©Ò±o¤§©Ò±o¡A©Î¬O¤w¸g¹L¤F®Ö½Ò´Á¶¡¤§¥H«e¦~«×®ü¥~©Ò±o¡A³o¨Ç¸êª÷³£µL¶·¦Ap¤J°ò¥»©Ò±oÃB½Òµ|¡A©Ò¥H¨Ã«D¶×¤J¤§¸êª÷³£ÄÝ®ü¥~©Ò±o¡F²Ä¤G¡A®ü¥~©Ò±o¬O¥H¡u©Ò±o¹ê²{¬°·Ç¡v¡A¦Ó«D¥H¶×¦^ª÷ÃB¬°·Ç¡A©Ò¥H¨Ã«D¤£¶×¦^®ü¥~¤§¸êª÷´N¨S¦³¥Ó³ø®ü¥~©Ò±o¤§¸q°È¡C°]¬F³¡¤w©ó¤µ¦~ªìµo§G¨ç¥O¡A®ÖÄÀÓ¤H¶×¦^®ü¥~¸êª÷À³§_¸É³ø¡Bpºâ¤Î¸Éú°ò¥»µ|ÃB¤§»{©wì«h¤ÎÀ˪þ¤å¥ó³W©w¡A«Øij¥i°Ñ°u¹B¥Î¡C
ª`·N¨Æ¶µ¥|¡nªÑ§Q©Ò±o½Òµ|¤è¦¡¤£¦P±N¼vÅT°ò¥»µ|ÃB»P¤@¥b©Ò±oµ|ÃB¤§®tÃBpºâ
¥H©¹ªÑ§Q©Ò±o¤j¤áÀò°tªÑ§Q¶·p¤Jºî¦X©Ò±oÁ`ÃB¾A¥Î³Ì°ª²Ö¶iµ|²vªÌ¡A¤µ¦~³øµ|¥i¿ï¾Ü¾A¥Î28%¤À¶}pµ|¡A¥HÀò±o¸û¤jªº¸`µ|®Ä¯q¡C¦ý¬O¡AY¿ï¾ÜªÑ§Q©Ò±o¤À¶}pµ|ªÌ¡A¦b¥[p®ü¥~©Ò±o«á¨ä©Ò±o°ò¥»µ|ÃB¡A»P¤@¯ë©Ò±oµ|ÃB¤§®tÃBªºpºâ¥i¯à·|¦³©Ò¤£¦P¡CÁ|¨Ò¦Ó¨¥¡]¨£ªí¤G¡^¡A¬Û¦Pªº©Ò±oª÷ÃB»PÃþ§OY¿ï¾ÜªÑ§Q©Ò±o¤À¶}pµ|¥[p®ü¥~©Ò±o«á¤Ï¦Ó»Ýnú¯Ç³Ì§Cµ|t¡C´«¨¥¤§¡A¤£¦P¤è®×¤U¥i©Ó¨üµL»Ý½Òµ|ªº®ü¥~©Ò±oª÷ÃB¤£¦P¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/17 ¤U¤È 03:45:06
²Ä 3091 ½g¦^À³
|
FB825 º¦Â½¤Ñ, ¤£ª¾¨ä¥u°µ12¦ì AD. ¥i¥H°ê»Ú±ÂÅv¡I
¤£ª¾ASLAN004 MOA ¦PDUPILUMAB ¤w³Q18¸U¤HÅçµý¹L!
¸ê°TÄY«¤£¹ïºÙ
¬ü¡B¥xªÑ¥«©|¥¼¤ÏÀ³ 1.¨È狮»PCSL¦@¦P¶}µoASLAN004¨ì1a Á{§É§¹¦¨,MOA ³Q½T»{¦PDupilumab ¸ô®|ªº10»õ¬ü¤¸§é²{§Q¯q¡C 2019/05/31 MOA ³Q½T»{, ¤w¸g°ê»Ú±ÂÅv¡A¨È·à©Ò±o§Q¯q¦ô§é现È10»õ¬ü¤¸¡C¥tCSL¥ç±o10»õ¬ü¤¸ªº¼ç¦b§Q¯q¡A¦@20»õ¬ü¤¸¡C
ñ约°ò¦¡A°Ñ¦Ò°ê»Ú¦P级¦X¬ù¡A¦ô³Ì°ª销°â30»õ¬ü¤¸¡C (·í®ÉDupilumab ¥«³õ»{¦P¥¼¨Ó³Ì°ª¥i销50»õ¬ü¤¸)
2.2020¦~¤¸¤ë Dermira/Lebrikizumab AD ªº¨ÖÁʧé²{»ùÈ 29»õ¬ü¤¸. 2020/01 §¨Ó¨ÖÁÊDermira ¤½¥q
11»õ¬ü¤¸²{ª÷+ ¤ä¥Iù¤óROCHE Lebrikizumab¥þ²yAD¶}µoÅv,°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù12.35»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%.
§é²{Ȧô 11»õ¬ü¤¸+18»õ¬ü¤¸=29»õ¬ü¤¸,
3.2020/7/17,Àq§J¥þ²y¾P°â/ASLAN004 ¦ô50»õ¬ü¤¸³Ì°ª¾P°â
a.¦]Dupilumab ¥«³õ»{¦P°ª¾P°âÃB´£¤É¨ì110»õ¬ü¤¸¡C ASLAN004ÀH¥«³õÂX¤j¡A¥¼¨Ó·s°ê»Ú±ÂÅvÈ¨Ì¾Ú ³Ì°ª¾P°â¦ô¥i¹F50»õ¬ü¤¸
b¡D2020¦~¤¸¤ë§¨Ó¨ÖDermiraªº§é现»ù¡A¤w¹F29»õ¬ü¤¸¡C LebriKiulmabªº¤T´Áý³Ý¡A2017¦~¸Ñª¼¥¢±Ñ¡CªÍ³¡C0PD¥ç¥¢±Ñ¡C
Dermiraªº§é现»ùLebriKiulmab¥u¦³ AD ¾AÀ³¯g¡A¤w¹F29»õ¬ü¤¸ ASLAN004 ¦P Dupilumab Àø®Ä¥i¬° LebriKiulmab 1/0.75=1.33¿
29*1.33=38.7 »õ¬ü¤¸
C¡D¨È·à ý³Ý/ªÍ³¡COPD ¨â¤j¾AÀ³¯g¦¨¥\¾÷·|,¦PDupilumab MOA¡C ¦ôp ¾P°â°ªÂI¥i¥t¼W15»õ¬ü¤¸ªº¾P°â»ùÈ.(µ¥¨È·à±À1aý³ÝÁ{§É¦A¦ô)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2020/7/17 ¤U¤È 03:44:09
²Ä 3090 ½g¦^À³
|
¬ü°ê¥u¦³ªÑ®§n¦©¦Ê¤À¤§30µ|¡A°ê¥~¤H§ë¸ê¬üªÑÀò§Q§Kµ|¡A¨Ò¦p2¬ü¤¸¶R¶i¡A10¬ü¤¸½æ¥X¡AÁÈ8¬ü¤¸¡A§Kµ|¡C ¥xªÑ¤]¬O¤@ºØ¡AÃÒ¨é¥æ©ö©Ò±oµ|¤w¼o°£¡C ¥H¤W¦³¿ù½Ð«ü¥¿¡C www.google.com/amp/s/blog.moneydj.com/joe/2017/05/25/%25E6%258A%2595%25E8%25B3%2587%25E7%25BE%258E%25E8%2582%25A1%25E5%258F%25AF%25E4%25BB%25A5%25E5%2596%2584%25E7%2594%25A8%25E8%25B3%2587%25E6%259C%25AC%25E5%2588%25A9%25E5%25BE%2597%25E5%2585%258D%25E7%25A8%2585%25E7%259A%2584%25E5%2584%25AA%25E5%258B%25A2/amp/ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/17 ¤U¤È 03:37:02
²Ä 3089 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/17 ¤U¤È 03:26:46
²Ä 3088 ½g¦^À³
|
¥¼¨Ó¥²´Iºô¡A8/25 ¤é¥H«á¥i¡A¨ó§U¥æ©ö«ÝÂà´«ADR ªº¥¼¤W¥«¥xªÑ6497 ¡A¨ÌADR »ù®æ¬°°ò¦,¥æ©öª½¨ì Âà´«´Áµ²§ô¡C
¦³«H¤ßªºªø§ëªÌ¡A¤£·|Âà¡A´Nµ¥¨ÖÁʲMºâ¡A¤Ö±¼³Q¥xÆW½Ò°ê¥~©Ò±o20%µ|(ÁȶW¹L690¸U).
°OªÌ¤£²M·¡ASLAN004 ¹ê¤O/¤£ÁA¸Ñ AD°ê»Ú±ÂÅv¥«³õ¡AASLAN004 ¤w¸g°ê»Ú±ÂÅv¤A¦^¡A¤A½T»{M〇A ÁÙ¦b¥ÎÀù¯g¸~½FªºÆ[©À¡A¨Ó°Ý°ÝÃD!
°ÝÃD¤@°Ý´Nª¾¦³µL¡C
𣎴ª¾¹DÀsÀYdupilumb ¤½¥qREGN ªÑ»ùªñ¥b¦~º¦300»õ¬ü¤¸ .
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2020/7/17 ¤U¤È 03:23:36
²Ä 3087 ½g¦^À³
|
1. èè°OªÌ¦³°Ý¬°Ô£ªá¤j¿ú±ÂÅv001¶i¨Ó¡A«o¨S¦³¥ô¦ó¦¨ªG¡AÁÙ¦³¿N¿ú³t«×¤Ó§Ö¡A¤@¶}©l¶i¦æ¤Ó¦h¹êÅç¡A¦n¤j³ß¥\¡A¾ÉP²Ä¤@¦¸µo¦æADR¶Ò¨ìªº¿ú¡A¤@¦~´N´X¥Gªá¥ú¡An¶i¦æ²Ä¤G¦¸¶Ò¸ê¡Aı±o§èªº´N¬O³oÓ¡A¤½¥q²bȤ@¤U±q10¦h¶ô¡A¤@©u´N´î¤Ö´X¶ô¿ú¡A¨ì2019Q2²bÈ´N¶^¯}5¤¸¤F¡A¤½¥qªá¿ú³t«×¹ê¦b¤Ó§Ö¡AÀ³¸Ó¤£n¤@¦¸¶i¦æ¤Ó¦h¹êÅç¡Aµ¥¨ì¤U¥b¦~¤~»¡·|§â«¤ß©ñ¦b004¤W±¡A¨È·à±d¤@¶}©l´N¤£À³¸Ó¤@¦¸¶i¦æ¤Ó¦h¹êÅç¡A¤@½uGÀù¸ò¤G½uÁx¹DÀù¿ï¤@Ó¥ý¶}µo´N¦n¤F¡A¤]¤£¦Ü©ó·|¦³¸êª÷°ÝÃD¡A¦Ó¥B¤½¥q°ª¼hÁ~¤ô¹ê¦b¤Ó°ª¡A³oÂI¤]¨S¦³¤H¥h½èºÃ¡A¦pªGªá¿ú³t«×¤£¦A´î¤Ö¡A§Ú·Q¤½¥q¥¼¨ÓÁÙ¬O«ÜÃø¨«ªºªø»·¡C
2. 001¸Ñª¼¥¢±Ñ¨â¦¸¡A¤]³£¨S¦³¬Ý¨ì¤½¥q°ª¼h¬°¦¹t³dÃ㾡A¥_·¥¬P³£´«±¼CEO¤F¡A§Ú·Q³o´XӦѥ~¯uªº¤£¦æ¡AÀ³¸ÓÁÙ¬On´«±¼ªº¡C
3. ´Nºâ²{¦³ªº13¸U±i¥xªÑ¥i¥HÂà´«¦¨ADR¡A¦ý¬O¤@¦¸¼W¥[¨º»ò¦hADRªÑ¥÷¡A³o¼Ë¥¼¨Ó¤½¥qADRªºªÑ»ùÁÙ¥i¥Hºû«ù¦b²{¦b¤ô¦ì¤W¶Ü? ³oÂI¤½¥q¥²¶·nª`·N¡A¦b¥xÆW§ë¸ê¤HÂà´«¦¨ADR¤§«e¡A·|¤£·|즳ADR«ù¦³¾á¤ß¥¼¨Ó¥i¯à³Q¦Y¨§»G¡A¦Ó¤j¶q©ß°âªÑ²¼¡A³oÂIȱoª`·Nªº¡C
4. ¹ê¦b«ÜÃø·Q¹³2016 ¨È¬w³Ì¨Î¥Í§Þ¤½¥q ¨È·à±d ³ºµM¤µ¦~´NnºMÂd¤F¡A¤@¶¡¦n¤½¥q³Q³o¨Ç¦Ñ¥~¸gÀ禨³o¼Ë¡AÃø©Ç쥻ªºµo¨¥¤H¡B¥xÄyÂå¾Çªø¤@Ó¤@Ó¨«¤H¡A¯u¤ß§Æ±æ¸³¨Æ·|¥i¥H´«±¼³o¤@§å¦Ñ¥~¡A´«·s¤H¨Ó±a»â¤½¥q¡C
5. §Ú·Q¦b³oÃä¤j¦h¼Æ¤H¡A«ùªÑ¦¨¥»³£«Ü°ª§a¡An¯à¦^¥»¡A¤]¥u¯à¬ßµÛ004¯à¦¨¥\¡A¤£¹L¥Ø«e¶i«×¹ê¦b¤ÓºC¡A¯uªº¤£ª¾¹DÁÙn¦h¤[¡A¤j®a§ë¤Jª÷¿ú¸ò®É¶¡¤~¯à¦^¦¬©O?
¥H¤W¤@ÂIÂI·N¨£! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2020/7/17 ¤U¤È 03:15:11
²Ä 3086 ½g¦^À³
|
¦³¤Hª¾¹D´«ªÑ¤ñ¨Ò¤´¬O5±i¥xªÑ´«1±iADR¶Ü ? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/7/17 ¤U¤È 03:10:32
²Ä 3085 ½g¦^À³
|
¤T¤j¤è®×.
1. 8¤ë/25¤é«e¥i¦b¥xÆW¥«³õ½æ±¼.
2. ¥xªÑ´«ADR
3.¤£´«¤]¥i¥H,¨É¦³¶}°Ò¤½¥q¦PªÑªF¦Pµ¥Åv¤O,³Q¨ÖÁʮɥi¤À¦P¼Ë¿ú.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GºCºC¶]10142302 |
µoªí®É¶¡:2020/7/17 ¤U¤È 03:02:30
²Ä 3084 ½g¦^À³
|
À°¤j®a°Ý¹D¤@Ó«ÂI¥i¯à¨S¦³¦¬ÁÊ»ù |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 3501 ~ 3600 «h¦^ÂÐ >> |